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Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that localises 
to focal adhesions. FAK is crucial for many cellular processes that are disturbed in 
malignancy, including proliferation, cell cycle, cell survival, adhesion, and 
migration. Mouse models have shown that FAK is involved in tumour formation and 
progression. Other studies demonstrated a functional correlation between FAK 
expression, tumour progression and malignancy in human cancer, making FAK a 
potentially important therapeutic target. Several FAK inhibitors have been developed 
most of which target the FAK kinase function. However, FAK may predominantly 
act as a scaffolding molecule rather than as a kinase, therefore, disruption of FAK’s 
interaction with protein binding partners could be a good strategy to inhibit some 
cancer processes.  
The identification and characterisation of novel FAK interactions may help to 
uncover important molecular mechanisms that, in turn, regulate key cellular 
processes involved in tumour formation and/or progression. Disruption of their 
function, or inhibition of their binding to FAK, will define their roles and identify 
whether they are good anti-cancer targets. 
In this thesis work, I set out to identify novel binding partners of FAK, and study the 
role of a sub-set of these in tumour biology by impairing them in squamous cell 
carcinoma cancer cells in vitro. To do this I employed protein microarray and phage 
display methodologies using FAK∆375 and FAK-FERM recombinant proteins as 
bait, respectively. I identified a number of novel proteins that interact directly with 
FAK. Then I set out to characterise some of these proteins. 
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 The first of these, Axl, is a protein receptor tyrosine kinase that has previously been 
linked with tumour progression and metastasis in number of human cancers. I 
confirmed the interaction between FAK and Axl in SCC cells and showed that the 
FAK-Axl interaction is predominantly a scaffolding function of FAK, which seems 
to be unregulated, at least by any of the major phosphorylation events characterised 
for FAK. I also found that Axl controls cell spreading, cell polarisation and invasive 
migration in this cancer cell lines. 
The second protein I characterise is the autophagy protein Ambra1. I found that 
Ambra1 is required for selective targeting of active Src to the autophagy pathway – a 
process that SCC cancer cells use when they are under adhesion stress, such as when 
FAK is deleted.  
Thus, Axl and Ambra1 are potentially important proteins in SCC biology. They bind 
to FAK and function at cell adhesions to promote cancer-associated cellular 
processes. Analysis of FAK binding proteins may be a useful strategy to discover 




µg  micrograms 
µl  microlitre 
µM  micromolar 
nM  nanomolar 
α  alpha 
A  alanine 
Ambra1 activating molecule in Beclin1 – regulated autophagy 
Arp2/3  actin related protein 2/3 
ASAP1 Arf-GAP containing a SH3 domain, ankyrin repeats, and PH domain 
Atg  autophagy related  
ATP  adenosine-5’-triphosphate 
β  beta 
Bif-1  Bax-interacting factor-1 
bp  base pair 
BSA  bovine serum albumin 
CADTK calcium-dependent tyrosine kinase 
CAP  c-Cbl associated protein 
cDNA  complementary DNA 
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CML  chronic myeloid leukemia 
C-terminal carboxy-terminal 
D  aspartate 
DAPI  4’,6-diamidino-2-phenylindole  
DMEM Dulbeccos Modified Eagles Medium 
DNA  deoxyribonucleic acid  
ECL  enhanced chemiluminescence 
ECM  extracellular matrix 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor 
ERK  extracellular signal-regulated kinases 
FAK  focal adhesion kinase 
FAT  focal adhesion targeting 
FBS  foetal bovine serum 
FERM  functional ezrin radixin myosin 
FIP200 FAK interacting protein of 200 kDa 
FGFR  fibroblast growth factor receptor 
FRNK  FAK related non-kinase 
ɣ  gamma 
GAPDH glyceraldehydes 3-phosphate dehydrogenase 
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GRAF  GTPase regulator associated with FAK 
Grb7  growth factor receptor bound protein 7 
HER2  human epidermal growth factor receptor 2 
HUVEC human umbilical vein endothelial cell 
IF  immunofluorescence 
IP  immunoprecipitation 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
JAK  Janus kinase 
JNK  c-Jun N-terminal kinase 
K14  keratin 14 
mAb  monoclonal antibody 
MAPK  mitogen-activated protein kinase 
MEF  mouse embryo fibroblast 
MEM  Modified Eagles Medium 
MMP  matrix metalloproteinase 
NES  nuclear export signal 
NLS  nuclear localisation signal 
NRTK  non-receptor protein tyrosine kinases 
NSCLC non-small cell lung cancer 
4-OHT  4-hydroxy-tamoxifen  
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P  proline 
PBS  phosphate buffered saline 
PBS1/2 paxillin binding site 1/2 
PCR  polymerase chain reaction  
PDGF  platelet derived growth factor 
PDGFR platelet derived growth factor receptor 
PI  phosphatidylinositol 
PI3K  phosphatidylinositol 3 kinase 
PLCɣ  phospholipase C gamma 
PTB  phosphor-tyrosine binding 
PTEN  phosphatase and ten-sin homolog  
PTP  protein tyrosine phosphatase 
Pyk2  protein tyrosine kinase 2 
qRT-PCR quantitative reverse transcriptase – polymerase chain reaction 
RACK1 receptor for activated C kinase 1 
RAFTK related adhesion focal tyrosine kinase 
RNA  ribonucleic acid 
RT-PCR quantitative reverse transcriptase – polymerase chain reaction 
RTK  receptor tyrosine kinase 
SCC  squamous cell carcinoma 
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SEM  standard error of the mean 
SDS  sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SFK  Src family kinases 
SH  Src homology  
Shc  Src homologous and collagen-like protein 
siRNA  short interfering RNA 
SRB  sulforhodamine B  
TAM  Tyro-3, Axl, and Mer 
uPA  urokinase-type plasminogen activator 
UVRAG UV radiation resistance-associated gene 
VEGF  vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
WT  wild type 


















1.1 Protein tyrosine kinases 
Protein kinases are enzymes that transfer phosphate groups from adenosine-5’-
triphosphate (ATP) molecules to the side chains of specific amino acids present on 
target proteins. The result of this process is phosphorylation and this alters the 
biological properties of the target protein. According to which type of amino acid 
residue that is phosphorylated, protein kinases can be divided into either tyrosine or 
serine/threonine kinases. However, some kinases may display a dual specificity for 
both tyrosine and serine/threonine residues. 
Based on their topology and localisation, protein tyrosine kinases can be further 
divided into two families: receptor tyrosine kinases (RTKs) and non-receptor protein 
tyrosine kinases (NRTKs) [reviewed in (Neet and Hunter, 1996; Ullrich and 
Schlessinger, 1990)].  
Approximately 90 tyrosine kinase genes have been identified within the human 
genome, 58 of which are RTKs and the remaining 32 encode NRTKs [reviewed in 
(Robinson et al., 2000)].  
1.1.1 Receptor tyrosine kinases 
RTKs are transmembrane proteins that are responsible for signal transduction across 
the plasma membrane. They enable cells to respond to changes in their environment. 
Through phosphorylation RTKs regulate various intracellular signaling pathways 
that control cellular processes, such as proliferation, differentiation and apoptosis. 
They also have a critical role in development and disease. Based on the kinase 
domain sequence they are grouped into 20 subfamilies, and well known examples 
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include the epidermal growth factor receptor (EGFR), platelet derived growth factor 
receptor (PDGFR), fibroblast growth factor receptor (FGFR), and Tyro-3, Axl, and 
Mer (TAM) RTKs [reviewed in (Lemmon and Schlessinger, 2010)]. 
The majority of RTKs are single transmembrane receptors and possess a similar 
molecular architecture with an extracellular N-terminal region that binds to ligands, a 
single hydrophobic membrane-spanning region which plays a key role in receptor 
dimerisation, and a cytoplasmic portion that contains the tyrosine kinase activity 
[reviewed in (Maruyama, 2014)]. 
The extracellular portion of RTKs usually has a highly variable, multi-domain 
structure, with the most common modules being immunoglobulin-like repeats, 
fibronectin-type III repeats and cysteine rich domains. The variability of these 
extracellular domains provides the specificity for ligand binding [reviewed in 
(Hubbard and Miller, 2007)]. The intracellular domains of RTKs are more 
structurally similar and contain highly conserved tyrosine kinase domains. The 
kinase domains are frequently flanked by juxtamembrane domains and a carboxy-
terminal (C-terminal) tail, which are important for kinase regulation and downstream 
signaling [reviewed in (Lemmon and Schlessinger, 2010)]. 
The mechanism of RTK activation has been thoroughly characterised through 
structural and biochemical studies. It is now accepted that activation of RTKs occurs 
by oligomerisation of its ligand to the extracellular domain, which triggers the 
formation of functional dimeric receptors [reviewed in (Schlessinger, 2000)]. 
Dimerisation may occur between identical receptors, between isoforms of the same 
receptor or between members of the same subfamily. Dimerisation of the receptors 
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brings together the two kinase domains, which then phosphorylate a tyrosine residue 
present in the activation loop of each other [reviewed in (Schlessinger, 2000)]. 
Phosphorylation increases the catalytic activity and leads to the phosphorylation of 
other tyrosine residues present in the molecule, thereby forming docking sites for 
several downstream signal transduction proteins with Src homology (SH2) or 
phosphotyrosine-binding (PTB) domains (Figure 1) [reviewed in (Lemmon and 
Schlessinger, 2010; Schlessinger and Lemmon, 2003)]. These proteins are, in turn, 
phosphorylated and activated by the growth factor receptors, hence leading to the 
activation of a series of signaling pathways that mediate their biological effects. It 
has been shown that heterodimerisation may result in different autophosphorylation 
states compared to homodimerisation, therefore contributing to the diversity of 
signaling (Olayioye et al., 1998). 
Signaling processes linked with RTKs are often altered in tumour cells, and are 
associated with their more aggressive cellular growth or increased invasiveness. 
Therefore, RTKs have become of great interest as targets for anti-cancer therapies. 
There are two main categories of RTK inhibitors currently being developed: small-
molecule inhibitors that target the ATP-binding site of the intracellular tyrosine 
kinase domain and monoclonal antibodies (mAbs) that are directed against the 
extracellular domain of RTKs [reviewed in (Fauvel and Yasri, 2014; Shawver et al., 
2002; Zwick et al., 2002)]. One of the successful small-molecule inhibitor that is 
approved for patients with advanced non-small cell lung cancer (NSCLC) is 
Gefitinib (ZD1839, Iressa). Gefitinib inhibits the EGFR kinase activity by binding 
the ATP-binding site within the catalytic domain. Most patients with NSCLC that 
respond to Gefitinib treatment carry somatic mutations within the ATP-binding 
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pocket of EGFR. It has been shown that Gefitinib may mediate anti-tumour activity 
by inhibition of anti-apoptotic signals transduced by the mutant receptor (Sordella et 
al., 2004).  
Anti-RTK mAbs might work by preventing ligand-receptor interaction. They bind 
either to the ligand or the receptor. In the case of human breast cancers, cells 
expressing a constitutively active mutant form of the HER2 receptor enable the 
uncontrolled proliferation of cancer cells, even in the absence of EGF, which is 
required for the proliferation of normal cells. Mutations of HER2 gene occur mainly 
in the kinase domain of the receptor and result in conformational change and 
increasing kinase activity (Bose et al., 2013). Trastuzumab (herceptin), the 
humanized monoclonal antibody that targets HER2, benefits patients with early and 
locally advanced breast cancer (Moja et al., 2012). More recently, it is used for the 
treatment of metastatic disease as well. One of the mechanisms by which 
trastuzumab inhibits tumour growth is mediated through inhibition of the PI3K/Akt 
pathway. Trastuzumab binds to HER2 and blocks Src signalling and therefore 
increases the phosphatase and ten-sin homolog (PTEN) level and activity. PTEN is a 
phosphatase that negatively regulates Akt activity. Suppression of Akt signaling 
results in reduction in tumour cell growth and survival (Nagata et al., 2004). In 
addition, trastuzumab inhibits HER2 cleavage and generation of the active truncated 
membrane-bound fragment p95HER2 (Molina et al., 2001). Moreover, antibody 
dependent cellular cytotoxicity has been suggested as a possible mechanism of action 
of trastuzumab (Petricevic et al., 2013). Despite the responsiveness to this inhibitor, 
the majority of patients who initially respond to trastuzumab develop resistance 




Figure 1.1 Activation of a receptor tyrosine kinase through phosphorylation 
The receptor tyrosine kinase protein contains an extracellular domain that binds to ligand (in red), 
single membrane spanning region (in blue) and cytosolic domain that contains kinase catalytic site (in 
black). In the absence of a ligand, the tyrosine kinase domain is in a low-activity state. Ligand – 
mediated dimerisation leading to tyrosine kinase activation and tyrosine phosphorylation. After 
phosphorylation kinase domains become fully active and phosphotyrosines serve as docking sites for 
SH2 domain - containing proteins. 
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prevention of trastuzumab binding to HER2 receptor (Price-Schiavi et al., 2002), the 
upregulation of HER2 downstream signaling pathways (Pandolfi, 2004), signaling 
through alternate pathways as IGF-1R, c-Met (Lu et al., 2004; Shattuck et al., 2008), 
and failure to trigger an immune-mediated destruction of tumour cells [reviewed in 
(Pohlmann et al., 2009)]. 
1.1.2 Non-receptor protein tyrosine kinases 
NRTKs typically contain a tyrosine kinase domain, and protein-protein, protein-lipid 
and other interaction domains. Protein-protein interaction domains include SH2 and 
SH3 domains [reviewed in (Hubbard and Till)]. An SH2 domain (~100 residues) 
enables the protein carrying it to associate with another protein’s phosphotyrosine 
residue in a sequence specific manner, thus forming a physical complex between 
these two proteins. The SH3 domain (~60 residues) binds specifically to proline-rich 
sequence domains present on target proteins. Protein-lipid interaction domains, such 
as pleckstrin homology (PH) domains and FERM domains, can bind to 
phosphorylated phosphatidylinositol lipids that can lead to the recruitment of these 
proteins to the membrane. These are only a few examples of a very large number of 
modular protein/lipid interaction domains [reviewed in (Balla, 2005)]. 
Activation of NRTKs occurs through the phosphorylation of tyrosine residues 
present within the activation loop and results in increased enzymatic activity. 
However, tyrosine phosphorylation can also negatively regulate kinase activity, for 
example the phosphorylation of SrcY527 holds the molecule in a closed inactive 
conformation [reviewed in (Boggon and Eck, 2004)].  
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The family of NRTKs include, among others, the Src family kinases, the family of 
Janus kinases (JAKs), focal adhesion kinases (FAK) and the Abelson (ABL) family 
kinases. NRTKs regulate multiple cellular processes, including cell proliferation, 
survival, adhesion and migration that are crucial for tumour progression and 
metastasis; therefore, they become useful targets for anti-cancer therapy. One of the 
first successful small-molecule inhibitors that are approved by the US Food and Drug 
Administration (FDA) is Gleevec (Imatinib mesylate) (Zhang et al., 2009). Gleevec 
inactivates the kinase activity of the BCR-ABL fusion protein in Chronic Myeloid 
Leukemia (CML). Patients with CML treated with Gleevec often experience relapse 
due to drug-resistance. The main reason to this is point mutations within the BCR-
ABL kinase domain (Shah et al., 2002).  
1.2 Src kinase family members 
The Src kinase family is a family of NRTKs that includes nine members: Src, Lck, 
Hck, Fyn, Yes, Lyn, Blk, Fgr and Yrk. These are all regulatory proteins, which play 
a key role in cell differentiation, motility, proliferation and cell survival [reviewed in 
(Boggon and Eck, 2004; Engen et al., 2008)]. All the members of this family share 
the same domain organisation structure, with modular SH3, SH2 and tyrosine kinase 
domains followed by a C-terminal regulatory tail. All Src-family members also 
contain an N-terminal membrane-targeting region, which is always myristoylated, 
and in some Src-family members may be additionally palmitoylated. In addition, 
each family member also has 50-80 unique amino acids in their N-termini, which are 
involved in interactions with specific receptors or proteins [reviewed in (Boggon and 
Eck, 2004).  
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Each Src-family member has a different pattern of cellular expression and 
localisation. While some family members are ubiquitously expressed, such as Yes, c-
Src and Fyn, others demonstrate a restricted distribution. It has been shown that Lck 
plays a critical role in T-cell signalling, however Hck is expressed primarily in 
monocytic and granulocytic hematopoietic cells [reviewed in (Korade-Mirnics and 
Corey, 2000; Thomas and Brugge, 1997)]. 
1.2.1 c-Src 
In 1911, Peyton Rous discovered that a cell-free extract of a chicken tumour was able 
to induce oncogenesis in other healthy chickens. The ‘filterable agent’, later called 
Rous sarcoma virus, could cause cancer was at first controversial, but in 1970 it was 
proven that the malignant properties of RSV could be attributed to a viral gene, v-
Src. Subsequent research discovered a cellular equivalent of v-Src, termed cellular 
Src (c-Src) (Stehelin et al., 1976). This gene was found to be conserved within the 
vertebrate genome thereby indicating that the v-Src gene had been incorporated into 
the viral genome through recombination. Upon the characterisation of the v-Src and 
c-Src proteins, Src was shown to be a NRTK involved in signal transduction. 
1.2.2 Structure of Src 
The Src protein is 60kDa and is widely expressed in mammalian cells, with 
particularly high levels present in the brain, platelets and osteoclasts. 
The structure of Src and its regulation are well understood as a result of both 
structural and mutational studies. Src consists of four domains: a unique amino-
terminal domain containing a myristoylation segment; two SH domains, SH2 and 
SH3; a protein-tyrosine kinase domain, containing tyrosine Y416 (Y419, human); 
and a carboxy-terminal tail containing a negative regulatory tyrosine residue Y527 
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(Y530, human), which interacts with the SH2 domain following C-terminal Src 
kinase (Csk)-mediated phosphorylation. In v-Src Y527 is mutated, rendering it 
constitutively activated (Figure 2) [reviewed in (Engen et al., 2008)]. 
N-terminal myristoylation is required for both membrane localisation and biological 
activity of Src and it is crucial for the transformation of oncogenic Src mutants as 
mutations in the N-terminal domain reduce the transforming potential of v-Src. The 
SH2 domain of Src contains approximately 100 amino acids and it is able to 
recognise and bind to sequences containing a phosphorylated tyrosine residue, whilst 
the SH3 domain binds to proline-rich (PXXP) segments of target proteins [reviewed 
in (Boggon and Eck, 2004; Engen et al., 2008)]. The tyrosine kinase domain has a 
two-lobe structure that is also common to other protein kinases.  
1.2.3 Src activation 
In normal cells Src activity is tightly regulated, 90-95% of Src is in an inactive state 
and becomes transiently activated during specific cellular events. Several 
mechanisms of activation of Src have been proposed [reviewed in (Bjorge et al., 
2000; Ingley, 2008; Okada, 2012)].  
Phosphorylation of Y527 is one of the mechanisms for the regulation of Src activity. 
When Y527 is phosphorylated, the molecule adopts a folded, inactive configuration 
that is mediated by an intra-molecular interaction between the phosphorylated Y527 
and the SH2 domain of Src (Roussel et al., 1991). Concurrently, the SH3 domain 
binds to the linker region that connects the SH2 and kinase domains (Xu et al., 
1997). In the folded conformation, neither the SH2 nor the SH3 domain is accessible 
to the ligands. Subsequent dephosphorylation of Y527 by tyrosine phosphatases, such 




Figure 1.2 Src domain structures of cellular (c-Src) and viral (v-Src) 
The Src molecule is composed of a unique amino-terminal domain containing a myristoylation 
segment, SH2 and SH3 domains, a kinase domain with Y416 and a carboxy-terminal negative 
regulatory domain, containing Y527, which is absent in v-Src. 
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interactions of the Src tyrosine kinase and results in an ‘open’ active conformation. 
For example, over-expression of PTPα in rat embryo fibroblasts results in a 
transformed phenotype, a significant reduction in the Y527 phosphorylation level and 
increase in c-Src kinase activity (Zheng et al., 1992). Moreover, increased expression 
of PTP1B activates Src and induces a Src-dependent transformed phenotype in 
human breast epithelial cells (Arias-Romero et al., 2009). Full activation of Src also 
requires the phosphorylation of Y416, which is located in the kinase domain and this 
is achieved through autophosphorylation. Phosphorylated Y416 may stabilise the 
kinase domain in an active conformation (Martin, 1970). Once Src unfolds it 
becomes available for interacting with several molecules involved in intracellular 
signaling. In addition, Src activity can be regulated through its interaction with 
binding partners, such as FAK. FAK binds to SH2 domain of Src, disturbs the intra-
molecular interactions and results in the activation of Src (Schaller et al., 1994). 
Finally, Src activity can be regulated by ubiquitin-dependant degradation of active 
Src (Harris et al., 1999). 
Src activation can be initiated by several cellular mechanisms including growth 
factor receptors (PDGFR), G-protein coupled receptors and integrins (reviewed in 
(Bjorge et al., 2000; Ingley, 2008; Okada, 2012)]. Once activated Src signals to the 
nucleus through a variety of downstream signaling molecules, including STAT3 
(Cirri et al., 1997; Turkson et al., 1998), Ras (Smith et al., 1986), and PI3K 
(Sugimoto et al., 1984). 
1.2.4 Function of Src 
Src tyrosine kinase has multiple biological functions, including proliferation, 
differentiation, survival, the cell cycle, cell adhesion, motility and actin dynamics 
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[reviewed in (Frame, 2002; Parsons and Parsons, 2004)]. For example, Src tyrosine 
kinase is involved in the initiation of DNA synthesis (Broome and Hunter, 1997), the 
regulation of cell cycle transition G2/M (Taylor and Shalloway, 1996), and in the 
control of Myc expression by the platelet derived growth factor (PDGF) receptor 
(Broome and Hunter, 1997). In addition, Src tyrosine kinase activity is also required 
for focal adhesions turnover in order for cell migration to occur (Westhoff et al., 
2004).  
To date, nearly 200 Src binding partners have been identified including numerous 
important signaling proteins, such as FAK (Xing et al., 1994), which is a key binding 
partner and substrate in many of the functions of Src. 
1.2.5 Src and cancer 
Multiple studies have supported a role of Src tyrosine kinase in the development and 
progression of human cancers including breast, colon and pancreatic cancers, where 
Src kinase activity and protein levels are elevated [reviewed in (Chen et al., 2014; 
Irby and Yeatman, 2000; Sen and Johnson, 2011)]. These levels appear to increase 
with the stage of disease. Several mechanisms responsible for activation of Src 
kinase in cancer have been proposed [reviewed in (Irby et al., 1999)]: 1) activation 
by receptor tyrosine kinases, 2) activation through posttranslational modification, 
such as phosphorylation of Y527 by Csk, 3) activating mutations in a Src gene. For 
example, mutation in Src at codon 531 has been reported to play a role in Src 
activation in a subset of advanced human colon cancers (Irby et al., 1999). However, 
Src kinase is rarely mutated in human cancers.  
It has been shown that Src is involved in several aspects of tumour progression, 
including proliferation (Wu et al., 2013), invasion (De Luca et al., 2014), metastasis 
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(Chan et al., 2012; Zhang et al., 2012), and survival (Leung et al., 2009). Therefore, 
it is not surprising that Src become an important therapeutic target for cancer 
therapy. There are several Src kinase inhibitors that are undergoing in clinical trials, 
such as dasatinib, bosutinib and Saracatinib.  
1.3 Focal adhesion kinase 
1.3.1 FAK discovery 
FAK is a 125 kDa NRTK which was first isolated in 1992 through the co-
immunoprecipitation of tyrosine phosphorylated proteins from chicken embryo cells 
transformed with Rous sarcoma virus, v-Src (Schaller et al., 1992), and from growing 
cultures of BALB/c3T3 fibroblasts (Hanks et al., 1992). Both laboratories 
demonstrated that FAK localised to focal adhesions, and sequence and structural 
analyses suggested that it may represent a new family of protein tyrosine kinases. 
After years of extensive research, FAK has emerged as a key signaling molecule that 
plays an important role in transducing signals downstream of integrins and growth 
factor receptors. It has been shown that at focal adhesions, FAK functions as an 
adapter protein to recruit other focal adhesion proteins and their regulators. FAK is 
also involved in the regulation of a number of cellular processes, including cell 
spreading, migration, invasion, and proliferation [example references are (Brown et 
al., 2005; Owen et al., 1999; Schlaepfer and Mitra, 2004; Wang et al., 2000)].  
1.3.2 Expression of the gene encoding FAK 
The human fak gene (previously known as ptk2) has been mapped to chromosome 
8q24.3 (Fiedorek and Kay, 1995) and encodes a cytoplasmic protein tyrosine kinase 
which is 1052 amino acids in length (Whitney et al., 1993). The human FAK protein 
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shares more than 95% amino acid identity between both chicken and mouse FAK 
(Whitney et el., 1993), showing that it is well conserved during evolution.  
FAK is expressed ubiquitously and is detected in all cell types, examined so far 
mesenchymal cells, neuronal cells, platelets, monocytes and lymphocytes (Abedi and 
Zachary, 1995). 
1.3.3 FAK structure and function 
FAK contains three main domains: an N-terminal FERM (band 4.1, ezrin, radixin, 
moesin homology) domain, a central kinase domain, and a C-terminal domain 
containing the focal adhesion targeting (FAT) sequence and two proline rich regions 
(Figure 3). FAK is now believed to regulate a variety of cellular processes including 
cell migration, proliferation, survival and motility [reviewed in (Hall et al., 2011)]. 
1.3.4 FAK isoforms 
Multiple FAK isoforms occur as a result of alternative splicing or through the use of 
alternative promoters. For example, fibroblasts express an amino-terminally 
truncated form of FAK, known as FAK related non-kinase (FRNK) (Schaller et al., 
1993). FRNK mRNA is generated from an alternative promoter located within an 
intron downstream of the catalytic domain (Schaller et al., 1993) and functions as a 
physiological dominant negative inhibitor of integrin dependent FAK activity and 
downstream signaling (Richardson and Parsons, 1996), therefore exogenous 
expression of FRNK has been used as a dominant-negative mutant to inhibit FAK 
signaling in many studies. It has been proposed that FRNK inhibits FAK either by 
competitive displacement of FAK from focal adhesions or competing with FAK for 
specific binding partners and preventing downstream signal transduction (Heidkamp 




Figure 1.3 FAK domain structure and phosphorylation sites 
FAK consists of a FERM domain, a kinase domain and a carboxy-terminal domain containing the 
FAT sequence, and two proline rich regions that bind to SH3-domains of target proteins. FAK has 
multiple tyrosine phosphorylation sites, including Y397, Y407, Y576/577, Y861 and Y925.  
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The major form of alternative splice variant is known as FAK+, which contains a 
three amino acid (Pro-Trp-Arg) insertion within the C-terminal domain. It is 
expressed at very low levels in non-neuronal cells while is highly expressed in the 
central nervous system (Burgaya and Girault, 1996). Other FAK isoforms (FAK box 
6, box7 and box 28) contain alternative insertion of peptides of six, seven or twenty-
eight amino acids in length coded by additional exons surrounding the FAK-Y397 
site (Burgaya et al., 1997). The presence of additional exons does not prevent the 
targeting of FAK to adhesion sites; however alternatively spliced FAK isoforms 
exhibit elevated levels of tyrosine phosphorylation compared to wild type FAK 
(Messina et al., 2003). These isoforms are mostly found in brain tissues, thereby 
suggesting that neuronal FAK may have unique properties and/or functions. 
1.3.5 FAK family members 
A second member of FAK family was identified by four independent groups and 
termed Pyk2 (Lev et al., 1995), cell adhesion kinase β (Sasaki et al., 1995), related 
adhesion focal tyrosine kinase (RAFTK) (Avraham et al., 1995) and calcium- 
dependent tyrosine kinase (CADTK) (Yu et al., 1996). FAK and Pyk2 share around 
~45% overall sequence similarity, constituting the kinase domains, regions 
surrounding the conserved tyrosine phosphorylation sites responsible for binding 
SH2 domain containing proteins, and two proline-rich regions responsible for 
binding SH3 domain containing proteins [reviewed in (Schlaepfer et al., 1999)].  
Like FAK, Pyk2 contains a central kinase domain flanked by N- and C-terminal non-
catalytic regions. It has four tyrosine phosphorylation sites: Y402, Y579/80 and 
Y881 at analogous positions to that of FAK (Y397, Y576/577 and Y925), and Y402 
is the major autophosphorylation site. It also serves as a binding site for the SH2 
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domain of Src (figure 4) [reviewed in (Avraham et al., 2000; Lipinski and Loftus, 
2010)]. 
Alternative splicing of pyk2 mRNA transcript generates a truncated variant of Pyk2 
with a 42 amino acid deletion within the C-terminal domain (Dikic and Schlessinger, 
1998; Xiong et al., 1998), and this is mainly expressed in thymocytes, B cells, 
monocytes and natural killer cells (Dikic and Schlessinger, 1998). 
Despite their structural similarity, Pyk2 and FAK show a number of significant 
differences. While FAK is expressed in virtually almost all tissues and cell types, 
expression of Pyk2 appears to be more restricted to cells of hematopoietic lineages 
and the central nervous system (Avraham et al., 1995; Lev et al., 1995). In addition, 
despite carrying a FAT domain, Pyk2 is not normally associated with focal 
adhesions, but instead is mostly found in the perinuclear area of the cell [reviewed in 
(Schaller, 2010)]. There is also ample evidence to suggest that intracellular Ca2+ 
levels regulate its activation (Guo et al., 2004; Lev et al., 1995). While FAK-/- mice 
die at approximately day 9 of embryonic development (Ilic et al., 1995), Pyk2 
deficient mice remain viable and fertile (Guinamard et al., 2000). 
Several reports showed that deletion of FAK could lead to increased expression of 
Pyk2 to compensate for the loss of FAK (Fan and Guan, 2011; Sieg et al., 1998; 
Weis et al., 2008). For example, Pyk2 protein expression was upregulated in 
mammary cancer stem cells (MaCSCs) and metastatic nodules after FAK deletion in 
mammary tumour cells (MFCKO-MT mice), and its inhibition significantly reduced 




Figure 1.4 Pyk2 domain structure and phosphorylation sites 
Pyk2 is composed of amino-terminal FERM, kinase, and carboxy-terminal FAT domains. It also has 
three proline rich regions that mediate interaction with SH3-domain containing proteins. Pyk2 has 
four tyrosine phosphorylation sites. Y402 is an autophosphorylation site which serves as a docking 
site for SH2 domain of Src. Adapted from (Lipinski and Loftus, 2010). 
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1.3.6 FAK phosphorylation  
FAK has multiple phosphorylation sites (Y397, Y407, Y576, Y577, Y861 and 
Y925), among which, Y397 is the autophosphorylation site of FAK and is involved 
in its initial activation following integrin engagement (Calalb et al., 1995; Schaller et 
al., 1994; Schlaepfer and Hunter, 1996). Moreover, phosphorylated Y397 is required 
for interactions with a number of SH2 domain containing proteins, including the Src 
family of protein tyrosine kinases (Xing et al., 1994), the regulatory subunit of 
phosphoinositide (PI) 3-Kinase, p85 (Chen et al., 1996), the Src homologous and 
collagen-like protein (Shc) (Barberis et al., 2000), the growth factor receptor bound 
protein 7 (Grb7) (Han and Guan, 1999), and phospholipase C gamma (PLCγ) (Zhang 
et al., 1999).  
Recruitment of Src to phosphorylated FAK-Y397 is important event as it promotes 
Src dependent phosphorylation of some of the remaining FAK tyrosine residues 
[reviewed in (Schlaepfer et al., 1999)]. Phosphorylation of Y576 and Y577, which 
are located in the activation loop of the kinase domain, is necessary for full catalytic 
activity, and mutation of these residues reduces FAK catalytic activity (Calalb et al., 
1995). However, mutagenesis studies demonstrated that FAK-Y397 is also important 
for its maximal kinase activity and downstream signaling (Calalb et al., 1995). 
Moreover, it has been demonstrated that FAK-Y576/577 may regulate trans-
phosphorylation of FAK on Y397 (Leu and Maa, 2002). Src can also phosphorylate 
Y861 and Y925 located in the C-terminus of FAK. Phosphorylation of Y861 
promotes the binding of FAK to the cytoplasmic tails of integrins, which is necessary 
for VEGF stimulated migration (Eliceiri et al., 2002). It is also thought that 
phosphorylated Y861 mediates the anti-apoptotic activity of FAK (Abu-Ghazaleh et 
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al., 2001). Phosphorylated Y925 creates binding sites for Grb2-SH2 (Schlaepfer et 
al., 1994) and this provides a mechanism of activation for the Ras/mitogen-activated 
protein kinase (MAPK) pathway (Schlaepfer et al., 1994; Schlaepfer et al., 1999). In 
addition, Grb2 binding to Y925 also recruits dynamin to focal adhesions, which is 
important in their disassembly (Ezratty et al., 2005). Therefore, Src dependent 
phosphorylation of FAK plays an important role in multiple signaling pathways 
downstream of integrins and growth factor receptors.  
At least four different serine phosphorylation sites (S732, S840, S843 and S910) 
have been recognised within the C-terminal domain of FAK (Ma et al., 2001). 
Although the function of these serine residues has been less well studied, there is 
evidence, which implies that the phosphorylation of these serine residues is 
associated with FAK inactivation, such as during mitosis (Ma et al., 2001).  
1.3.7 The FERM domain of FAK 
The FERM domain is named after the four proteins it was originally identified in, 
band 4.1, ezrin, radixin and moesin. FERM domains are found in many cytoskeletal 
proteins as well as in signaling proteins and multiple tyrosine phosphatases, and they 
serve as a link between the actin cytoskeleton and the plasma membrane [reviewed in 
(Girault et al., 1999)]. In general, FERM domains have been shown to mediate both 
intra-molecular and inter-molecular protein-protein interactions (Dunty et al., 2004; 
Girault et al., 1999). FERM domains are constructed of three sub-domains (F1, F2 
and F3) that adopt a clover-leaf structure and share structural homology with 
ubiquitin, acyl-CoA-binding protein and pleckstrin homology-phosphotyrosine 
binding (PH-PTB) domains respectively [(Ceccarelli et al., 2006), reviewed in 
(Frame et al., 2010)].   
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The FAK-FERM domain associates with several target proteins, including the 
cytoplasmic tail of β1 integrin (Chen et al., 2000), growth factor receptors such as 
EGFR (Sieg et al., 2000), the epithelial and endothelial tyrosine kinase (ETK) (Chen 
et al., 2001), the actin related protein 3 (Arp3) subunit of the Arp2/3 complex 
(Serrels et al., 2007), the hepatocyte growth factor receptor c-Met (Chen and Chen, 
2006), the EphA2 receptor tyrosine kinase (Carter et al., 2002), and the scaffolding 
protein receptor for activated C kinase 1 (Rack1) (Serrels et al., 2010). For example, 
FAK directly binds to Met through its F2 sub-domain and promotes HGF-induced 
cell invasion (Chen and Chen, 2006). Moreover, FAK interactions have been shown 
to play a role in the regulation of multiple cellular processes, such as the formation of 
early adhesion structures required for cell spreading, and for directional sensing 
required during cell polarity and invasion (Serrels et al., 2010).  
In addition to protein binding, there are indications that the FAK FERM domain is 
also involved in the regulation of FAK activity and phosphorylation, as deletion of 
the amino-terminal domain of FAK leads to an increase in kinase activity (Cooper et 
al., 2003). There is also evidence demonstrating that deletion of the first 375 amino 
acids of FAK leads to elevated FAK phosphorylation even when Y397 is mutated to 
phenylalanine (Cohen and Guan, 2005). This finding suggests that under certain 
conditions FAK phosphorylation may be Src independent.  
Structural and functional studies suggested that FAK activity is regulated via intra-
molecular interactions (Dunty et al., 2004; Lietha et al., 2007). The direct interaction 
between the N-terminal FERM and kinase domains masks both the linker region 
containing FAK-Y397 and the activation loop within the kinase domain (Lietha et 
al., 2007), therefore displacement of the FERM domain is an important initial step in 
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FAK activation. Binding of FERM domain interacting protein partners, such as C-
Met, leads to FAK activation (Chen and Chen, 2006), whereby the FERM domain is 
released and FAK-Y397 is autophosphorylated. This is followed by Src binding to 
the autophosphorylation site of FAK in order to facilitate phosphorylation of the 
remaining five tyrosine residues (Y407, Y576, Y577, Y861 and Y925) [reviewed in 
(Mitra et al., 2005)], thereby resulting in a fully activated FAK molecule. 
Although FERM domains are known to bind cytoskeleton- or membrane-linked 
proteins, it seems that the FAK FERM domain has yet another function. Under 
conditions of cellular stress, the FERM domain can facilitate nuclear translocation of 
FAK (Lim et al., 2008). This nuclear targeting of FAK is due to the presence of a 
nuclear localisation signal (NLS) sequence in the FERM domain of FAK (Lim et al., 
2008). Nuclear FAK has been shown to promote cell proliferation and survival 
through FERM-enhanced degradation of the p53 protein (Lim et al., 2008). 
1.3.8 The kinase domain of FAK 
This domain shares a high degree of sequence similarities with other protein tyrosine 
kinases; however, unlike some other NRTKs, FAK does not contain SH2 and SH3 
domains that are involved in protein-protein interactions (Schaller et al., 1992).  
Although recent studies show that the FAK FERM domain has a prominent role in 
the intramolecular regulation of FAK activity by binding to the kinase domain 
(Cooper et al., 2003; Lietha et al., 2007), previous studies have indicated that FAK 
kinase activity can also be regulated in several other ways: by direct binding of the 
negative regulator FAK-interacting protein of 200kDa (FIP200) to the kinase domain 
(Abbi et al., 2002); by interactions with SOCS proteins, such as SOCS-3 and SOCS-
1, which target FAK for poly-ubiquitination and degradation (Liu et al., 2003), by 
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competition with FRNKs for focal adhesion binding sites (Nolan et al., 1999), and by 
PTPs such as PTPα which act upstream to regulate FAK-Y397 phosphorylation in 
response to integrin stimulation (Zeng et al., 2003). 
Moreover, it has been shown that FAK activity is regulated through its interaction 
with lipids such as phosphatidylinositol 4,5-biphosphate (PIP2) binds to the FAK 
FERM domain and triggers conformational changes in FAK (Cai et al., 2008).  
1.3.9 The C-terminal domain of FAK 
The C-terminal domain of FAK includes the focal adhesion targeting (FAT) 
sequence and two proline-rich regions located between the FAT sequence and the 
kinase domain. The importance of the FAT domain comes from the fact that it is 
both necessary and sufficient for targeting of FAK to focal adhesions, which was 
demonstrated by deletion experiments (Hildebrand et al., 1993). Deletion of amino-
terminus of FAK had no effect on the localisation of FAK, while the deletion of FAT 
domain abolished its focal adhesion localisation. Moreover, when the FAT domain 
was fused to cytosolic protein, was capable of mediating focal adhesion localisation 
(Hildebrand et al., 1993; Hildebrand et al., 1995).  
The FAT domain has been shown to bind to two focal adhesion associated proteins, 
paxillin and talin (Chen et al., 1995; Hildebrand et al., 1995). Paxillin is one of the 
first proteins recruited to focal adhesions as they are formed, and there are two 
binding sites for paxillin within the FAT domain of FAK, known as paxillin binding 
site 1 (PBS1) and 2 (PBS2) (Hildebrand et al., 1995). FAK is recruited to focal 
adhesions through its interaction with paxillin, and the disruption of this interaction 
leads to mislocalisation of FAK (Tachibana et al., 1995). This suggests that binding 
of paxillin to FAK is necessary for proper localisation. This is further supported by 
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data showing that in the absence of paxillin there is inefficient localisation of FAK to 
focal adhesions (Hagel et al., 2002). However, the requirement for paxillin in FAK 
adhesion recruitment is controversial, because other studies have shown that FAK 
mutants that are unable to bind paxillin can still correctly localise to focal adhesions 
(Hildebrand et al., 1995; Schaller et al., 1993). Therefore, the role of paxillin binding 
to FAK in focal adhesion localisation remains unclear. 
Talin is an adaptor protein, which was initially discovered as a protein highly 
enriched at focal adhesion site (Burridge and Connell, 1983). It has been 
demonstrated that talin plays an essential role in ‘inside-out’ signaling required for 
integrin activation. For example, Talin head domain binds to the integrin β-tail and 
induces the conformational changes in the integrin ectodomain (Ye et al., 2010a). 
Talin contains an N-terminal head (talin-H) followed by a rod domain (talin-R). 
Talin-H consists of four sub-domains: F0, F1, F2 and F3, from which F2 and F3 are 
involved in binding to FAK [reviewed in (Das et al., 2014)]. Although it was widely 
believed that talin is required for FAK recruitment and activation at focal adhesions 
(Chen et al., 1995; Zhang et al., 2008), Lawson et al. have recently proposed an 
alternative model, which suggests that it is FAK that recruits talin to focal adhesions 
(Lawson et al., 2012). When talin binding site on FAK is mutated, talin fails to 
localise to nascent adhesions, however this mutation does not disrupt integrin-
mediated FAK recruitment and activation (Lawson et al., 2012). 
The proline-rich regions of FAK mediate interactions with SH3 domain containing 
proteins, such as p130Cas (Polte and Hanks, 1995), c-Cbl associated protein (CAP) 
(Ribon et al., 1998), GTPase regulator associated with FAK (GRAF) (Hildebrand et 
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al., 1996) and Arf-GAP containing a SH3 domain, ankyrin repeats, and PH domain 
(ASAP1) (Liu et al., 2002). 
P130Cas is an adaptor protein that plays a central role in actin cytoskeletal 
reorganization. Its interaction with proline-rich region of FAK spanning amino acids 
712-718 was first identified using a two-hybrid screen, which was later confirmed by 
co-immunoprecipitation (co-IP) experiments in mouse fibroblasts (Polte and Hanks, 
1995). CAP is an adaptor protein that plays a key role in the regulation of the actin 
cytoskeleton and cell adhesion. It consists of N-terminal sorbin homology (SoHo) 
domain and three C-terminal SH3 domains [reviewed in (Tomasovic et al., 2012)]. 
GST pull-down experiments showed that CAP interacts with FAK through the third 
SH3 domain (Ribon et al., 1998). GRAF bids to proline-rich regions of FAK through 
SH3 domain interaction and preferentially stimulates RhoA and cdc42 activity 
(Hildebrand et al., 1996). ASAP1 interacts with proline-rich motif of FAK via its C-
terminal SH3 domain. It has been shown that over-expression of ASAP1 inhibits cell 
spreading and the localisation of paxillin and FAK to focal adhesions (Liu et al., 
2002). 
1.4 FAK regulation of cellular functions 
FAK plays an important role in the regulation of several biological processes, 
including cell proliferation, cell migration, cell survival and apoptosis [reviewed in 
(Abbi and Guan, 2002)]. In this section the evidence associating FAK with these 
biological processes will be discussed, with an emphasis on the relevance to cancer.  
  
 44 
1.4.1 FAK – proliferation and cell cycle 
Numerous studies have demonstrated a regulatory role of FAK in cell cycle 
progression. For example, inhibition of FAK through the expression of exogenous 
dominant negative FRNK, or by microinjection of anti-FAK monoclonal antibodies, 
causes cell cycle arrests at G1/S phase boundary (Gilmore and Romer, 1996; 
Hungerford et al., 1996). Early experiments suggested that FAK may regulate cell 
cycle progression through regulating transcription of cyclin D1 (Zhao et al., 2003; 
Zhao et al., 2001).  
Overexpression of FAK in smooth muscle cells increased expression of S-phase 
kinase-associated protein 2 (Skp2) and increased proliferation (Bond et al., 2004). 
FAK stabilises Skp2 protein that recognises phosphorylated p27Kip1, and facilitates 
its ubiquitination and degradation. p27Kip1 is a negative regulator of the cell cycle 
[reviewed in (Sgambato et al., 2000)]. 
In addition, FAK is necessary for EGF-mediated proliferation (Flinder et al., 2013). 
In this study, the authors showed that hepatocytes transfected with various FAK 
mutants (FAK-Y397F, FAK-Y861F and FAK-Y925F) demonstrated markedly lower 
level of Cdk2 expression in response to EGF compared to cells expressing FAK-WT, 
suggesting that Cdk2 protein expression is regulated by FAK.  
Although, FAK signaling plays a role in the regulation of cell cycle progression, it 
does not appear to be required. For example, FAK-/- cell and cells treated with FAK 
RNAi still proliferate (Ilic et al., 1995). 
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1.4.2 FAK and cell migration 
Cell migration is central to many physiological and pathological processes, including 
embryonic development, wound healing, inflammation and tumour metastasis. Cell 
migration involves a continuous formation, maturation and disassembly of focal 
adhesions that are formed the edge of the lamellipodial protrusions in spreading cells 
[reviewed in (Gardel et al., 2010; Jockusch et al., 1995)]. The function of focal 
adhesions is to link actin filament bundles to the extracellular matrix (ECM) via 
integrins, and hence provides the traction required for cell migration. Many proteins 
are present in focal adhesions that specifically control the actin dynamics required 
during cell migration, such as adaptor proteins, structural proteins, and cell surface 
receptors, including integrins and other signaling molecules. 
There is ample evidence indicating the positive role of FAK in cell migration via 
multiple signaling partners. Initial studies in FAK deficient mouse embryo 
fibroblasts (MEFs) demonstrated that a FAK deficiency led to a reduction in the rate 
of focal adhesion turnover, and impaired integrin and growth factor induced cell 
migration [reviewed in (Parsons et al., 2000)]. This defect in cell migration was 
rescued by reconstitution of FAK-deficient cells with wild type FAK, but not by 
FAK mutants lacking kinase activity (FAK-KD) or lacking the autophosphorylation 
site (FAK-Y397F) and thus the ability to bind Src family kinases, demonstrating that 
the catalytic activity of FAK is required. Further evidence indicates that FAK 
mutants that cannot bind to p130Cas also fail to induce cell migration (Reiske et al., 
1999). Similarly, over-expression of FAK in Chinese hamster ovary fibroblasts led to 
enhanced migration (Cary et al., 1996), while overexpression of the C-terminal 
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portion of FAK, functions as a dominant negative FAK and inhibits cell migration 
(Gilmore and Romer, 1996).  
In our laboratory, work showed that FAK, via its FERM domain, could bind directly 
to, and activate the actin-related protein 2/3 (Arp2/3) complex, thereby stimulating 
leading edge protrusion (Serrels et al., 2007). Arp2/3 complex binds to the side of an 
existing actin filaments and stimulates the formation of branched actin filament 
networks [reviewed in (Campellone and Welch, 2010)]. 
Furthermore, inhibition of FAK expression in mouse fibroblasts by the FAK siRNA 
resulted in altered lamellipodia formation (Tilghman et al., 2005). As the 
lamellipodium is an important structure for the establishment of polarity during 
migration, this work suggests that, the ability of FAK to control cell migration is 
achieved through the regulation of cell polarity. Work produced in our laboratory 
indicates that FAK indeed controls directional cancer cell migration via cell polarity 
(Serrels et al., 2010). FAK promotes PDE4D5 recruitment to the leading edge of 
polarising cells via the molecular scaffold RACK1. It has been shown that 
FAK/RACK1/PDE4D5 complex is necessary for nascent adhesion stabilisation and 
wound-induced polarisation.  
In addition, FAK promotes cell migration through direct modulation of the proteins 
that are involved in the re-modelling of the actin cytoskeleton, including the Rho 
subfamily of small GTPases and Neuronal Wiskott-Aldrich syndrome protein (N-
WASP) (Ren et al., 2000; Wu et al., 2004). For example, FAK binds to N-WASP and 
promotes its function by regulating its sub-cellular localisation. N-WASP then 
activates the Arp2/3 complex to induce actin polymerisation (Wu et al., 2004). 
  
 47 
Finally, Grb7 is required for FAK effects on migration (Han and Guan, 1999; Han et 
al., 2000). Therefore FAK regulates multiple pathways required for efficient cell 
movement.  
1.4.3 FAK and cell invasion 
Cell invasion is a complex process that can occur through changes in the surface 
expression of integrins [reviewed in (Hood and Cheresh, 2002)], the release of 
matrix metalloproteinases (MMPs) that are involved in the degradation of the ECM 
[reviewed in (Fingleton, 2006)] and by changes in gene expression in transformed 
cells (Johnston et al., 2000).  
FAK is critical for cell invasion and metastasis through regulating the expression and 
activation of MMP2, MMP9 and membrane type 1 (MT1)-MMP (Hsia et al., 2003; 
Wang and McNiven, 2012). Degradation of the ECM by MMPs is mediated by 
specialised surface protrusions, knows as podosomes (Wu et al., 2005) and 
invadopodia (Linder, 2007). Invadopodia is also known as podosome type adhesion. 
Both podosomes and invadopodia contain ‘actin-rich core’ that is formed by proteins 
involved in actin nucleation. Although, podosomes and invadopodia share similar 
overall architecture, there are some differences, such as, in podosomes ‘actin-rich 
core’ is surrounded by a ring structure formed integrin receptors, mainly β2 and β3 
integrins. However, this organisation is not well defined in invadopodia [reviewed in 
(Block et al., 2008; Murphy and Courtneidge, 2011)]. It has been shown that FAK 
promotes the expression of MMP9 and the activation of MMP2 through the 
Src/p130Cas/Dock180 signaling cascade. This cascade induces activation of Rac and 
c-Jun NH2-terminal kinase (JNK). Subsequent phosphorylation and activation of c-
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Jun led by Rac and JNK activation, mediates the transcription of several genes, 
including MMP genes (Hsia et al., 2003).  
The FAK/PI3K/AKT signaling pathway also contributes to hepatocellular carcinoma 
(HCC) cell invasion through the regulation of MMP2 and MMP9 (Chen et al., 2013). 
MMP2 and MMP9 expression and activation, and HCC cell invasion, are abolished 
by siRNA-mediated FAK knockdown (Chen et al., 2013). Moreover, fibronectin 
induced lung cancer cell migration and invasion occurs through 
FAK/PI3K/MMP9/RhoA signaling pathway (Meng et al., 2009). In addition, 
dominant-negative inhibition of FAK activity by FRNK inhibited v-Src stimulated 
cell invasion through Matrigel and blocked experimental metastasis in a nude mouse 
(Hauck et al., 2002). This was associated with decreased MMP2 mRNA levels and 
MMP2 secretion.  
Over-expression of MT1-MMPs has been found in many human tumours and is 
associated with increased invasion and metastasis [reviewed in (Egeblad and Werb, 
2002)]. Although podosomes are the primary site for ECM degradation, it appears 
that this process could also take place at focal adhesions (Wang and McNiven, 2012). 
Wang and McNiven (2012) showed that ECM degradation at focal adhesions is 
MT1-MMP dependent, and that this protease is targeted to focal adhesions by a 
physical interaction with the FAK-p130Cas complex. They also demonstrated that 
MT1–FAK–p130Cas complex formation is regulated by Src mediated 
phosphorylation of Y573 at the cytoplasmic tail of MT1 (Wang and McNiven, 2012). 
MT1-MMP is a zinc dependent type 1 transmembrane metalloproteinase. Several 
substrates of MT1-MMPs have been identified, including type 1 collagen, 
fibronectin, laminin-1 and -5, CD44 and αv integrin (Sato et al., 2005). 
  
 49 
Another study suggested that FAK could contribute to cell invasion by regulating the 
expression of urokinase-type plasminogen activator (uPA). uPA is a serine proteinase 
that catalyses the conversion of plasminogen to the active proteinase plasmin, which 
is able to degrade various ECM components and basement membrane proteins, and 
plays a role in cell migration and tissue remodelling. FAK catalytic activity regulates 
uPA expression in 4T1 breast carcinoma cells, and thus facilitates metastatic breast 
cancer progression (Mitra et al., 2006a).  
Taken together, FAK appears to regulate cell motility and invasion by distinct 
pathways; by promoting the dynamic regulation of focal adhesions and peripheral 
actin structures during migration, as well as by MMP-mediated matrix degradation 
[reviewed in (Tomar and Schlaepfer, 2009)]. 
Many cancer cells can exhibit two different modes of invasion, referred to as 
mesenchymal-like (MMP dependent) and amoeboid-like (MMP independent) 
mechanisms. Mesenchymal type of invasiveness is driven by small GTPases, mainly 
by Rac and cdc42, while amoeboid-like invasiveness is promoted by the Rho/ROCK 
signaling pathway (Nobes and Hall, 1995; Sahai and Marshall, 2003). During 
mesenchymal-like invasion MMPs are recruited at focal adhesions, where they 
degrade the ECM and generate path for migration cells. However, amoeboidly 
migrating cells move without ECM degradation [reviewed in (Pankova et al., 2010)]. 
There is evidence, that some tumour cells undergo a mesenchymal to amoeboid 
transition that allows cells to invade without MMPs. For example, when HT1080 
fibrosarcoma cells were treated with protease inhibitors, they acquired an amoeboid-
like invasive phenotype, which was achieved by modulation of α2β1 integrin 
receptors. Phosphorylation of FAKY397 was also reduced in these cell lines. 
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However, it is not clear reduced FAKY397 phosphorylation is a consequence of 
suppressed integrin activity, or whether it contributes to impaired integrin mediated 
adhesion of invading cells (Carragher et al., 2006). The precise function of FAK in 
these modes of invasion remains to be explored; however, since FAK has been 
implicated in MMP expression, it is likely that FAK is required for mesenchymal-
like invasion.  
1.4.4 FAK and angiogenesis 
Angiogenesis is a process by which new blood vessels are formed from pre-existing 
capillaries. New blood vessel formation is required for many physiological processes 
such as embryogenesis, wound healing and organ regeneration. It is also an 
important factor in several pathological processes, including tumour growth and 
metastasis.  
The balance of pro- and anti-angiogenic signals tightly controls physiological 
angiogenesis; however there is an imbalance between positive and negative 
angiogenic factors in tumour cells. Several potential regulators of angiogenesis have 
been identified, including fibroblast growth factors (FGFs), vascular endothelial 
growth factor (VEGF), epidermal growth factor (EGF), and angiogenin. Tumour 
associated angiogenesis progress through two phases: the avascular phase, which 
corresponds to a small liaison of less than 2mm in diameter, and the vascular phase, 
which ensures tumour growth. These two phases are separated by ‘angiogenic 
switch’, which depends on increased production of positive regulators of 
angiogenesis (Bergers and Benjamin, 2003). 
There is a significant body of data supporting the influence of FAK on angiogenesis. 
A possible role of FAK in angiogenesis was first observed by Polte et al. in 1994, 
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since during mouse embryonic development, FAK expression was abundant within 
blood vessels (Polte et al., 1994). Furthermore, increased tyrosine phosphorylation 
and kinase activity of FAK was found in migrating human umbilical vein endothelial 
cells (HUVECs) adjacent to wounds (Romer et al., 1994), and a conditional knockout 
of FAK in mouse endothelial cells also resulted in embryonic lethality due to 
vascular defects (Shen et al., 2005). It has been shown that the in vitro deletion of 
FAK in mouse endothelial cells causes reduced tubulogenesis, decreased cell 
survival, proliferation and migration (Shen et al., 2005). In contrast, overexpression 
of FAK in vascular endothelial cells directly promotes angiogenesis in transgenic 
mice (Peng et al., 2004). Several studies have also highlighted the importance of 
FAK activity in mediating tumour angiogenesis (Halder et al., 2006; Halder et al., 
2007; Mitra et al., 2006b). For example, it has been shown that FAK regulates VEGF 
expression and induces an angiogenic switch in cancers (Mitra et al., 2006b), thereby 
suggesting that FAK kinase inhibitors could be useful anti-angiogenesis agents.  
Several anti-angiogenic drugs have been developed some of which are in clinical 
trials. Some drugs appear to directly target molecules involved in new blood vessel 
formation (SU5416), while others inhibit proliferation of endothelial cells [reviewed 
in (Rosen, 2000). SU5416 is a small molecular inhibitor, which targets VEGF 
receptor. It has been shown that anti-VEGF therapy has significant effects in various 
human cancers; however some cancer patients, who initially respond, show escape 
from anti-VEGF treatments (Loges et al., 2010). For example, there is evidence that 
blockade of VEGF signaling leads to up-regulation of other pro-angiogenic growth 
factors, such as members of FGF family (Casanovas et al., 2005).  
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1.4.5 FAK and cell survival 
Programmed cell death is a vital cellular homeostatic mechanism characterised by 
distinct biochemical (fragmentation of genomic DNA) and morphological changes 
(shrinkage of the cell, membrane blebbing, formation of apoptotic bodies) [reviewed 
in (Portt et al., 2011)]. The initiation phase of apoptosis involves the recognition of a 
death stimulus. In general, apoptosis can be triggered by two pathways called 
intrinsic or extrinsic. The intrinsic pathway is triggered by internal signals such as 
DNA damage. Two of the pro-apoptotic proteins, Bax and Bak, promote the release 
of pro-apoptotic factors from the mitochondrial inter-membrane space that leads to 
the recruitment and activation of caspase 9. The extrinsic pathway involves the 
binding of death receptors to protein ligands that are expressed on the surface of 
other cells. This binding activates the receptor that leads to the generation of 
activated caspase 8 [reviewed in (Tait and Green, 2008)]. Both of pathways 
culminate in the generation of caspase 3 and 7, which leads to the cleavage of a 
number of cellular proteins and cell death.  
The first evidence that FAK can control cell survival was reported by Frisch et al. 
(1996), who showed that a membrane targeted, activated form of FAK was able to 
rescue kidney epithelial cells from suspension-induced cell death, known as anoikis 
(Frisch et al., 1996). Anoikis is a Greek word and means “without house”, thus they 
used this word to describe the apoptotic response of cells to the absence of cell-
matrix interaction. Their study demonstrated that both FAK-Y397 phosphorylation 
and the kinase activity of FAK were required for cell survival. In addition, increased 
FAK expression has also been linked to the suppression of apoptosis in the HL60 
leukaemia cell line and again, phosphorylation of FAK, as well as its kinase activity, 
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was required (Sonoda et al., 2000). Furthermore, inhibition of FAK by antisense 
oligonucleotide (Wu et al., 2006) or the injection of monoclonal FAK antibodies has 
been shown to induce apoptosis in different cell types (Hungerford et al., 1996; Otey, 
1998). There have also been several reports documenting that FAK associations with 
both PI3K and p130Cas are important in FAK regulated cell survival (Bellas et al., 
2002; Chan et al., 1999). For example, FAK over-expression protects endothelial 
cells from adenosine (Ado) induced apoptosis, and this protection is dependent on 
PI3K activity (Bellas et al., 2002).  
Finally, FAK has been shown to promote cell survival by affecting p53 
transcriptional activity. p53 is a nuclear transcription factor with a pro-apoptotic 
function, and FAK can both directly bind to p53 and block its transcriptional activity 
(Golubovskaya et al., 2005). FAK can also bind to Mdm2, a negative regulator of 
p53, which can lead to proteasomal degradation of p53 (Lim et al., 2008). 
1.4.6 FAK and autophagy 
One of the proteins that binds to FAK I selected for this study, is an autophagy 
protein, therefore I will describe this section in more detail.  
Autophagy is a cellular degradation pathway that involves sequestration of 
cytoplasmic materials within autolysosomes in order to maintain cell homeostasis. So 
far, three types of autophagy have been described: macro-autophagy (autophagy), 
micro-autophagy and chaperone-mediated autophagy [reviewed in (Boya et al., 2013; 
Marino et al., 2014)]. One of the first steps of autophagy is the formation of double-
membrane vesicles called autophagosomes. Autophagosomes are assembled at the 
phagophore assembly site (PAS), which is mediated by multiple autophagy-related 
(Atg) proteins. The nucleation and assembly of phagophore membrane requires 
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Beclin1/PI3K core complex consisting of PI3K class III (PI3KC3), p150 and Beclin1 
[reviewed in (Yang and Klionsky, 2010)]. Beclin1 (also named Atg6) belongs to Atg 
family of proteins. Beclin1 was shown to restore starvation-induced autophagy in 
Atg6-disrupted yeast strains, whereas Beclin1 over-expression in human MCF7 
breast carcinoma cells lacking detectable levels of endogenous Beclin1 activates 
autophagy (Liang et al., 1999). Beclin1 is a known interacting partner of PI3KC3. 
PI3KC3 is a lipid kinase that phosphorylates phosphatidylinositol (PI) to produce 
phosphatidylinositol 3-phosphate (PI3P). Beclin1/PI3K complex promotes 
generation of PI3P, which then acts as a platform for Atg and other autophagy 
proteins [reviewed in (He and Klionsky, 2009)]. p150 is a serine/threonine kinase. It 
has been shown that p150 recruits PI3KC3 to the membrane, and its intact kinase 
domain required for PI3KC3 activity (Panaretou et al., 1997). It is considered to be a 
regulatory subunit of PI3KC3.  
More recently, Ambra1 has been identified as a part of the multi-protein core 
complex (Fimia et al., 2007). It has been demonstrated that Ambra1 plays an 
important role in embryogenesis, as Ambra1 deficiency in mouse embryos causes 
neuronal tube defects, which is associated with impaired autophagy. Ambra1 is a 
positive regulator of autophagy as it binds to Beclin1 and promotes Beclin1 
association with PI3KC3 (Fimia et al., 2007).  
When autophagosome formation is completed, they are released to the cytoplasm 
where they fuse to lysosomes. Formation of autolysosomes allows degradation of 
cargo by lysosomal enzymes. The degraded products are then exported back into the 
cytosol for reuse [reviewed in (Funderburk et al., 2010)]. For example, amino acids 
and fatty acids produced by autophagy can be used to synthesise new proteins or are 
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oxidized by the mitochondria to produce ATP for cell survival. It has been shown 
that mice lacking Atg5 (Atg5-/-) die during neonatal period. These mice exhibit 
decreased amino acid levels, decreased cardiac ATP production and myocardial 
damage, demonstrating that recycling function of autophagy is critical to maintain 
cellular energy homeostasis and cell survival during the neonatal period (Kuma et al., 
2004).  
Autophagy is a tightly regulated process that plays a role in cell growth, development 
and homeostasis. Several positive or negative regulators of autophagy have been 
identified, including UV radiation resistance-associated gene (UVRAG) (Liang et al., 
2006), Bax-interacting factor-1 (Bif-1) (Takahashi et al., 2007), and B-cell 
lymphoma 2 (Bcl-2) (Pattingre et al., 2005). Autophagy was long considered to be a 
non-selective bulk protein degradation system; however, recent reports clearly 
indicate that it can also be a highly selective process. Selective autophagy is 
mediated by specific receptors, which directly bind to a cargo that needs to be 
degraded [reviewed in (Boya et al., 2013)].  
There is evidence that FAK may regulate selective autophagy of active Src in 
squamous cell carcinoma (SCC) cells (Sandilands et al., 2012a). Recent work in our 
laboratory has shown that active Src is degraded via autophagy in FAK-/- SCC cells. 
In SCC cells Src is localised at focal adhesion, however in the absence of FAK 
autophagy regulators, such as Atg12, Atg7 and LC3, can affect the trafficking of 
active Src to autophagic puncta (Sandilands et al., 2012a). Localisation of Src is 
restored to focal adhesions when FAK-WT is re-expressed to FAK-/- SCC cells, or 
when FAK-/- SCC cells are treated with autophagy inhibitor 3-Methyladenine (3-
MA). In addition, transfection of FAK-/- SCC cells with siRNA targeting either Atg5 
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or Atg12 also restores Src localisation to adhesions. Moreover, it was shown that c-
Cbl acts as a cargo receptor when FAK signaling is disrupted, suggesting that FAK 
regulates selective autophagy of active Src through c-Cbl (Sandilands et al., 2012a)  
FAK deletion also results in the selective targeting of Ret for autophagy dependant 
degradation (Sandilands et al., 2012b). Overall, these experiments suggest that FAK 
prevents the targeting of active Src or Ret to autophagosomes. 
1.4.7 FAK and cancer 
FAK is an important mediator of signal transduction by integrins and growth factor 
receptors, and participates in a wide range of cellular processes including cell 
proliferation, cell survival, adhesion, angiogenesis and migration. As the 
development of malignancy is often associated with perturbation in these processes, 
it is therefore not surprising that FAK activity is altered within cancer cells. 
Increases in FAK expression were first observed in high grade and metastatic 
sarcomas (Weiner, et al., 1994) and since then elevated FAK expression has been 
reported in many different human cancers based on Western blot and 
immunohistochemical analysis. High levels of FAK expression have been found in 
breast (Lark et al., 2005; Pylayeva et al., 2009; Watermann et al., 2005), colon 
(Owens et al., 1995), prostate (Tremblay et al., 1996), lung (Carelli et al., 2006), 
gastric (Su et al., 2002), thyroid (Owens et al., 1996), ovarian (Judson et al., 1999) 
and pre-invasive and invasive oral (Kornberg, 1998) cancers. Moreover, elevated 
expression of FAK protein, in squamous cell carcinoma (SCC) cells, is due to 
increased fak gene copy number (Agochiya et al., 1999); however, elevated FAK 
protein expression does not always correlate with copy number increase of FAK 
gene. For example, FAK expression is increased in tumours containing mutations in 
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p53. Mutant p53 does not bind to FAK promoter, and therefore does not inhibit its 
activity compared to wild type p53 (Golubovskaya et al., 2008a). 
There is also evidence that not just the over-expression of FAK, but also its 
phosphorylation and activity is correlated with malignant transformation (Benlimame 
et al., 2005; Lim et al., 2004). For example, FAK is required for oncogenic 
transformation and cell invasion mediated by ErbB2/3 receptor signaling, which 
promotes phosphorylation of FAK at Y397, Y861 and Y925 (Benlimame et al., 
2005). In this study, they overexpressed single and paired combinations of ErbB2 
and ErbB3 receptors using FAK+/+ and FAK-/- mouse embryonic fibroblasts 
(MEF), and FAK-/- MEFs in which FAK was reconstituted. They found that FAK 
deficient cells fail to promote cell transformation and invasion induced by ErbB2/3 
receptors; however, the restoration of FAK rescued the ability of ErbB2/3 receptors 
either to induce anchorage-independent growth on soft agar, or to form lung 
metastasis after intravenous cell administration. These data suggest the importance of 
FAK in these processes (Benlimame et al., 2005). It has been shown that increased 
FAK expression is frequently linked to poor prognosis; however, elevated FAK 
expression does not predict patient outcome in colon adenocarcinoma patients 
(Theocharis et al., 2003). 
It is noteworthy that mutations in FAK have not been reported in human cancers till 
recently, when FAK-Del33 mutation was identified in both breast and thyroid 
cancers (Fang et al., 2014). FAK-Del33 mutation completely deletes exon 33, which 
is located in the FAT domain of FAK, and leads to enhanced cell motility and 
migration through modulating FAK/Src signaling pathway. The frequency of fAK-
Del33 mutation is ~14.2% in breast carcinomas. 
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Although FAK overexpression, its phosphorylation and increased activity have been 
linked with tumour invasiveness and metastasis for many types of cancer, there are 
some exceptions reported. For example, weak expression of FAK in cervical cancers 
is correlated with pelvic lymph node metastasis, recurrent disease and poor prognosis 
(Gabriel et al., 2006). Moreover, FAK dephosphorylation and down regulation of its 
kinase activity is associated with EGF induced cell invasion and metastasis in human 
carcinoma cell lines over-expressing the EGFR (Lu et al., 2001). It therefore remains 
a little unclear how, and when, FAK activity contributes to cancer phenotypes – and 
there is the suggestion that this may be context-dependent. 
1.4.8 In vivo study of FAK 
The importance of FAK in cancer progression and in angiogenesis has been shown in 
several animal studies. As genetic deletion of fak is embryonic lethal (Ilic et al., 
1995) alternative approaches for modulating FAK expression and function has been 
used including gene targeting, knock-out and inducible expression of genes (Garcia 
and Mills, 2002).   
By using fak heterozygous mice (fak+/-) with reduced expression of FAK protein, it 
has been shown that FAK is required for the formation of benign skin tumours called 
papillomas, in response to DMBA/TPA induced topical carcinogenesis (McLean et 
al., 2001). However, no malignant conversion was observed in this study due to the 
fact that FAK protein expression was elevated during papilloma formation, and that 
both papillomas from fak+/- and fak+/+ mice displayed equal levels of FAK. Why 
FAK protein level is elevated during papilloma formation is unclear; however there 
is a possibility that FAK protein expression is essential for maximal H-ras signaling 
in order to induce key changes within the cell that are required for tumour initiation, 
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as it has been shown that activation of ERK by activated mutant Ras (Ras/ERK 
pathway) is still adhesion dependent, and FAK is believed to be upstream of Ras in 
signaling between integrins and the Ras/ERK pathway (McLean et al., 2001).        
Later, it was demonstrated that FAK is involved in both papilloma formation and 
their subsequent malignant conversion to carcinomas (McLean et al., 2004). In this 
study they used Cre/loxP technology to generate mice that are homozygous for 
floxed fak allele and also express 4-hydroxy-tamoxifen (4-OHT) regulated Cre 
recombinase under the control of keratin-14 promoter (K14CreERT2/FAKflox/flox) 
(McLean et al., 2004). Cre/loxP system was originally discovered in bacteriophage 
P1. Cre recombinase is an enzyme that recognises DNA sequence of loxP site and 
mediates integration and excision of DNA into and out of genomes that have loxP 
sites engineered into them. Cre/loxP system is functional in mammalian cells and 
used for generating conditional gene knockout mice models (Garcia and Mills, 
2002).  
FAK has also been directly implicated in mouse p53-induced mammary tumour 
development (van Miltenburg et al., 2014). Moreover, by using an inducible mouse 
model (Pdgfb-iCreER;FAKfl/fl), where FAK is deleted in endothelial cells, it has 
been shown that FAK is important for directional cell migration in response to VEGF 
and bFGF, reduced proliferation and increased apoptosis (Tavora et al., 2010). This 
study suggests that FAK is required for tumour angiogenesis.  
Due to its importance in tumour development and progression, several FAK kinase 
inhibitors have been developed.  
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1.4.9 FAK inhibitors 
Most widely used FAK inhibitors are: TAE226 and PF-562,271, but there are many 
others from different companies at various stages of pre-clinical or clinical testing. 
TAE226 is a small molecular inhibitor that targets the ATP binding site and inhibits 
FAK phosphorylation at both Y397 and Y861. Large number of studies using 
TEA226 FAK inhibitor has shown promising results (Golubovskaya et al., 2008b; 
Halder et al., 2007; Liu et al., 2007; Sakurama et al., 2009; Shi et al., 2007; Wang et 
al., 2008). However, this drug did not enter clinical trial due to its off-target effects 
on IGF-R1.  
PF-562,271 blocks the ATP binding site of FAK and Pyk2. It has been reported that 
PF-562,271 inhibits in vivo breast cancer cell growth and metastasis through 
induction of tumour and endothelial cell apoptosis and inhibition of migration 
(Roberts et al., 2008). Administering of PF-562,271 also prevents TGF-β signaling 
and metastasis in breast cancer mouse model (Wendt and Schiemann, 2009). 
Moreover, treatment of mice with PF-562,271 led to significant decrease in tumour 
invasion and metastasis of pancreatic cancer through inhibiting the migration of 
cancer cells, cancer-associated fibroblasts and tumour-associated macrophages, 
suggesting a novel mechanism that PF-562,271 may inhibit cancer metastasis by 
altering the tumour microenvironment (Stokes et al., 2011). In contrast with 
TEA226, PF-562,271 has been tested for phase I clinical trials targeting advanced 
solid tumours (Infante et al., 2012).  
Other FAK inhibitors include PF-04554878 and GSK2256098. PF-04554878 is 
currently in phase I clinical trials for the treatment of advanced non-hematologic 
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malignancies, while GSK2256098 has completed phase I trials [reviewed in (Dunn et 
al., 2010)]. Although FAK inhibitors show significant promise for cancer therapy, 
the nonspecific nature of the ATP binding has raised concerns about potential 
toxicity.  
Most of the FAK inhibitors block its catalytic activity. However, FAK may 
predominantly act as a scaffolding molecule rather than as a kinase, therefore, 
disruption of FAK’s interaction with protein binding partners could be a good 
strategy to inhibit some cancer processes. Only a few small molecule inhibitors that 
target protein-protein interactions (PPIs) have been developed due to the lack of 
high-throughput screening technologies and the lack of small compounds in 
compound libraries that could selectively modulate protein complexes. However, 
several recent studies led to development of appropriate methodologies that should in 
future lead to identification of potential binding sites on protein-protein interfaces, 
known as “hot spots” that could be targeted by small compounds (Gonzalez-Ruiz and 
Gohlke, 2006; Nero et al., 2014). Several small molecule inhibitors targeting FAK 
scaffolding functions have been developed, such as small molecule compounds C4, 
INT2-31, M13 and R2 (Golubovskaya et al., 2013a; Golubovskaya et al., 2013b; 
Kurenova et al., 2013; Ucar et al., 2012). M13 compound targets FAK-Mdm-2 
interaction and has been shown to significantly reduce breast and colon tumour 
growth in vivo (Golubovskaya et al., 2013b). Furthermore, R2 compound disrupts the 
binding of FAK with p53, and in turn increases p53 transcriptional activity and 
expression of p53-targets, such as p21, Mdm-2 and Bax in colon cancer cells. In 
addition, R2 blocks tumour growth in HCT116 p53+/+ xenografts in vivo 
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(Golubovskaya et al., 2013a). As these compounds do not target ATP binding site, 
they may provide new opportunities for cancer treatment. 
1.4.10 Summary and thesis aims 
FAK is a non-receptor protein tyrosine kinase that is involved in many cellular 
processes including cell proliferation, migration and apoptosis. FAK is elevated in 
the majority of human cancers. Moreover, strong correlation between FAK 
expression / phosphorylation and tumour invasive phenotypes has been found. 
Several FAK inhibitors have been developed, most of which target its catalytic 
activity. However, FAK kinase activity is not always essential for its signaling 
function; therefore development of small molecular inhibitors that prevent the 
association of FAK to its binding partners would block its downstream signaling 
pathways. 
Although there is strong evidence that FAK is an important player in tumour 
development and progression, the exact mechanism by which FAK can influence the 
processes involved in tumorigenesis and metastasis requires further studies. 
Therefore, in order to gain a better understanding of how FAK may regulate key 
processes required during tumour formation and progression, the approach adopted 
was to identify novel protein interactions and study the role of a sub-set of these in 
tumour biology by impairing them in SCC cancer cells in vitro. SCC cells are a good 
model for the validation and functional characterisation of novel interactions as SCC 
cells that are genetically deficient for FAK (FAK-/- SCC cells) and FAK-/- SCC 
cells re-expressing various FAK mutants enable us to analyse the contribution of 
individual phosphorylation sites and domains of FAK in the interaction and the 
downstream signaling events.  
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To accomplish this, both commercially available human protein arrays and phage 
display were employed as complimentary approaches in order to identify novel FAK 
binding partners and assess the role of these in cancer-associated phenotypes.  
Many novel interactions were identified and it was decided to focus on two of these, 
namely Axl and Ambra1, and to study their interactions with FAK and their roles in 
further detail.  
The reasons why these were chosen are as follows: Axl is a protein receptor tyrosine 
kinase that has previously been linked with tumour progression and metastasis in 
number of human cancers, and Ambra1 is an autophagy protein that positively 
regulates early stages of autophagy. Further characterisation of FAK/Ambra1 
interaction might help us understand molecular mechanisms of selective autophagy 
of active Src in SCC cells when FAK is deleted, as reported recently by colleagues in 
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2 Materials and Methods 
2.1 Materials 
2.1.1 General chemicals and reagents 
Supplier: ECRC, Edinburgh, UK 
Sterile PBS 
Sterile PBS/1mM EDTA 




MEM non essential amino acids 
Opti-MEM, reduced serum media  
200mM L-glutamine 
2.5% trypsin solution 
Puromycin 
Axl recombinant human protein 
Supplier: Sigma Chemical Co, Poole, UK 
 Foetal bovine serum (FBS) 
 Sodium pyruvate 
 Dimethyl sulphoxide (DMSO) 
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 Dithiothreitol (DTT) 
 Ethylenediaminetetraacetic acid (EDTA) 
 Glycerol 
 Lithium chloride 
 Methanol 
 Potassium chloride 
 Sodium dodecyl sulphate (SDS) 
 Sodium deoxycholate 
 Sodium chloride (NaCl) 
 Sodium bicarbonate (NaHCO3) 
 Sodium azide (NaN3) 
 Tris hydrochloride 
 Ammonium persulphate (APS) 
 2-mercaptoethanol  
 Bromophenol blue  
Polybrene 
Trichloroacetic acid (TCA) 
Sulforhodamine B (SRB) 
4-hydroxy-tamoxifen  
Supplier: Qiagen, Crawley, UK 
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Polyfect transfection reagent 
HiPerFect transfection reagent 
Supplier: Merck Biosciences, Sussex, UK 
Hygromycin B 
Supplier: Melford Laboratories, Suffolk, UK 
IPTG 
Supplier: Transduction Laboratories, BD Biosciences, Oxford, UK 
Fibronectin 
2.1.2 Molecular biology techniques  
Supplier: Qiagen, Crawley, UK 
Miniprep DNA kit 
Maxiprep DNA Kit 
Gel Purification Kit 
PCR Purification Kit 
RNA extraction Kit 
Superscript First-Strand cDNA synthesis kit 
Supplier: Sigma Chemical Co, Poole, UK 
Agarose 
Ethidium bromide 
Coomassie brilliant blue R-250 
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Supplier: Agilent Technologies, Cheshire, UK 
PfuUltra Hotstart PCR Master Mix 
Supplier: Quantace Ltd., London, UK 
SensiMixTM One-Step kit 
Supplier: Ambion Life Technologies, Paisley, UK 
TURBO DNA-freeTM Kit 
Supplier: Invitrogen Life Technologies Ltd, Paisley, UK 
PCR/Q-PCR primers 
Zero Blunt TOPO PCR cloning kit 
One Shot TOP10 chemically competent E.coli 
One Shot BL21 (DE3) chemically competent E.coli 
imMedia Growth Medium, agar, kanamycin 
imMedia Growth Medium, agar, ampicillin  
Supplier: New England Biolabs, Hertfordshire, UK 
 Not I restriction enzyme  
 Alkaline phosphatase, Calf Intestinal (CIP) 
Hiperladder I molecular weight ladder 
Supplier: Roche applied science, West Sussex, UK 
 Rapid DNA ligation kit 
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2.1.3 Cell culture plasticware 
Supplier: BD Biosciences, Oxford, UK 
 Falcon tissue culture dishes (60mm, 90mm and 120mm) 
 Falcon tissue culture plates (6, 12, 24 and 96 well) 
Supplier: TCS biologicals, Botolph Clayton, UK 
Nunc tissue culture flasks 
Nunc cryotubes 
Supplier: Corning Life Sciences, Amsterdam, Netherlands 
Transwell inserts  
2.1.4 siRNA and shRNA 
Supplier: Thermo Scientific (Dharmacon), Epsom, UK 
 SMART pool: siGenome mouse Axl siRNA (M-040941-01-0005) 
Set of 4 Upgrade: siGenome mouse Axl siRNA (MU-040941-01-0002) 
SMART pool: siGenome mouse Ambra1 siRNA (M-059556-01-0005) 
Supplier: Thermo Scientific (Open Biosystems) 
Mouse pSM2 retroviral shRNA for Axl (individual clones: RMM1766-
96881588, RMM1766-96885903). 
2.1.5 Immunofluorescence  
Supplier: Olympus UK Ltd, Hertfordshire, UK 
Olympus FV1000 Confocal microscope  










Supplier: Jackson Immunoresearch Laboratories, Luton, UK 
Vectashield Microscope Mounting Medium with DAPI 
2.1.6 Immunoblot 
Supplier: Thermo Scientific Pierce Ltd, Northumbria, UK 
Micro BCA Protein Assay Kit 
Supplier: Roche Applied Science, West Sussex, UK 
cOmplete Protease Inhibitor Cocktail Tablets 
PhosSTOP – Phosphatase Inhibitor Cocktail Tablets  
Supplier: Invitrogen Life Sciences Ltd, Paisley, UK 
NuPage Bis-Tris gels 
NuPage MOPS Buffer 
NuPage LDS Sample Buffer (4x) 
NuPage Electrophoresis Apparatus 
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Supplier: Protran, Schleicher and Schuell, London, UK 
Nitrocellulose membrane 
Supplier: Sigma Chemical Co, Poole, UK 





Anti-mouse/rabbit IgG (whole molecule) - agarose  
Mouse/rabbit IgG agarose 
Protein A – sepharose  
Supplier: Chemicon International, Harrow, UK 
Re-blot Plus Strong Antibody Stripping Solution (10x) 
Supplier: GE Healthcare, Little Chalfont, UK 
ECL reagent  
High molecular weight TM rainbow markers 
Supplier: Whatman, Maidstone, UK 
 3mm filter paper 
Supplier: Thermo Fisher Scientific Loughborough,, UK 
 X-ray film 
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Supplier: Jencons, Leighton Buzzard, UK 
 Wet blotting apparatus 
2.1.7 Protein microarray 
Supplier: Invitrogen Life Technologies Ltd, Paisley, UK 
ProtoArrayR Human Protein Microarray PPI Kit 
2.1.8 Phage display library 
Supplier: New England BioLabs Ltd., Herts, UK 
Ph.D.TM – 12 Phage Display Peptide Library Kit 
2.1.9 Antibodies 
Antibodies for immunoblotting, immunoprecipitation and immunocytochemistry 
were as follows: anti-FAK, anti-Src 36D10, anti-phospho-Src-Y416, anti-GAPDH, 
anti-Axl, anti-LC3B, anti-PI3KC3, anti-His-tag, anti-rabbit/mouse (DA1E) IgG XP 
(TM) isotype control, and anti-mouse and anti-rabbit IgG-HRP conjugated secondary 
antibodies were from Cell Signaling Technology (Hertfordshire, UK), anti-phospho-
FAK-Y397, anti-phospho-FAK-Y576/577, anti- phospho-FAK-Y925, anti-FAK 
(clone 4.47, used for FAK IPs), anti-Ambra1 antibodies were from Millipore 
(Bedford, USA). Anti-phospho-FAK-Y861, anti-mouse and anti-rabbit Alexa 488 
and 594 were purchased from Invitrogen (Paisley, UK). Anti-β-actin and anti-
PIK3R4 (p150) antibodies were from Sigma (Dorset, UK). Anti-RACK1, anti-
Beclin1, anti-Paxillin, anti-pY20, and anti-GM130 antibodies were obtained from 
Transduction Laboratories, BD Biosciences (Oxford, UK). Anti-Axl antibody was 




2.1.10 Cell culture solutions 
Trypsin 
0.25% trypsin in sterile PBS/1mM EDTA 
2.1.11 Stock solutions and buffers 
Protein extraction 
RIPA Buffer 
50mM Tris/HCl pH7.4 
150mM NaCl 
1% Triton X-100 
0.5% Sodium deoxycholate 
0.1% Sodium dodecyl sulphate (SDS) 
NP40 Buffer 
150mM NaCl 
50mM Tris pH8 
0.5% NP40 
Western blotting 
Acrylamide gel – 7.5% 
10ml 30% acrylamide 




400µl 10% SDS 
375µl 10% APS 
20µl TEMED 
Stacker gel 
3.2ml 30% acrylamide 
2.5 ml Tris pH6.8 
14ml H2O 
200µl 10% SDS 
200µl 10% APS 
20µl TEMED 
Sample Buffer - 2x  
800µl 2-Mercaptoethanol  
1.3ml Tris pH6.8 
2ml Glycerol 
5ml 10% SDS 
1.3 ml H2O 
Bromophenol Blue to colour 
Tank Buffer – 10x 
0.05 M Tris 




Transfer Buffer – 10x 
50mM Tris 
40mM glycine 
0.04%  SDS 
20% Methanol 
Wash Buffer 
0.2% Tween 20 in Tris Base solution 
Phage display 
Stabilizing buffer 
0.1M NaHCO3 pH8.6 
Blocking buffer 









2.2.1 Protein microarray 
Protein array experiment was performed using ProtoArray-Human Protein 
Microarray v5.0 for Protein-Protein Interaction (PPI) kit from Invitrogen. The 
buffers used in this experiment were supplied in PPI kit. Blocking buffer consisted of 
50mM HEPES pH7.5, 25% glycerol, 0.08% triton X-100, 200mM NaCl, 20mM 
reduced glutathione, 1X synthetic block and 1mM DTT. The washing buffer 
contained 1X PBS, 0.1% Tween 20, and 1X synthetic block. 
In accordance with the manufacturer’s instructions the array was placed with the 
barcode facing up into a well of a chilled 4-chamber incubation tray and blocked 
with blocking buffer for 1 hour on a shaker set at 50rpm. Purified FAK∆375 
recombinant protein was diluted in washing buffer at a final concentration of ~ 
10µg/ml. After blocking, the blocking buffer was removed using a pipette tip and 
then 120µl of diluted protein was loaded onto the microarray membrane, and the 
membrane was covered using a Lifterslip. The array was probed for 90 minutes with 
no shaking at 4oC, then washed five times for 5 minutes with gentle agitation. The 
array was then probed with anti-FAK (1µg/ml in washing buffer) antibody for 90 
minutes followed by five-5 minutes washes, and then probed with anti-Alexa 
fluor647 (1µg/ml in washing buffer) antibody for 90 minutes. The array was then 
washed 5 times for 5 minutes in wash buffer and dried by centrifugation at 200xg for 
5 minutes. All steps were performed at 4oC except the final step which was carried 
out at room temperature.  




The arrays were scanned using an Axon GenePix4000B microarray scanner 
(Molecular Devices) to obtain an array images and the images were saved as 16-bit 
TIFF files. The scanner settings were as follows: wavelength – 635nm, laser power – 
100%, pixel size - 10µm, and PMT gain – 600.  
ProtoArray Prospector Imager is a component of the ProtoArray Prospector software 
package, which allows microarray image processing for data analysis. The raw image 
from the scanner usually requires some manipulations (rotation, scaling, zoom, 
colour inversion, or change resolution) before it can be used for signal extraction. 
After preparing the image of an array, a grid of spots was overlaid onto the image. 
The grid was loaded from the .GAL (GenePix Array List) file, which describes the 
location and identity of all spots on the protein array.  
Finally, the image files were processed using commercially available ProtoArray 
Prospector data analysis software (available at www.invitrogen.com/protoarray) to 
determine signal intensity of the bound protein probe (FAK∆375) detected by the 
anti-FAK and anti-Alexa fluor647 antibodies. The basic approach used by the 
software is to: 1. Calculate the fluorescent signal values taking into account 
corrections for background and negative control features on the microarray 2. 
Calculate z-scores for all the corrected intensities and 3. Identify the features that 
have z-scores greater than cut-off value (3 is the default). These are the protein 
features scored as positive for interactions.  
2.2.2 Phage display 
The wells of a 96-well microtiter plate were coated with 150µl of target molecule 
(FAK-FERM recombinant protein) diluted in 0.1M NaHCO3 pH8.6 at final 
concentration of ~20µg/ml and incubated overnight at 4oC with gentle agitation. The 
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coating solution was then removed and the wells were blocked with 150µl/well 
blocking buffer for 1h at 4oC, followed by washing six times with 200µl/well 
washing buffer. The washing steps were performed rapidly in order to avoid drying 
out the plate. Next, the phage library was diluted in TBST (10µl page library + 90µl 
TBST), then added to the wells and incubated for 1h at room temperature with gentle 
agitation. Non-binding phage were discarded and the plate washed ten times with 
washing buffer. After washing off free phage particles, the wells were treated with 
100µl of 0.2M Glycine – HCl (pH2.2), 1mg/ml BSA, and incubated for 15 min with 
gentle agitation at room temperature in order to elute the phage bound to the ligand. 
The elute then was collected in a micro-centrifuge tube, and neutralized with 15µl of 
1M Tris-HCl pH9.1.  
To amplify the elute, it was added to the 20ml ER2738 bacterial culture and 
incubated with vigorous shaking for 4.5h at 37oC. The bacterial cells were then 
centrifuged for 10min at 12,000 x g at 4oC. 16ml of supernatant was transferred to a 
fresh tube and 2.7ml (1/6 volume) of 2.5M NaCl in 20% PEG was added to it and 
kept overnight at 4oC to allow the phage to precipitate. Next day PEG precipitation 
was centrifuged at 12,000 x g for 15 min at 4oC. The supernatant was removed and 
the tube was centrifuged again briefly to remove residual supernatant. The phage 
pellet was suspended in 1ml TBS, transferred to a micro-centrifuge tube and 
centrifuged at maximum speed for 5min at 4oC. Resulting supernatant was 
transferred to a fresh tube, 160µl of 2.5M NaCl in 20% PEG added on ice for 1 hour, 
then centrifuged at 13,000 rpm for 10min at 4oC. The supernatant was discarded and 
the pellet re-suspended in 200µl of TBS. Amplified page population (10µl of phage 
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elute) were subjected to further rounds (3 rounds) of binding/amplification cycles to 
enrich the pool in favour of binding sequences.  
For preparation of individual clones for sequencing, serial dilutions (1:10) of phage 
elution was performed. 10µl of diluted page solution were incubated with 200µl of 
overnight culture of ER2738 for 5min and then plated on LB agar plates. The phage 
DNA was then analysed by sequencing. The sequencing primers were supplied by 
the phage display libraries kit. The selected DNA sequences were translated into 
amino acid sequences and then compared to a protein database using Basic Local 
Alignment Search Tool (BLAST) to identify the targets for the FAK-FERM domain. 
Phage display experiment was performed once as a screening strategy for subsequent 
validation by alternative assays.  
2.2.3 Generation of recombinant proteins 
Generation of Ambra1 mutants 
Ambra1 mutants: F1, F2 and F3 (Fimia et al., 2007) were generated by PCR 
amplification using specific primers. Ambra1 cDNA sequence cloned in pLPCX 
vector (which was a gift from Prof. Cecconi, Rome) was used as a template. 100ng 
of DNA and 100ng of each primer was added to PfuUltra Hotstart DNA polymerase 
in a total volume of 50µl. Samples were preheated at 95oC for 10min before the 
standard PCR. 
The primers were as follows:  
Ambra1_F1_F  GCGGCCGCATGAAGGTTGTCCCAGAAAAGA 
Ambra1_F1_R GCGGCCGCCTATTCCTGGGCCTGTTGG 




Ambra1_F3_F  GCGGCCGC ATGTCTGCACCTTCGCTTG 
Ambra1_F3_R GCGGCCGC CTACCTGTTCCGTGGTTCTCC 
PCR reactions were ligated into pCR Blunt II-TOPO cloning vector (Invitrogen Life 
Technologies Ltd, UK) according to manufacturer’s instructions and transformed 
into chemically competent TOP10 bacteria. Transformations were plated on 
kanamycin (50µg/ml) agar plates to select for positive clones. Isolation of plasmid 
DNA by mini-prep was followed by NotI restriction enzyme (RE) digestion (1.5 
hour, at 37oC). NotI digested F1, F2 and F3 fragments of Ambra1 were gel-purified 
and ligated into pGex-4T-3 vector at NotI site, placing the insert in frame, by using 
rapid DNA ligation kit. pGex-4T-3 vectors, expressing Ambra1 mutants, were 
transformed into chemically competent TOP10 cells and plated on ampicillin 
(100µg/ml) agar plates to select positive clones. The correct orientation of inserted 
fragments was confirmed by restriction digest.  
pGex vectors expressing FAK mutants, FAK-FERM, FAK-Kinase and FAK-C-
terminal were previously generated in the Frame lab. 
pGex vector expressing FAK∆375 mutant was a gift from M. Menza (Beatson 
Institute).  
Expression and purification of recombinant proteins 
To express GST-fusion proteins (GST-FAK-FERM/Kinase/C-Terminal, GST-
FAK∆375, GST-Ambra1-F1/F2/F3), pGex vectors were transformed into BL21 
(DE3) cells (Invitrogen, UK) in LB medium. Bacterial cultures were grown at 37oC 
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until OD600 reached 0.6, and then GST-fusion proteins were induced by 1mM IPTG 
at 24oC overnight  
The cells from 100ml culture were re-suspended in 50mM Tris, pH8.0, 300mM 
NaCl, 1mM EDTA, 3mM DTT, 0.1% Triton X100 and lysozyme and lysed by 
sonication. Insoluble materials were pelleted at 15,000xg for 15 minutes and 200µl 
of 50% slurry of Glutathione Sepharose 4B beads (GE Healthcare) was added to the 
clarified supernatants. After 1 hour samples were washed three times in PBS and 
finally re-suspended in 150ul of PBS. All steps were performed at 4oC unless 
otherwise indicated.  
Coomassie staining 
SDS-PAGE gels were rinsed once in dH2O and then 20ml of staining solution (40% 
methanol, 10% acetic acid, 0.1% Coomassie Blue) added for 2 hours on a shaker at 
room temperature. Gels were then rinsed twice in dH2O and exposed to de-staining 
solution overnight (5% Methanol, 7.5% acetic acid).  
2.2.4 In vitro binding  
FAK-FERM, FAK-Kinase and FAK-C-terminal GST-fusion proteins (5µg) were 
incubated with 250ng of purified His-tagged Axl ICD (Sigma Chemical Co, UK) in 
binding buffer (20mM Tris-HCl, pH 7.5, 25mM KCl, 1mM MgCl2, and 50mM NaCl) 
for 30 min at 4°C with rotation. The samples were then washed three times with 
binding buffer, boiled in SDS-PAGE sample buffer for 10 minutes, and analysed by 
SDS-PAGE and immunoblotting using anti-His antibody.  
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2.2.5 GST pull-down assay 
For GST pull-down experiment Squamous Cell Carcinoma cells (SCC) deficient in 
FAK (FAK-/-), were lysed in RIPA buffer and equal volumes of lysates, containing 
~1mg of total proteins, were incubated with GST fusion protein-bound beads (~5µg) 
for 1 hour at 4oC. Following four washes with ice cold PBS, the beads and 
precipitated proteins were eluted with 2x SDS-PAGE sample buffer, boiled and 
loaded onto 10% SDS-PAGE gels for analysis as described in 2.2.13. 
2.2.6 Generation of FAK mutant cells 
FAK-/- SCC cells expressing FAK mutants were generated by infecting cells with 
FAK-WT, FAK-Y397F, FAK-Y407F-Y925F or FAK-KD in pWZL retroviral vector. 
Multiple pools of FAK-WT, FAK-Y397F, FAK-Y407F-Y925F and FAK-KD 
reconstituted FAK-/- SCC cells were selected, examined for equivalent protein 
expression and maintained in 0.4mg ml-1 hygromycin B. 
2.2.7 Generation of SCC cell lines with stable knockdown of Axl 
We obtained two retroviral constracts containing short hairpin RNAs (shRNAs) 
directed to different coding regions of Axl from Thermo Scientific (Open 
Biosystems, clones: RMM1766-96881588, RMM1766-96885903). FAK-/- and 
FAK-WT SCC cells were infected with pSM2 retroviral Axl shRNA vectors. Cells 
were selected and maintained in puromycin (1.5µg/ml).  
2.2.8 Retroviral infection 
Phoenix Eco packaging cells were plated on 10cm tissue culture dishes for 24 hours 
prior to transfection using Lipofectamine 2000 transfection reagent as per 
manufactures instructions (Invitrogen, UK). Media was removed after 6 hours and 
replaced with fresh SCC media containing 20% FBS. After 24 hours the viral 
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supernatant was collected, filtered through 0.45µM membrane and added to SCC 
cells in the presence of 5µg/ml polybrene. Fresh media was added to the Phoenix 
Eco cells, a second infection carried out 24 hours later and a third infection 24 hours 
after that. 
2.2.9 Routine cell culture 
SCC cells were routinely grown in Minimum Essential Medium (MEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 2mM L-glutamine, NEAA, 
sodium pyruvate and MEM vitamins in flasks, while Phoenix Eco cells and Ambra1 
-/- MEFs were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS and 2mM L-glutamine. The cells were kept in a dry 
37oC, 5% CO2 incubator. To sub-culture adherent cells the media was removed by 
aspiration, the monolayer rinsed with PE, then with 10% trypsin/PE solution. Upon 
detachment the cells were re-suspended with MEM, counted and then transferred 
into tissue culture flasks or plates.  
2.2.10 siRNA 
SCC cells were plated overnight on 90mm plates in complete media. 10µl of Axl, 
Ambra1 or Scrambled siRNA (20µM stock) was mixed with 40µl of HiPerFect 
transfection reagent in 1ml serum free MEM (SFM) and incubated for 15min at room 
temperature to allow the formation of transfection complexes. The media from SCC 
cells was removed and replaced with 4mls of complete media and the siRNA 
containing solution to give a final volume of 5ml and a final siRNA concentration of 
40nM. Media was changed after 24 hours and cells incubated for a further 48 hours 
at 37oC in CO2 incubator.  
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2.2.11 Preparation of protein extracts 
Cells were transferred directly from the incubator onto ice, washed twice with ice-
cold PBS and harvested in RIPA or NP40 lysis buffer containing freshly added 
protease and phosphatase inhibitors (Roche Applied Science, UK) for 15 minutes. 
Cells were scraped and the lysate transferred to a microcentrifuge tube. The lysate 
was then clarified by centrifugation at 13,000 rpm for 15 minutes at 4oC. The 
supernatant was collected and protein concentration was determined using micro 
BCATM Protein Assay Kit (Pierce Ltd., Northumberland, UK) and the light 
absorbance then measured with an Eppendorf BioPhotometer (Eppendorf, Hamburg, 
Germany) at a wavelength of 562nm. 
2.2.12 Immunoprecipitation 
For immunoprecipitation experiments, 1mg of cell lysate was immunoprecipitated 
with 2µg of primary antibody overnight at 4oC, followed by 60 minutes incubation 
with 20µl of anti-mouse or anti-rabbit IgG agarose beads. In the case of IgG control, 
cell lysate was incubated with 20µl of mouse IgG agarose beads. The beads were 
collected by centrifugation and washed three times with ice-cold lysis buffer, and 
once with 0.6M Lithium Chloride. Samples were eluted with 20µl of 2x SDS–
polyacrylamide gel electrophoresis sample buffer and heated for 10 minutes at 
100oC. 
2.2.13 Immunoblot analysis 
Protein separation was achieved by running 20µg of each lysate and 5µl of pre-
stained molecular weight rainbow TM protein marker (GE Healthcare, Little Chalfont, 
UK) on either 7.5%, 10%, 12% or 4-12% gradient SDS Page gels. Gels were 
typically run at 180V for 55min. Following electrophoresis proteins were transferred 
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to nitrocellulose membranes using wet blotting apparatus with an applied voltage of 
100V for 1hr10min. Membranes were then blocked in 5% bovine serum albumin 
(BSA), re-constituted in TBS plus 0.2% Tween 20 (TBST), for one hour at room 
temperature with gentle agitation. Primary antibodies (diluted 1 in 1000) in 5% 
BSA/TBST were added overnight at 4°C, followed by three 10 minutes washes in 
TBST. Detection was achieved using horseradish peroxidise (HRP)-conjugated 
secondary antibody for 45 minutes. Membrane was washed again (three times, 15 
minutes each wash) and visualized with ECL. When necessary, blots were stripped 
using the Re-Blot Plus Strong antibody stripping solution (Chemicon International, 
Harrow, UK) according to the manufacturer’s instructions. The blots shown are 
representative of experiments repeated at least three times except the blot used in 
figure 4.3(b), which was done twice. 
2.2.14 Immunofluorescence 
Cells (5x104) were grown in 12 well plate on glass coverslips, rinsed in 1x TBS, 
fixed in 3.7% formaldehyde, 100mM Pipes pH6.8, 10mM EGTA, 1mM MgCl2, 
0.2% Triton X100 for 10 minutes and washed in TBS with 0.1% Triton X-100. After 
blocking with 2% BSA/0.1% Triton X-100/TBS for 1 hour at room temperature, 
cells were incubated with primary antibodies overnight at 4oC (dilutions shown 
below). Primary antibody incubation was followed by three washes with TBS 
containing 0.1% Triton X-100 and subsequent incubation with secondary antibodies 
conjugated to Alexa 488 or 594 fluorescent dyes (1 in 200) for 45 minutes. Cells 
were washed 3 times for 5 minutes each and then mounted on glass slides using 
Immunofluorescence vectasheild mounting medium with DAPI and visualised using 
an Olympus FV1000 confocal microscope. Images (1024x1024 pixels) were 
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obtained with a x60 magnification oil-immersion objective. Images shown are 
representative of the localisation observed in the majority of cells and experiments 
were repeated at least three times.  
Primary antibody dilution for Immunofluorescence 
Antibody         Dilution  
Anti-FAK         1/200 
Anti-phospho SrcY416      1/500 
Anti-RACK1        1/100 
Anti-LC3         1/100 
Anti-Ambra1         1/200 
Anti-GM130        1/200 
TRITC phalloidin (it’s a fluorescent dye)    1/200 
2.2.15 Cell polarisation assay 
1mg/ml human fibronectin (FN) solution was diluted in sterile PBS to a final 
concentration of 0.01mg/ml. Coverslips were then coated with FN and incubated at 
37oC for at least 1 hour. After washing coverslips twice with sterile PBS, cells were 
plated on FN at a density of 3 x 106 cells per well on a 12 well dish for 2 hours, in 
order for cells to form a confluent monolayer. Cells were then wounded using a 
pipette tip, washed twice in PBS, twice in complete media, and maintained in 
complete media for 1.5 hours at 37oC. Cells were then fixed as described above and 
stained for TRITC phalloidin, GM130 and DAPI.  
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The cell polarisation assay was carried out three times and 150 cells lining the wound 
edge were counted and analyzed. Cells with the Golgi apparatus orientated towards 
the wound were scored as positive. Data shown is a mean ± SEM of 3 independent 
experiments. Statistical tests were performed by using Student’s t-test. P<0.05 was 
considered significant and denoted by *. 
2.2.16 Cell spreading assay 
To investigate cell spreading SCC cells were trypsinized, washed, re-suspended in 
PBS, and then incubated with rotation at 4oC for 1 hour. The cells were pelleted by 
centrifugation at 1,000 rpm for 5 minutes, and re-suspended in serum-free medium. 
Cells (2x105) were then plated on fibronectin-coated (0.01 mg/ml human FN) 
coverslips for 30 min and fixed and stained as described above using TRITC 
phalloidin and anti-RACK1 antibody.  
Cells were imaged by confocal microscopy and scored for protrusive structures. Over 
100 cells under each condition (for each experiment) were counted in ten 
independent microscopic fields. Data shown is a mean ± SEM of 3 independent 
experiments. Statistical tests were performed by using Student’s t-test. P<0.05 was 
considered significant and denoted by *. 
2.2.17 Invasion assay 
Cell invasion was assessed using an in vitro inverse invasion assay. 100µl of growth-
factor-reduced Matrigel was diluted 1:1 in cold PBS and allowed to set at 37oC for 1 
hour in polycarbonate transwells. Cells (1 x 104) were seeded onto the underside of 
the transwell filter and allowed to adhere for 4h. Transwells were washed and placed 
in serum-free medium. Normal growth medium containing 10% serum was added 
above the Matrigel, and cells were allowed to invade for 72 hours. Cells were then 
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stained with 5µM calcein-AM for 1 hour at room temperature and horizontal z 
sections through Matrigel were examined at 10µm intervals with an Olympus 
FV1000 confocal microscope. The amount of dye (positive pixels) was calculated for 
each z section with ImageJ software and expressed as a percentage of the section that 
represents the base of the transwell filter. Data shown is a mean ± SEM of 3 
independent experiments. Statistical tests were performed by using Student’s t-test. 
P<0.01 was considered very significant and denoted by three *. 
2.2.18 Sulforhodamine B (SRB) assay 
FAK-WT and FAK-WT cells transfected with either scrambled- or Axl siRNA were 
seeded onto 96-well plates at a cell density of 1x103 cell per well. Cells were fixed at 
day 0 and day 3 with 25% trichloroacetic (TCA) for 1 hour at 4oC. The fixed cells 
were then washed ten times with water and allowed to dry. To stain the cells, 50µl of 
SRB dye was added to each well. After 30 minutes incubation at room temperature, 
SRB solution was removed and the plate was washed five times with 1% glacial 
acetic acid in order to remove unbound dye. The plate was dried and bound SRB dye 
was solubilised by adding 150µl of 10mM Tris Base buffer (pH10.5) to each well 
and incubated for 5 minutes at room temperature on a shaker. To determine the 
optical density of SRB, the plate was read in a 96-well plate reader with the 
wavelength 540nm. The OD of SRB in each well is directly proportional to the cell 
number.  
SRB assay was performed three times and data are represented as the mean and 




2.2.19 Total RNA isolation 
RNA was isolated from Keratinocytes, FAK-WT SCC, FAK-/- SCC and MEFs using 
the Qiagen RNA Extraction Kit (Qiagen, Crawley, UK). To reduce the genomic 
DNA total RNA was treated with TURBO DNase enzyme (2U) for 20 minutes at 
37oC. Afterwards, 1/10th volume of reaction mixture of DNase inactivation reagent 
were added to the samples and further incubated for 5 minutes at room temperature. 
Samples were then centrifuged at 10,000g for 1.5 minutes and the RNA was 
transferred to fresh tubes. The total RNA concentration was determined by 
absorbance measurement (260 and 280 nm).  
2.2.20 qRT-PCR analysis 
qRT-PCR was performed using the SensiMix One-Step kit., SYBR Green I protocol. 
Components of master mix used for reaction were 50 x SYBR Green I solutions, 
Sensi-Mix one step, MgCl2, RNase inhibitor, forward and reverse primers (5µM 
each) and dH2O. The primers were as follows: 
Axl-Forward: 5’ CCCCCGAGGTACTTATGGAT 3’ 
Axl-Reverse: 5’ CAAGTGCTCCCAGCAGTACA 3’ 
B2M-Forward: 5’ CGGCCTGTATGCTATCCAGA 
B2M-Reverse: 5’ CGGCCTGTATGCTATCCAGA 
20µl of PCR master mix and 5µl of RNA template, dH2O or standards were loaded 
separately in a duplicate form.  
Typical profile times are as follows: Reverse transcription step (one cycle) 42oC 30 
minutes; enzyme activation (one cycle) 95oC 10 minutes; amplification (35 cycles), 
95oC for 10 seconds (denaturation), 57oC for 20 seconds (annealing); 72oC for 20 
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seconds (extension). Melting curve 65oC to 99oC, hold every 5 seconds. 72oC for 10 
minutes (1 cycle), 15oC for 10 minutes (1 cycle).  
Relative fold levels were determined with mB2M used as housekeeping control.  
2.2.21 PCR analysis 
RNA was isolated from cells and converted to cDNA using Superscript First-Strand 
cDNA synthesis kit. 2µl of cDNA was added to 18µl of pre-aliquoted master mix 
(PfuUltra Hotstart PCR Master Mix) containing 100nM of forward and reverse 
primers. Following amplification, PCR products were separated by agarose gel 
electrophoresis using a 1.2% agarose gel. 
The primers were as follows: 
B2M-Forward: 5’ GGGAAGCCGAACATACTGAA 3’ 
B2M-Reverse: 5’ TGCTTAACTCTGCAGGCGTAT 3’ 
Ambra1-Forward: 5’ ATGAAAGTTGTCCCAGAGAAGAAT 3’ 
Ambra1-Reverse: 5’ TCATTTTAATGATGTAGATCTTTG 3’ 
2.2.22 Statistical analysis 
Bar charts were created in Excel and represent a mean ± SEM of 3 independent 
experiments. Statistical tests were performed using Student’s t-test, p<0.05 was 
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3 Protein binding array 
3.1 Background 
3.1.1 Protein-protein interactions 
Proteins are important macromolecules that facilitate most biological processes in a 
cell, including cell cycle control, cell differentiation, transcription, translation, and 
post-translational modification. The majority of proteins probably interact with other 
proteins in order to function properly. Therefore, to fully understand protein 
function, they can be studied in the context of their interacting partners. Protein-
protein interactions can be distinguished based on the lifetime of the complex: a 
permanent interaction that usually is very stable and a transient interaction (Nooren 
and Thornton, 2003). Transient interactions play an important role in the regulation 
of cellular processes and commonly occur between binding domains of signaling 
proteins, such as SH2 and SH3 (Ozbabacan et al., 2011; Perkins et al., 2010).  
Several biochemical, genetic and computational technologies have been developed 
for the detection of protein-protein interactions. Examples of biochemical interaction 
technologies are cross-linking, co-immunoprecipitation (co-IP), and the so called 
pull-down assay, which is similar to co-IP, except that here GST-tagged protein is 
used instead of antibody. Genetic approaches include yeast two-hybrid, phage 
display and protein microarrays. Some of these techniques are used for the 
identification of novel binding partners (Stynen et al., 2012). 
In this research protein microarrays and phage display libraries were employed as the 
major experimental tools, and a brief description of their general properties and 
functions are given below.  
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3.1.2 Protein microarrays 
For detecting protein-protein interactions, protein arrays offer an in vitro alternative 
method to yeast two-hybrid. Protein microarrays (‘protein chips’) have been 
increasingly used for the profiling of protein expression, the determination of protein 
functions and the identification of molecular interactions between thousands of 
proteins in a single experiment. In contrast to the yeast two-hybrid system, the in 
vitro nature of protein arrays allows for the control of the protein concentrations, the 
interaction conditions (pH, temperature, ionic strength) and specific cofactor 
requirements. A protein microarray consists of a large number of proteins spotted in 
rows and columns in a very small space with spot sizes less than 250µm (Hall et al., 
2007).  
Protein chips are prepared by firmly attaching proteins onto the treated surface of 
microscopy glass slides. Several different slide surfaces are used for protein chips, 
and these can be divided into three major groups: 1) the first group is two-
dimensional (2D) plain glass slides, which bind proteins through the formation of 
covalent bonds or by electrostatic interactions. 2D glass slides offer strong 
attachment, however close protein surface contact may affects the three dimensional 
(3D) structure of proteins; 2) the second group contains 3D gel or membrane coated 
surfaces, such as poly-L-lysine, agarose and nitrocellulose. These surfaces bind 
proteins by adsorption. The advantage of 3D surfaces is that proteins preserve their 
native conformation; 3) the third group includes affinity tag surfaces such as nickel-
nitrilotriacetic (Ni-NTA) and avidin slides, and protein attachment to these surfaces 
is achieved through affinity binding to histidine residues or biotin, respectively. The 
advantage of affinity tag surfaces is that because proteins are attached through 
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affinity tag, proteins will be immobilized in uniform orientation where their active 
sites are exposed to reagent and available to interact with labelled sample 
(Angenendt, 2005; Bertone and Snyder, 2005; Hall et al., 2007). Regardless of the 
strategy used, the main aim is to maintain protein in its native conformation so that 
its binding ability is retained.  
It is also very important to block the remaining surface well prior to performing the 
protein microarray experiment in order to minimise unspecific binding of the target 
molecules. Labelled target proteins are added to the protein chip which may bind to 
some of the immobilised proteins. Unbound targets are washed away while bound 
targets are detected by various methods. The detection of protein binding can be 
achieved in two ways: 1) directly, by using labelled target molecules (fluorescence 
labeling, radioisotope labeling), or 2) indirectly in two steps (by using a tagged 
probe, which can then be detected in a second step using fluorescent secondary 
antibodies). Fluorescence labeling is the preferred detection method because it is 
simple, safe and effective (Bertone and Snyder, 2005; Zhu and Snyder, 2003). In 
addition, fluorescence labels are compatible with laser microarray scanners. The 
images obtained via microarray scanners are then subsequently analysed with the 
appropriate software (ProtoArray Prospector Software v5.2).  
Over recent years several forms of protein microarrays have been developed: 1) 
analytical, also known as capture protein arrays, 2) functional protein arrays and 3) 
reverse-phase protein arrays. 1) Analytical protein arrays display different types of 
ligands, including antibodies, antigens, aptamers or small molecules on a glass slide. 
This type of array can be used for monitoring protein expression levels, protein 
profiling or clinical diagnostics (Phizicky et al., 2003). 2) Functional protein arrays 
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are used to examine functions of proteins that are immobilized on a glass slide. They 
display folded and active proteins on the support surface and can be used to 
investigate protein interactions with other proteins, nucleic acids, lipids and other 
small molecules (LaBaer and Ramachandran, 2005). In contrast to analytical arrays, 
functional protein arrays contain full length, functional proteins or protein domains 
(Merkel et al., 2005). An example of functional protein array used for the detection 
of protein-protein interaction was presented by Zhu and colleagues. They used 
protein chips that displayed several thousands of purified yeast proteins to identify 
calmodulin binding partners (Zhu et al., 2001). These studies identified 39 
calmodulin targets in total six of which were known targets (Zhu et al., 2001). 3) In 
reverse-phase protein arrays, a complex sample, such as a tissue lysate or serum, is 
immobilized on the glass support surface and targets are then detected with 
antibodies overlaid onto them. This type of array can be used for the detection of 
proteins altered as the result of a disease. For example, reverse-phase protein array 
was used for the identification of novel biomarker proteins of pancreatic cancer 
(Huang et al., 2014) and chronic myeloid leukaemia (Quintas-Cardama et al., 2012). 
The advantages of protein microarrays are: 
• It is a powerful technique that enables sensitive, large-scale analysis with 
economical use of samples and reagents 
• Direct target detection 
• Lower cost relative to other methods such as a mass spectrometry 
• Easy to use 
However, despite recent progress, there are number of technical drawbacks: 
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• In order to spot proteins onto a glass slide they must be purified from cells, 
and therefore a ‘purified’ protein may also contain co-purified interacting 
proteins, which may interfere with protein binding. This can be avoided using 
in vitro expression methods; however, proteins produced this way may not be 
properly folded.  
• As a protein array is an in vitro method, interactions that do not normally 
occur within a cell may take place (false positives) (Chen and Snyder, 2010).  
• Lack of post-translational protein modification 
3.1.3 Phage display 
Phage display was originally developed by George Smith in 1985, when the DNA 
fragment was inserted into the M13 bacteriophage gene encoding the capsid protein, 
and the encoded polypeptide was displayed on the surface of phage as a fusion to 
capsid protein [reviewed in (Pande et al., 2010)]. Since then the technique has 
evolved and become widely used within biomedical research. Phage display 
technology represents a system in which bacteriophage display foreign peptides or 
proteins on their surface, and this is accomplished by incorporating the nucleotide 
sequence of the protein or peptide of interest into a phage genome as a fusion to the 
gene encoding the capsid structural protein (Figure 3.1). This fusion ensures that the 
protein is displayed on the surface of the phage and different sets of genes can be 
inserted into the genome of multiple phages such that a single phage will only 
display one protein or peptide on its surface (Willats, 2002). Collections of such 




Figure 3.1 A phage display library 
A library of DNA sequences encoding peptides or proteins is cloned into a phage genome as a fusion 
with the coat protein gene. Foreign proteins, pX and pY, are then displayed within the phage coat 




surface of the phage particle, it is therefore available for interaction with a potential 
target molecule. Consequently, this method is a particularly convenient tool for 
understanding protein-protein interactions. 
Screening of phage displayed peptide libraries can be achieved through affinity 
selection process called biopanning (Krumpe and Mori, 2007). Phage clones from the 
library are incubated with the immobilised target molecule. Unbound phages are 
washed away and phages bound to the target are recovered by elution. To narrow the 
diversity of true binding clones, eluted phages are amplified in bacteria, which can be 
screened again. The screening procedure involves several cycles of selection, until 
phage pool is enriched in specific binding phage (Krumpe and Mori, 2007). 
Phage display peptide libraries have been successfully used in diverse applications, 
including epitope mapping, vaccine development and identification of novel 
interacting proteins [reviewed in (Pande et al., 2010)].  
There are many advantages to using phage display to study protein interactions:  
• The main advantage of phage display is that it provides the possibility of 
rapidly screening large numbers of proteins or peptides against a potential 
binding partner 
• The technique is relatively simple and inexpensive, can provide results in a 
matter of weeks and requires no special equipment. It only requires growth 
of bacteria that is used for amplification of selected phages  
• It gives us information about direct interactions 
• By linking a selected protein or peptide with its encoding gene, phage display 
allows us to easily identify DNA sequences of binding proteins or peptides 
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• The identity of selected peptides or proteins can be simply identified through 
DNA sequencing.   
However, there are also several disadvantages: 
• The tightest binding phage may not represent actual biological partners (false 
positives), meaning that some of the proteins may physically interact, but 
that such as interaction may not take place physiologically due to the distinct 
subcellular localisation of these proteins 
• False positive results may also appear due to phage binding to other 
components of the screening system, such as contaminants in the target 
sample, plastic plates, blocking agents (Vodnik et al., 2011). Some proteins 
are sticky and they may also generate false positive results 
• Phage display screening yields large number of phage clones; therefore it is 
difficult to assay all of the sequences 
• It is an in vitro technique and so may not reflect the biological reality 
• The lack of post-translational protein modification is an important factor 
affecting phage display proteins or peptides. It is known that phosphorylation 
or glycosylation processes play an important role in the functionality of 
many proteins; therefore its absence could affect the interaction of phage-





As previously described in chapter 1, FAK is crucial for many cellular processes that 
are disturbed in malignancy, including cell proliferation, adhesion, migration and 
invasion, thus FAK is important therapeutic target. Several FAK inhibitors have been 
developed most of which target the FAK kinase function (Golubovskaya, 2014).  
Kinase defective FAK retains some of FAK’s functions, suggesting that FAK mainly 
acts as a scaffolding molecule rather than as a kinase (Sieg et al., 2000). In addition, 
Fan et al. recently demonstrated FAK scaffolding function in breast cancer (Fan et 
al., 2013). For example, FAK binds to endophilin A2 and mediates its 
phosphorylation by Src, which leads to increased surface expression of MT1-MMP 
and promotes invasion of Src-transformed fibroblasts in vitro. These authors also 
showed that when the interaction between FAK and endophilin A2 was disrupted 
through mutations of amino acids (Pro-878 and Pro-881) within C-terminal proline-
rich motif of FAK, mammary tumour growth and metastasis in murine model of 
human breast cancer was suppressed (Fan et al., 2013). Therefore, disruption of FAK 
scaffolding function could be a good strategy to anticancer therapy.  
The identification and characterisation of novel FAK interactions will aid in 
uncovering important molecular mechanisms, which may regulate key cellular 
processes involved in tumour formation and progression, and disruption of these 
complexes, may improve FAK-targeted cancer therapeutics.  




3.2.1 Identification of FAK Binding Partners Using a Protein 
Microarray 
For this study, the human Protoarray from Invitrogen was chosen, which is 
composed of over 8000 recombinant proteins of various functional classes spotted in 
duplicate onto a nitrocellulose coated glass slide. To probe this array, GST-tagged 
recombinant FAK protein, GST- FAK∆375, was used, in order to avoid auto-
inhibitory interactions between the FAK FERM and kinase domains (figure 4.2). 
The GST-FAK∆375 fusion protein was overlaid onto the protein array and, as a 
control for non-specific binding partners, a different array was probed with only 
primary and secondary antibodies. The resulting signals were analysed using the 
ProtoArray Prospector Software v5.2, which can be set to score positive hits on the 
protein array. Only duplicate signals of equal intensity, which corresponded to the 
same protein, were scored as positive. To distinguish false positive signals, the 
protein array overlaid with GST-FAK∆375 was compared to the results of the array 
probed with the primary and secondary antibodies only. 
Using this approach, a number of novel candidate binding partners were uncovered 
in addition to already identified FAK binding partners, such as Src, Fyn and Abl 
(Table 3.1). Proteins were selected for future study based on reagent availability, 
protein function and subcellular localisation. One protein chosen for future study was 
the receptor protein tyrosine kinase, Axl. Similar to FAK, Axl is also involved in the 
regulation of several cellular processes, such as cell proliferation, cell survival and 




Figure 3.2 Comparison of FAK and FAK∆375 domain structures 
FAK contains three major domains: the FERM, kinase domain and carboxy-terminal domain 
containing FAT sequence. In FAK∆375 the FERM domain has been removed in order to avoid auto-
inhibitory conformation of FAK. 
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A number of studies have demonstrated the importance of Axl in cancer. For 
example, Axl is up-regulated in a vast majority of tumours, including leukaemias, 
gliomas, melanoma, prostate, pancreatic and breast cancer [reviewed in (Paccez et 
al., 2014)]. In addition, over-expression of Axl correlates with poor prognosis as well 
as increased invasiveness (Gjerdrum et al., 2010; Vuoriluoto et al., 2011). 
Furthermore, a monoclonal antibody that binds to Axl and blocks ligand Gas6 
binding to the receptor has been shown to reduce metastasis of MDA-MB-231 breast 
cancer cells to distant organs (Ye et al., 2010b). These data implied that Axl was a 








1 PKCɣ NM_002739 Protein Kinase C gamma 
 
Novel  
2 SRPK1 NM_003137 SR protein-specific kinase 1 
 
Novel 
3 MAPK2K6 NM_031988 Mitogen-activated protein kinase 2 
 kinase 6 
Novel 
4 PKCɑ NM_002737 protein kinase C alpha 
 
Novel 
5 PIM1 NM_002648 Proto-oncogene serine/threonine 




NM_002755 Mitogen-activated protein kinase 2 














NM_001006932 Ribosomal protein S6 kinase Novel 
10 NEDD9 
 






NM_212535 Protein kinase C beta 1 Novel 
12 Axl 
 
NM_001699 Axl receptor tyrosine kinase Novel 
13 ABL1 NM_005157 Abelson murine leukaemia viral 
oncogene homolog 1 
Known 










NM_006281 Serine/threonine kinase 3 Novel 
17 TGFß1 
 
NM_015927.2 Transforming growth factor beta 1 Novel 
18 CK2ɑ 
 
NM_001896.2 Casein kinase 2 alpha Novel 
19 AURKB 
 
NM_004217 Aurora Kinase B Novel 
 
 
Table 1 List of the potentially novel FAK interacting proteins identified by Protoarray 
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3.2.2 Phage display 
The second approach used to identify potential FAK binding partners was that of 
phage display. As described, this technique involves biopanning a random peptide 
library against a target protein and amplifying the phage-peptides that bind. The 
process includes eluting and amplifying the phage that binds to a target, plating to 
yield phage clones for isolating clones DNA, and sequencing of the resultant DNA 
for characterisation of the peptide. The library used in this experiment was comprised 
of peptides each containing 12 amino acids.  
3.2.2.1 Generation of a bait protein 
The FAK FERM domain was used as a bait protein. The FAK sequence encoding 
amino acid residues 37-413 was amplified by PCR and cloned into the pGex6P3 
vector in frame with the GST coding sequence (Serrels et al., 2007). For expression 
of GST fusion proteins, E. coli BL21 was transformed with the vector pGEX6P3-
FAK FERM, which carries a tac promoter for Isopropyl β-D-1-thiogalactopyranoside 
(IPTG)-inducible recombinant protein expression. Following overnight growth and 
induction of protein expression with IPTG, the bacteria were harvested by 
centrifugation. Bacterial pellets were then lysed and the clarified supernatant 
containing the soluble protein extract was incubated with glutathione agarose beads. 
Bound GST fusion protein was eluted and analysed by SDS-PAGE.  
3.2.2.2 Bio-panning and amplification of phage clones 
The phage library were then incubated with the bait protein and after a total of three 
cycles of biopanning and amplification, the eluted phages were cultured with 
ER2738 and plated in order to select single colonies. 
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3.2.2.3 Sequencing of DNA inserts 
Eleven clones were selected for analysis and the sequence of the DNA inserts was 
translated to obtain the encoded peptides. After analysing these peptides using the 
NCBI Basic Local Alignment Search Tool (BLAST) several potential binding 






Potentially Novel FAK Interacting Proteins 
LTPSSPASTGNK MACF1, Ncam1, Liprin, Rptor, Prkcz2, Cttnbp1, c-Abl, Smad5, Laminin_b 
YTPSYWGNSLTA ERBB4, Laminin_a5, CSF2RA, Cntn2, Cntnap3, Inta7 
SWGPFTTAPPNN ProtoCad, Wnk1, Ceacam1, ATG2, LYST 
NGPLEIQPSARL Sorbs3, Myo9a, PIK3CD, Mylk 
YIPITTLLTHSH Stk36, Stk17b 
SFPHMTKSHTSN PdzD2, Otog 
YTDSAARSNTVV Pde4A, Laminin_a2, Cflar, Tpx2, Stk4, Stk3, MVP, Ambra1 
SISWQSGHPMSL Atf7, Otog 
VPVHPTPLQPRL Taf3a, Rnf11, Atf7IP, TBC1, Mll2, Rassf5, Espl1, Arhgap5, Sos1 
SILSTMSPHGAT Neo1, Lyst, Mbnl1 
LEASAVYKSKNR Rin3, Rap1B 
 
Table 2 List of the 12-amino acid sequences identified (left) and the potentially novel FAK 
interacting proteins (right).  
DNA sequences obtained by phage display were translated into amino acids 
sequences (left) and analysed using NCBI Local Alignment Search Tool. All the 








A number of studies have highlighted an important role for FAK during tumour 
development and metastasis; however, the mechanism(s) by which FAK mediates 
these processes remains to be fully elucidated. The current study was designed to 
identify novel binding partners of FAK using protein arrays and phage display 
methodologies.  
Initially, we used the human ProtoArray, which is comprised of over 8000 proteins 
derived from multiple gene families of biological importance, including kinases, cell 
signalling proteins, metabolic proteins and membrane associated proteins. Arrays 
such as this have advantages over using conventional proteomics, such as mass 
spectrometry analysis, as they provide information faster, require less material, and 
are not prone to contaminants such as keratins. However, they also possess several 
disadvantages, such as the absence of recombinant protein post-translational 
modifications and a lack of information as to under what conditions any potential 
interactions may occur, in addition to fact that only direct interactions can be 
detected and not complexes. Therefore a number of other approaches, including mass 
spectrometry, would be optimal. 
Using the ProtoArray we identified both known FAK binding proteins, such as Fyn, 
Src, PKC and Abl, in addition to a number of unknown binding partners with a 
variety of functions. These proteins included receptor and non-receptor protein 
kinases, for example 1) receptor protein tyrosine kinase Axl regulates many cellular 
processes (cell survival, cell proliferation and migration) (Korshunov, 2012); 2) 
casein kinase II subunit alpha (CK2α) is a serine/threonine protein kinase and 
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regulates numerous cellular processes (cell cycle progression, apoptosis and 
transcription) (Duncan and Litchfield, 2008); 3) aurora kinase B (AURKB) is part of 
the chromosomal passenger complex (CPC) and acts as a key regulator of mitosis 
(Xu et al., 2012); 4) serine/threonine-protein kinase 3 (STK3) has been shown to play 
a critical role in tumour suppression by restricting proliferation and promoting 
apoptosis, and 5) ribosomal protein S6 kinase (RS6K) acts downstream of mTOR 
signaling and promotes cell proliferation, cell growth and cell cycle progression; etc 
(Magnuson et al., 2012). From the list of potential FAK binding partners, the 
receptor protein tyrosine kinase Axl was selected and further studies on the 
interaction of FAK/Axl are described in Chapter 4.  
As mentioned above, there are disadvantages when using protein arrays to look for 
novel protein-protein interactions. Therefore phage display was also employed as a 
second approach using FAK-FERM domain this time, although similar to every 
screening approach false positives may be detected. These can occur for a variety of 
reasons, for example an irrelevant interaction between a phage displayed peptide and 
the bait. Furthermore, each phage only displays a 12 amino acid fragment of a 
protein, which could result in conformational alterations and thereby influence 
binding ability. Thus, it is essential that interactions identified in a phage display 
screen are confirmed by at least one alternative assay.  
Using phage display, several previously reported FAK binding proteins were 
detected, such as cAbl and NCAM1. Proteins that are involved in various cellular 
processes that have not been previously described in association with FAK were also 
identified. For example, 1) microtubule-actin cross-linking factor 1 (MACF1) 
belongs to the plakin family of cytoskeletal linker proteins and has recently been 
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shown to be involved in the Wnt signaling pathway (Chen et al., 2006); 2) Smad5 is 
a component of the intracellular signaling of transforming growth factor-beta (TGFβ) 
family members, and TGFβ signaling has been shown to promote tumour 
development and progression (Lebrun, 2012); and 3) Sorbs3 (which is also known as 
Vinexin) is a cytoskeleton protein localised at focal adhesions and plays a role in cell 
spreading, migration and anchorage-independent growth (Mizutani et al., 2007).  
Proteins involved in autophagy were also identified, such as, autophagy-related 
protein 2 (Atg2) and activating molecule in Beclin1-regulated autophagy protein 1 
(Ambra1). The Atg2 protein is required for vesicle nucleation/formation during 
autophagy and is necessary for the localisation of Atg18 to the pre-autophagosomal 
(PAS) structure and the binding of Atg18 to Atg9 (Feng et al., 2014). Ambra1, which 
was also identified, promotes the interaction between Beclin1 and VPS34, therefore 
mediating autophagosomes nucleation (Fimia et al., 2007).  
How FAK regulates selective autophagy of active Src is not currently clear and so 
this study examined Ambra1 as a potential FAK binding partners that are involved in 
autophagy. We focused on Ambra1 protein because it had been reported that Ambra1 
plays a key role in autophagy-dependent protein turnover, and that it’s a positive 
regulator of early stages of the autophagy pathway (Fimia et al., 2007). This work is 
described in Chapter 5. 
Protein microarrays and phage display were used to identify novel FAK binding 
partners. We identified several proteins by using each tool. However we did not 
detect any protein that was present in both experimental results. This could be due to 
the different FAK domains used as bait (GST-FAK-FERM and GST-FAK∆375) for 
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these experiments. Moreover, we were not able to sequence all the colonies produced 
by phage display. Even though both techniques provide quick and simple strategies 
for examination of protein-protein interactions on a large scale, both protein 
microarray and phage display lack posttranslational protein modifications, which are 
often important for many protein functions. Therefore, using mass spectrometry for 














The interaction between FAK and Axl 
  
 113 
4 The interaction between FAK and Axl 
4.1 Results 
4.1.1 Generation of FAK deficient SCC cells 
In this study I used SCC cells that had been generated from chemically induced SCC 
in mice. These animals expressed in their skin a floxed form of fak under the control 
of Cre recombinase. The loxP sites were introduced into fak gene at the position 
containing amino acids 413-433, which corresponds to the exon encoding part of the 
kinase domain (McLean et al., 2004). Cre recombinase was regulated by the skin 
specific keratin-14 promoter (K14CreERT2/FAKflox/flox), which is highly active in 
dividing cells of the epidermis from day E14.5 (Vasioukhin et al., 1999). Cre was 
fused to the mutated hormone-binding domain of the human estrogen receptor (ER), 
in which the amino acid corresponding to Glycine 521 (G521) was mutated to an 
Arginine (G521R). G521R mutant does not bind to 17β-estradiol, but it does bind to 
synthetic ligand tamoxifen or 4-hydroxy tamoxifen (4OHT) (Feil et al., 1996). It has 
been shown that the fusion protein Cre-ERT is functional tamoxifen dependent 
recombinase in transgenic mice (Feil et al., 1996). A schematic representation of 
K14CreERT2/FAKflox/flox system is shown in Figure 4.1. 
The K14CreERT2/FAKflox/flox mice were then subjected to a two-stage chemical 
carcinogenesis. Single treatment with 7,12-dimethylbenzanthracene (DMBA) results 
in an activating mutation of the Harvey Ras (H-Ras) gene, and subsequent repeated 
treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) induce the formation of 






Figure 4.1 Schematic diagram of the K14CreER/FAKflox/flox system used 
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The FAK deficient (FAK-/-) cells were generated by treatment of SCC cells with 
4OHT. Cells were then sub-cloned and selected by analysing clones for FAK 
expression/deletion (Serrels et al., 2012). To confirm loss of the FAK protein, FAK-
/- SCC cells were lysed and analysed by immunoblotting using anti-FAK antibody. 
The blot showed that FAK was completely deleted in FAK-/- cells (Figure 4.2a). The 
blot was also probed with an anti-actin antibody to demonstrate that equal amount of 
lysates were loaded onto the gel. Immunoblot analysis of FAK-/- cell lysates using 
an antibody to the carboxyl terminus of FAK also revealed that FAK-/- cells do not 
express either FRNK or other transcript variants of FAK.  
The FAK status was also analysed by immunofluorescence (IF), where FAK+/+ and 
FAK-/- SCC cells were fixed and stained using a rabbit polyclonal anti-FAK 
antibody. It was found that FAK was localised at focal adhesions in FAK+/+ cells 
while it was not visible in FAK-/- cells (Figure 4.2b). 
FAK-/- cells were used to generate SCC FAK-WT cells by re-expressing the wild 
type FAK (FAK-WT) protein. The re-introduction of FAK-WT was achieved 
through the generation of stable cell lines using the hygromycin B-resistant pWZL 
retroviral vector (Sandilands et al., 2012a). Following retroviral infection of FAK-/- 
cells, FAK-WT expressing cells were identified by selection using hygromycin B. 
The stably expressing FAK-WT protein level was detected by immunoblot analysis 
using an anti-FAK antibody, and an anti-actin antibody was again used as a loading 
control (Figure 4.2c). We think that SCC cells are a good model to study FAK/Axl 
interaction as FAK-/- SCC cells allow generation of different FAK mutant-
expressing SCC cells that will let us analyse the contribution of FAK 
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phosphorylation or its kinase activity in the regulation of this interaction and the role 




Figure 4.2 Characterisation of SCC cells   
(a) Protein extracts from SCC FAK+/+ and FAK-/- cells were separated by SDS-PAGE, transferred to 
nitrocellulose, blotted and probed with either anti-FAK (upper panel) or anti-actin (lower panel). (b) 
FAK+/+ and FAK-/- cells were fixed and stained with anti-FAK (green) and DAPI (blue) prior to 
visualisation by confocal microscopy. (c) Protein extracts from FAK-/- and FAK-/- cells stably re-





4.1.2 Axl is up-regulated at both the RNA and protein levels in 
SCC cells   
Over-expression of Axl has been reported in many human primary cancers, including 
squamous cell skin cancers (Cichon et al., 2014; Green et al., 2006). To identify 
whether Axl gene expression was altered in mouse SCC cells compared to normal 
skin keratinocytes, quantitative (q-) RT PCR was performed. Gene expression was 
normalised against the housekeeping gene, mouse beta-2 microglobulin (mB2M). 
The q-RT PCR data demonstrated that Axl mRNA expression was significantly 
upregulated (>10 fold) during in SCC cells derived from DMBA/TPA model when 
compared to keratinocytes (Figure 4.3a). This finding is in agreement with previous 
studies (Cichon et al., 2014; Green et al., 2006) and immunoblot analysis was 
performed to confirm this finding at the protein level (Figure 4.3b).  
The full-length human Axl protein contains 894 amino acids (879 aa in mouse) and 
has a molecular weight of 104 kDa (97 kDa in mouse). However, it has been shown 
that the extracellular domain of Axl contains six N-linked glycosylation sites, and 
two other post-translationally modified forms (100 and 130 kDa) have also been 
identified, representing partial and complete glycosylation (Li et al., 2012). In SCC 
cells Axl appears as multiple species, ranging from ~55 kDa to 130 kDa (Figure 
4.3b), from which 55 kDa and 130 kDa species are most prominently expressed. Axl 
antibody specificity was confirmed by Axl siRNA transfection of FAK-WT and 
FAK-/- SCC cells (Figure 4.3d). The results indicated that Axl expression was 
upregulated at the protein level, representative example of which is shown in Figure 
4.3c. Taking all of these findings into consideration, SCC cells are an interesting 




Figure 4.3 Axl is up-regulated at both RNA and protein levels in SCC cells 
Quantitative RT-PCR of Axl gene expression in keratinocytes and FAK-WT SCC cells (b) 
Immunoblot analysis of Axl protein expression in keratinocytes versus FAK-/- and FAK-WT SCC 
cells. Actin blot is also included (c) Quantifications of full length Axl protein in keratinocytes versus 
FAK-/- and FAK-WT SCC cells (number of replicates = 2). (d) FAK-WT SCC cells were transfected 
with Axl siRNA. 72 hours after transfection cells were lysed and subjected to immunoblot analysis. 
The resulting protein blot was probed with anti-Axl and anti-actin antibodies. Scrambled siRNA were 
also included as a control. 
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4.1.3 GST pull-down  
To test the interaction between FAK and Axl and determine the regions of binding in 
FAK, glutathione S-transferase (GST) pull-down experiments were performed using 
a GST-tagged fragment of each individual domain of FAK and GST-alone.  
GST-FAK fusion proteins and GST-alone (Figure 4.4a) were expressed in E. coli, 
and then purified and incubated with the FAK-WT cell lysates. After pull down of 
GST-fusion proteins and GST as a control, the samples were analysed by 
immunoblotting using an anti-Axl antibody (Figure 4.4b). The Axl protein was 
pulled down with some of the GST-fusion proteins to a greater or lesser extent, but 
not by GST alone, thus supporting the interaction of these two proteins that had been 
identified by protein microarray analysis. The results also demonstrated that there 
may be multiple regions within FAK that can bind to Axl, but it is likely that the 
kinase domain is a major component mediating FAK/Axl interaction. 
4.1.4 In vitro binding assay 
To determine whether FAK/Axl interaction is a direct physical interaction between 
these two proteins, in vitro binding assays were conducted using purified GST-fusion 
fragments of individual FAK domains and the His-tagged Axl intracellular domain 
(His-Axl ICD).  
GST-fusion FAK domains conjugated to glutathione agarose beads were incubated 
with the His-tagged Axl intracellular domain containing amino acids – 473-894, and 
bound proteins were immunoblotted using anti-His antibody. Glutathione agarose 
beads conjugated to GST alone were also used as a control to confirm that the 




Figure 4.4 Axl pull-down  
a) Fusion proteins produced in bacteria were separated by SDS-PAGE and stained with Coomassie 
Blue. b) FAK-WT SCC cell lysates were incubated with purified GST-FAK-FERM, GST-FAK-
Kinase, GST-FAK-C-terminus and GST- itself as a control. Bound proteins were detected by 
immunoblotting using anti-Axl antibody c) Representative example of quantitative analysis of GST 




The results demonstrated that the His-tagged Axl ICD did interact with GST-FAK-
kinase; there was also detectable interactions between other GST-FAK domains and 
His-Axl ICD but not with the GST negative control protein (Figure 4.5a), hence 
supporting the data identified by GST-pull down experiment, that there may be 
multiple binding sites within FAK that binds to Axl, but the kinase domain binds 
more robustly (Figure 4.5b). 
4.1.5 Immunoprecipitation analysis validated the specific binding 
of Axl to FAK 
To test whether FAK and Axl are associated in complex within SCC cells described 
here, co-immunoprecipitation (co-IP) studies using FAK-WT cells were performed. 
Co-IP of cell lysates with an anti-Axl antibody was followed by immunoblotting 
with either anti-Axl or anti-FAK antibodies as probes, which confirmed that FAK 
does bind to Axl in mammalian cells. In contrast, co-IP with a non-immune IgG 
control did not precipitate FAK (Figure 4.6). 
4.1.6 Regulation of the FAK/Axl interaction  
Next, we examined whether the interaction between FAK and Axl proteins was 
regulated by FAK-Y397 phosphorylation, Src dependent phosphorylation of FAK or 
by FAK’s kinase activity. This was achieved using FAK-/- cells expressing FAK-
WT, FAK-Y397F (an auto phosphorylation site mutant that has an impaired response 
to integrin signaling), FAK-Y4F-Y9F (which has all of the Src-dependent 
phosphorylation sites mutated to phenylalanine, and so cannot be phosphorylated by 
Src), and FAK-KD (as a kinase-defective version of FAK due to the mutation of 
lysine (K) 454 to arginine (R) in the ATP loop (as used before in Sandilands et al., 




Figure 4.5 In vitro binding  
a) GST-FAK-FERM, GST-FAK-Kinase, GST-FAK-C-terminus and GST-itself fusion proteins were 
incubated with His-Axl ICD. Bound proteins were immunoblotted using anti-His antibody. b) 





Figure 4.6 Interaction between FAK and Axl proteins 
Cell extracts from FAK-/- SCCs re-expressing FAK-WT were immunoprecipitated 
with anti-Axl antibody. The immunocomplexes were then analysed by 
immunoblotting with anti-FAK and anti-Axl antibodies. Total cell lysates were also 







To generate FAK mutant cell lines, FAK-/- cells were infected with pWZL retroviral 
vectors encoding FAK-Y397F, FAK-Y4F-Y9F and FAK-KD tyrosine kinase mutant 
cDNAs (Sandilands et al., 2012a). Infected cells were selected using hygromycin B 
to provide a pooled clone of each. Stable expression of the FAK-WT or mutant 
proteins was confirmed by immunoblotting (Figure 4.7a, lower panel). SCC cell 
lysates were also used in immunoblotting experiments, where they were probed 
using phospho-specific antibodies to FAK-Y397, Y576/577 or Y925. FAK-WT was 
tyrosine phosphorylated on all residues, and phosphorylation of Y397 in cells 
expressing FAK-Y397F was not detected since this residue had been mutated in this 
protein (Figure 4.7a, upper panel). SCC cells expressing the FAK-Y397F mutant also 
demonstrated reduced phosphorylation of FAK-Y576/577 and FAK-Y925 when 
compared to FAK-WT. This was expected, since Y576/577 and Y925 are Src 
dependent phosphorylation sites (Calalb et al., 1995; Schlaepfer and Hunter, 1996), 
and the binding of Src to FAK protein requires phosphorylation of Y397 (Schaller et 
al., 1994, Xing et al., 1994). Src binding to phosphorylated Y397 leads to 
phosphorylation of the remaining tyrosine residues within FAK (Calalb et al., 1995). 
The Y397 residue was phosphorylated in FAK-Y4F-Y9F mutant protein; however, 
there was no detectable phosphorylation of Y576/577 and Y925 as expected. The 
kinase defective FAK-KD mutants showed reduced phosphorylation of all tyrosine 
residues compared to FAK-WT. 
To determine whether the FAK/Axl interaction was influenced in SCC cells 
expressing FAK mutants, co-IP experiments were performed. Cell lysates from 
FAK-WT, FAK-Y397F, FAK-Y4F-Y9F and FAK-KD expressing SCC cells IP-ed 




Figure 4.7 Regulation of FAK/Axl interactions 
a) Lysates from FAK-/- SCC cells stably re-expressing FAK-WT, FAK-Y397F, FAK-Y4F-Y9F and 
FAK-KD were immunoblotted with anti-FAK, anti-FAKY397, anti-FAKY925 and anti-
FAKY5576/577 antibodies. b) Cell extracts from FAK-/- SCCs re-expressing FAK-WT, FAK-Y397F, 
FAK-Y4F-Y9F and FAK-KD were IP with anti-Axl antibody. The immunecomplexes were then 
analysed by immunoblotting with anti-FAK and anti-Axl antibodies. Total cell lysates were also 
directly probed with the same antibodies. (c) Quantification of Axl/FAK interactions. Columns and 





The results indicated that there was no significant difference in FAK/Axl binding in 
the different FAK mutant cell lines compared to FAK-WT (Figure 4.7b). Therefore, 
we concluded that this interaction was not regulated by FAK-Y397 phosphorylation, 
Src dependent phosphorylation of FAK, or FAK’s kinase activity. Hence, it appears 
that the FAK/Axl interaction is predominantly a scaffolding function of FAK and 
seems to be un-regulated by phosphorylation, at least not by any of the major 
phosphorylation events characterised for FAK so far. 
4.1.7 Axl has no effect on the phosphorylation of FAK 
Since Axl is a receptor tyrosine kinase, we next investigated whether the physical 
association of Axl with FAK could be an important trigger for FAK-phosphorylation. 
To address this question, Axl siRNA was used to robustly reduce expression of Axl 
protein in FAK-WT SCC cells (Figure 4.8a) and cell lysates were analysed by 
immunoblotting using phospho-specific antibodies for FAK in order to obtain a FAK 
phosphorylation profile. Scrambled siRNA was also used as a control (Figure 4.8b). 
The results show that the levels of Y397, Y576/Y577, Y861 and Y925 
phosphorylation between scrambled and Axl-siRNA transfected cells remained 
unchanged, suggesting that Axl has no effect on FAK phosphorylation. 
4.1.8 Downregulation of Axl has no effect on SCC cell 
proliferation  
To examine whether Axl plays a general role in the regulation of SCC cell 
proliferation, an SRB assay was performed using Axl knockdown FAK-WT SCC 
cell lines that were generated using Axl specific siRNA. To ensure that knockdown 
of Axl expression was achieved successfully, the time-course of altered Axl 




Figure 4.8 Reducing of Axl expression has no effect on FAK phosphorylation 
(a) Analysis of siRNA-induced alterations of Axl protein expression by immunoblotting. Protein 
extracts from FAK-WT cells transfected either Scrambled or Axl siRNA were immunoblotted with 
anti-Axl antibody. Immunoblotting of actin is also shown (lower panel). (b) FAK-WT SCC cells 
transfected with either scrambled or Axl siRNA were lysed and immunoblotting carried out using 
anti-pFAKY397, anti-pFAKY861, anti-pFAKY925 and anti-FAK antibodies. 
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The protein extracts from FAK-WT cells transfected with either scrambled or Axl 
siRNA were subjected to SDS phage and immunoblotted with anti-Axl and anti-actin 
antibodies as probes. The results in Figure 4.9a show decrease in Axl expression 24 
hours after siRNA treatment and this remained constant throughout the 72 hour time 
course (Figure 4.9a). 
FAK-WT cells were transfected with either scrambled or Axl siRNA. After 24 hours, 
cells were trypsinized and seeded onto 96 well plates at a cell density of 1×103 
cells/well. Untreated FAK-WT SCC cells were also included as positive control. To 
check whether Axl contributed to cell proliferation, the seeded cells were fixed with 
25% trichloroacetic (TCA) acid at day 0 and day 3. The fixed cells were stained with 
SRB dye for 30 min., after which the excess dye was removed by washing repeatedly 
with 1% glacial acetic acid. The protein-bound dye was dissolved in a tris-based 
solution to determine the optical density (OD) at 540 nm using a microplate reader.  
As shown in Figure 4.9b, Axl siRNA transfected cells demonstrated no significant 
difference (P > 0.05) in cell proliferation compared to scrambled siRNA treated 
FAK-WT SCC cells. Therefore this finding indicates that Axl is not required for 
SCC cell proliferation. 
4.1.9 Axl knockdown affects cell polarization of SCC FAK-WT 
cells 
In order to determine whether Axl contributes to cell polarisation, Axl expression 
was knocked-down using siRNA in FAK-WT cells and then ability of the cells to 




Figure 4.9 Down-regulation of Axl had no effect on SCC cell proliferation  
(a) Analysis of siRNA-induced alterations of Axl protein expression by immunoblotting. Protein 
extracts from FAK-WT cells transfected either scrambled or Axl siRNA were immunoblotted with 
anti-Axl antibody. Immunoblotting of actin is also shown (lower panel). (b) FAK-WT and FAK-WT 
cells transfected with either scrambled or Axl siRNA were seeded in 96 well plate. To check whether 
Axl contributed to cell proliferation, seeded cells were fixed with 25% TCA and then stained for 30 
minutes with SRB dissolved in 1% acetic acid. The OD at 540 nm was determined as absorbance 
value. Data presented are 1 of 3 independent experiments. Error bars represent standard errors of 
means. Statistical significance was calculated using a student t-test. 
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The polarised morphology of migrating cells involves the alignment of the Golgi 
apparatus in front of the nucleus towards the direction of movement. To determine 
whether Axl was required for cell polarity, scrambled and Axl siRNA transfected 
FAK-WT SCC cells were analysed using an assay that visualises the reorientation of 
the Golgi apparatus relative to the nucleus in cells along the wound (Etienne-
Manneville and Hall, 2001; Serrels et al., 2010). Cells were plated onto fibronectin 
(FN) for 2 hours, then wounded and left to polarise for 1.5 hours, before being fixed 
and stained with anti-GM130 (Golgi marker), nuclear DAPI stain and TRITC 
phalloidin. At least 100 cells were scored for each three independent experiment. 
Cells that displayed Golgi in front of the nucleus towards the wound were scored as 
polarised cells, while cells that had Golgi away from the wound, either on the sides 
or back of the nucleus, were scored as non-polarised cells, and the percentage of the 
polarised cells was calculated. We found that the polarisation of Axl siRNA 
transfected FAK-WT SCC cells was significantly suppressed in contrast to the 
scrambled siRNA FAK-WT SCC cells, thus demonstrating either an inability to 
sense the wound or turn towards it (Figure 4.10). 
4.1.10 Effect of Axl knockdown on SCC cell spreading  
We next investigated whether Axl participates in SCC cell spreading. Cell spreading 
is characterised by formation of protrusive structures. It has been shown that FAK 
binds to the receptor for activated C kinase 1 (RACK1) and localises in nascent 
contacts (Serrels et al., 2010).  
Nascent adhesion contacts are defined here as early structures that are formed 





Figure 4.10 Axl knockdown affects cell polarisation of FAK-WT SCC cells  
(a) Protein extracts from scrambled or Axl siRNA transfected FAK-WT SCC cells were 
immunoblotted with anti-Axl and anti-actin antibodies. (b) Scrambled and Axl siRNA transfected 
FAK-WT SCC cells were plated on FN for 2 hr, wounded, and after 1.5 hr fixed and stained for anti-
GM130 (green), TRITC phalloidin (red) and DAPI (blue). Solid arrows (left panel) show cells in 
which the Golgi is orientated toward the wound, and broken arrows (right panel) indicate cells in 
which the Golgi is orientated away from wound. (c) Percentage of each cell type with the Golgi 
orientated to the wound was calculated from a count of 100 cells in each experiment. Columns and 





Disruption of the interaction between FAK and RACK1 impairs localisation of 
RACK1 at nascent adhesions structures, and cells become rounded, suggesting that 
FAK regulates formation of nascent adhesions through its interaction with RACK1. 
As RACK1 is an early adhesion marker, we decided to examine RACK1 in 
peripheral protrusive structures in scrambled or Axl siRNA transfected FAK-WT 
SCC cells using an assay previously described in Serrels et al paper (Serrels et al., 
2010).  
Essentially, FAK-WT cells transfected with either scrambled or Axl siRNA and 
suspended in PBS for 1hr at 4oC. The cells were pelleted by centrifugation at 1,000 
rpm for 5 min, and re-suspended in SFM before plating onto coverslips covered with 
FN at a cell density of 2×105 cells/well. The cells were then allowed to spread for 30 
minutes before being fixed and stained for actin and RACK1 (Figure 4.11a). At least 
100 cells were scored for each three independent experiment. Cells with Rack1 in 
peripheral protrusive structures were scored as spreading cells, while cells with 
smooth edges without protrusive structures were scored as rounded cells. The spread 
cells were counted and quantified and the percentage of the spreading cells were 
calculated.  
The results showed that Axl knockdown cells demonstrate a significant decrease in 
their ability to spread (Figure 4.11b). 
4.1.1 Axl knockdown inhibits chemotactic cancer cell invasion 
It has been demonstrated that Axl overexpression is associated with motility and 





Figure 4.11 Axl knockdown cells demonstrate a significant decrease in their ability to spread 
Scrambled or Axl siRNA transfected FAK-WT SCC cells were either (a) lysed and analysed by 
immunoblotting using anti-Axl and anti-actin antibodies, or (b) suspended in PBS for 1hr at 4oC. After 
being harvested by centrifugation, the cells were re-suspended in SFM before plating onto FN-coated 
coverslips. The cells were then allowed to spread for 30 minutes before being fixed and stained for 
RACK1 (green), actin (red) and DAPI (blue). Solid arrows represent spreading cells, and broken 
arrows indicate rounded cells (c) Quantification of cell spreading on fibronectin. Columns and error 
bars represent the mean ± SEM (n=3). Statistical significance was calculated using a student t-test. 
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Therefore to examine the functional significance of Axl expression in SCC cell 
motility and invasiveness, stable Axl knockdown FAK-WT cells were generated 
using Axl shRNA retroviral clone in pSM2 backbone. Retrovirus were generated by 
transfecting Phoenix Eco packaging cells with Lipofectamine 2000 for 24 hours 
followed by collection of virus containing supernatant in SCC media containing 20% 
FBS. FAK-WT SCC cells were then infected with filtered virus containing 5µg/ml 
polybrene. Infection of SCC cells was carried out three times and followed by 
selection in puromycin. FAK-WT SCC cells expressing scrambled shRNA were also 
generated. SCC cells were then analysed for knockdown efficiency by western 
blotting (Figure 4.12a).  
FAK-WT cells expressing either scrambled shRNA or Axl shRNA were seeded onto 
transwell filters and allowed to invade through the Matrigel towards a chemotactic 
stimulus for 72 hours. The cells were then labelled with calcein AM dye and 
visualised in the Matrigel at 10µm intervals by confocal sectioning (Figure 4.12b), 
and the percentage of cells invading 60µm into the 3D-gel was quantified (Figure 
4.12c). We found that Axl knockdown significantly attenuated the chemotactic 
invasion of FAK-WT cells. FAK-/- SCC cells also fail to invade through Matrigel 
(Serrels et al., 2010). We suggest that FAK/Axl interaction may facilitate invasion of 







Figure 4.12 Axl knockdown inhibits chemotactic cancer cell invasion 
Stable Axl knockdown FAK-WT cells were generated using Axl shRNA retrovirus in pSM2 
backbone. Axl knockdown efficiency were analysed by immunoblotting using anti-Axl and anti-actin 
antibodies. (b) FAK-WT cells with a stably knockdown of Axl were seeded on transwell filters and 
allowed to invade Matrigel towards a serum gradient. After 72 hours cells were labeled with Calcein 
AM and visualized by confocal microscopy in the Matrigel at 10µm intervals. Scrambled control cells 
were also included in the assay. b) Quantitation of results is also shown. The data represents the mean 





Axl was originally identified as an oncogene in patients with chronic myeloid 
leukaemia (CML) (O’Bryan et al., 1991). Its activation has been implicated in 
various cellular responses, including cell proliferation, migration, adhesion and cell 
survival [reviewed in (Hafizi and Dahlback, 2006; Lemke, 2013)]. Due to its 
underlined importance in these processes, we considered that Axl may be an 
interesting novel binding partner of FAK. Several reports had demonstrated a 
functional link between Axl expression in tumour growth, migration and metastasis, 
and association between Axl overexpression and invasiveness and metastasis has 
been reported for lung (Shieh et al., 2005), prostate (Sainaghi et al., 2005), gastric 
(Wu et al., 2002) and breast cancers (Meric et al., 2002), as well as renal cell 
carcinomas (Chung et al., 2003).  
The data presented in this study provide strong evidence of the physical interaction 
between the FAK and Axl proteins in SCC cells, which was demonstrated by co-
immunoprecipitation and pulldown experiments. This verification is very important 
for associations found using protein array approaches, demonstrating that the 
association between FAK and Axl is not an artefact that occurs only in the protein 
array, but an actual physical interaction occurring in mammalian cells. 
In addition, the direct interaction of FAK and Axl was confirmed by in vitro binding 
assays using purified GST-fusion fragments of individual FAK domains and His-
tagged Axl intracellular domain. Our data demonstrate that there is perhaps more 
than one binding site on FAK; however, the kinase domain binds more robustly. This 
finding is in line with the fact that the FAK∆375 recombinant protein used in the 
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protein array screen contains the kinase domain. FAK’s kinase domain mediate 
interaction has also been reported previously, such as FAK interacts with FIP200 
through its kinase domain (Abbi et al., 2002). 
To strengthen our finding further I wanted to show whether FAK and Axl proteins 
co-localise in SCC cells, and if so, where. I attempted several IF experiments with 
two Axl antibodies from different companies, but these were unsuccessful. 
Antibodies did not work for IF, which prevented us from identifying any co-
localisation.  
To activate FAK, an activator protein is required to trigger FAK FERM domain 
release from the kinase domain before FAKY397 can be autophosphorylated (Lietha 
et al., 2007). To see whether FAK/Axl interaction requires phosphorylated Y397, Src 
dependent phosphorylation of FAK or FAK’s kinase activity, we studied association 
between FAK and Axl using FAK-/- SCC cells expressing different FAK mutants. 
This study demonstrated that FAK/Axl interaction is not dependent on 
phosphorylation of FAKY397, Src dependent phosphorylation sites or FAK’s kinase 
activity, indicating that the FAK/Axl interaction is predominantly a scaffolding 
function of FAK and is not modulated by any of the major phosphorylation events 
characterised for FAK. 
Several studies have previously suggested that FAK is phosphorylated on tyrosine 
and serine residues by diverse kinases after cell activation, including the RET 
receptor tyrosine kinase, which directly phosphorylates FAK on Y576/Y577 and 
Y925 (Plaza-Menacho et al., 2011), ERK, which phosphorylates FAK at S910. The 
latter creates a binding site for PIN1 (Zheng et al., 2009), and Rho-dependent kinase 
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(ROCK), which directly phosphorylates FAK on S732 (Le Boeuf et al., 2006). 
Therefore, to examine the potential role of Axl in the process of FAK 
phosphorylation, we performed an immunoblotting analysis using phospho-specific 
antibodies for FAK. Our data suggest that Axl does not regulate the phosphorylation 
of FAK at indicated tyrosine residues (Figure 4.8). 
Using an antibody directed against the intracellular portion of Axl, we detected not 
only high levels of full length receptor, but also higher level of the lower molecular 
weight (~55 kDa) protein (Figure 4.3b), that I assume that it is the cleaved 
intracellular fragment of Axl. Other Receptor Tyrosine Kinases (RTKs) have been 
reported to undergo similar proteolytic cleavage processes to release a soluble 
extracellular domain as well as a truncated kinase domain, including MET and CSF-
1R. The exact role of proteolytic cleavage in RTK function is unclear; however, it 
has been shown that soluble Axl (sAxl) generated by proteolytic cleavage mediated 
by disintegrin-like metalloproteinase 10 (ADAM10) plays a role in promoting cell 
migration and activation of membrane bound full-length Axl (Budagian et al., 2005).  
Pronounced Axl expression has been documented in a variety of cancers, where it 
has been shown to be crucial for maintaining tumour cell proliferation. For example, 
downregulation of Axl using a monoclonal antibody attenuates the growth of non-
small cell lung carcinoma xenografts by reducing cell proliferation and inducing 
apoptosis (Li et al., 2009). Similarly, Axl knockdown inhibits proliferation and 
induces apoptosis of osteosarcoma cells through downregulation of the Akt pathway 
(Zhang et al., 2013). However, Axl overexpression has no effect on the cell 
proliferation of bladder cancer cells (Sayan et al., 2012), suggesting that Axl is 
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required for cell proliferation only in some cancer types. The data we present here 
also show that Axl is not required for SCC cell proliferation in SCC cells in vitro. 
Axl has also been shown to regulate cancer cell migration. In breast cancer models, 
inhibition of Axl signalling by a dominant-negative Axl mutant, or by short hairpin 
RNA knockdown of Axl, decreased highly invasive breast cancer cell motility 
(Zhang et al., 2008). For cells to migrate a front-rear polarity axis must first be 
generated. Defects in cell polarity have been shown to be associated with 
tumorigenesis and metastasis. In order to determine whether Axl contributes to SCC 
cell polarity, we measured the reorientation of the Golgi apparatus relative to the 
nucleus in cells along the wound. After knocking down Axl protein expression, cells 
demonstrated a significant disruption of polarisation. This may have resulted from an 
inability to sense the wound or turn towards it. We also investigated the role of Axl 
on SCC cell spreading, which might contribute to cell migration. The data show that 
Axl knockdown cells demonstrate a significant decrease in their ability to spread. 
Based on our data we can conclude that Axl deficient SCC cells display impairment 
of the cell spreading and cell polarity required for migration.  
In addition to cell proliferation and migration, Axl overexpression has also been 
linked to cancer invasion. Axl knockdown blocks the invasive phenotype of breast 
cancer cells (Holland et al., 2010). It also regulates invasiveness in lung (Shieh et al., 
2005), pancreatic (Koorstra et al., 2009) and gastric (Sawabu et al., 2007) 
carcinomas. Moreover, the involvement of Axl in promoting cancer cell migration 
and invasion has also been demonstrated in vitro: overexpression of Axl in the 
weakly invasive breast cancer cell line MCF7 endowed the cells with a highly 
invasive phenotype (Zhang et al., 2008). Here, we identified that Axl knockdown 
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significantly attenuated the chemotactic invasion of SCC-FAK-WT cells. As Axl 
expression is also upregulated in this cell line, compared to normal skin 
keratinocytes, our data further imply an important role for Axl in invasiveness of 
SCC cells. FAK has also been shown to be critical for SCC cell invasion: FAK 
deficient cells did not invade at all relative to FAK-wt-expressing control cells 
(Serrels et al., 2010). Furthermore, it appears that both proteins (FAK and Axl) can 
regulate cancer cell invasion by a similar pathway – MMP-mediated matrix 
degradation (Canel et al., 2008; Tai et al., 2008). We therefore suggest that the 
FAK/Axl interaction may confer invasive potential on SCC cells. However, the 
possibility that Axl invasive activity in SCC cells is independent of FAK cannot be 
excluded. Therefore, FAK-Axl interaction requires further investigation that will be 
described in future work. However, using FAK as a target binding protein, I have 
identified Axl as a protein that is upregulated in SCC cells and mediates polarisation, 
cell spreading and invasion in vitro. 
Summary 
The main findings of this study are: 
1. We found a novel FAK binding partner, Axl. 
2. It appears that the FAK/Axl interaction is predominantly a scaffolding 
function of FAK that seems to be unregulated, at least by any of the major 
phosphorylation events characterised for FAK. 
3. Axl is not involved in the phosphorylation process of FAK. 
4. Axl has no effect on SCC cell proliferation; however, Axl knockdown 
resulted in a significantly impaired ability of SCC cell to spread or polarise. 
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5. Finally, Axl knockdown significantly attenuated the chemotactic invasion of 
SCC cells. 
Future work 
The majority of the questions that need to be addressed have arisen from observation 
concerning the effect of Axl knockdown on SCC cell invasion. While I have 
identified the phenotype resulting from Axl knockdown in cancer cells in vitro, the 
mechanism underlying this effect is unknown. Does the interaction between Axl and 
FAK contribute to regulation of SCC cell invasion? And if so, how do they 
contribute to it?  
A number of tools are available with which to address these questions:  
1. Map binding sites using peptide array analysis. This would enable us to 
generate an effector mutant FAK protein that cannot bind to Axl. This could 
be used to determine the role of the FAK/Axl interaction in SCC cell 
invasion. 
2. As both proteins regulate cancer cell invasion mainly by the MMP-mediated 
matrix degradation pathway, it would be interesting to measure the 
expression levels of MMPs, including MT1-MMP, MMP-2 and MMP-9, in 
Axl knockdown SCC cells. 
3. There is evidence indicating that sometimes, even when MMP expression is 
induced, the cells still did not invade or degrade the collagen matrix, or that 
they show little invasive phenotype unless they were treated with HGF, 
suggesting that MMP activity may be regulated post-translationally (Hotary 
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et al., 2000). Therefore matrix degradation assays would provide information 
on the ability of cells to degrade the collagen matrix.  
4. Because epithelial cells are in contact with the ECM only at the basal surface, 
and in order for cells to degrade the ECM, it is essential that they localise 
MMPs to the basal membrane. Therefore, it would be interesting to look at 
localisation of MMPs in Axl knockdown SCC cells. 
5. A number of Axl ‘inhibitors’ are available, including YW327.6S2 and R-428 
[reviewed in (Verma et al., 2011)]. YW327.6S2 is a monoclonal antibody that 
recognises and binds to both human and mouse Axl protein, and inhibits 
tumour growth in breast cancer mouse model (Ye et al., 2010b). R-428 is a 
small molecular inhibitor. Previous studies have shown that it inhibits tumour 
cell metastasis in mouse models of breast cancer (Holland et al., 2010). 
Therefore, R-428 Axl inhibitors can be used to determine the importance of 
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5 The interaction between FAK and Ambra1 
5.1 Results 
5.1.1 Identification of Ambra1 peptide binding sequences within 
FAK  
To test the interaction between FAK and Ambra1, and to map the sites of Ambra1 
binding on FAK, we first performed peptide array binding analysis in collaboration 
with Dr George Baillie, University of Glasgow. 
To do this full length Ambra1 (which was a gift from Prof Cecconi, Rome) was used 
to generate different Ambra1 mutants: F1, F2 and F3 (Fimia et al., 2007). The F1 
mutant represents amino-terminus of Ambra1 containing amino acids 1-532, F2 
includes the central region of Ambra1, spanning amino acids from 533 to 751, and 
F3 is the carboxy-terminus region contains amino acids from 767 to end (767-1269) 
(Fimia et al., 2007). These were sub-cloned in frame in pGex-4T-3 vector. GST-
fusion proteins were then expressed in bacteria and purified, separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and visualized 
using Coomassie Blue (Figure 5.1). Recombinant protein concentrations were 
determined by comparison with BSA protein. 
A scanning peptide array of full-length FAK was generated as a library of 
overlapping 25-mer peptides; each sequence was displaced 5 amino acids towards 
the carboxy-terminus. This immobilised peptide array was incubated with either 
purified GST or purified recombinant GST-Ambra1-F1, F2 or F3, then probed with 
anti-GST antibody. Arrays incubated with GST, GST-Ambra1-F1 or GST-Ambra1-




Figure 5.1 Generation of GST-fusion recombinant Ambra1 mutants 
Fusion recombinant proteins produced in bacteria were separated by SDS-PAGE and stained with 





We did however detect positive interactions on the FAK array probed with GST-
Ambra1-F3 signifying a possible interaction with this region of Ambra1 (Figure 5.2). 
Alanine scanning peptide arrays were then generated correlating to the peptides that 
were reacted with antibody in Figure 5.2 by substituting each residue in turn to 
alanine (A) to assess the contribution of each residue to Ambra1 binding. We showed 
that in the carboxy-terminal region of FAK (Figure 5.3) these positive interactions 
disappeared when a proline (P) at residue 875 or at residue 881 was substituted to 
alanine (Figure 5.3, solid arrows, mutation shown in red). This data suggests that 
P875 and P881 in the C-terminal of FAK may be binding to the F3 region of Ambra1 
and that mutation of these residues might interfere with this interaction. 
5.1.2 FAK interacts with Ambra1 in SCC cells 
To further confirm the interaction between FAK and Ambra1 in cells, we performed 
co-IP experiments in SCC cells. FAK-/- and FAK-WT cells were lysed, and 
immunoprecipitation carried out using anti-Ambra1 antibody (from Sigma). Samples 
were separated by SDS-PAGE and analysed by immunoblotting using anti-Ambra1 
and anti-FAK antibodies. We found that Ambra1 associates with FAK in FAK-WT 
cells, but not in FAK-/- cells as expected. In contrast, co-IP with control IgG did not 
bind to FAK (Figure 5.4a). There appeared to be multiple species of Ambra1 
recognized by the anti-Ambra1 antibody, which we considered might be different 
isoforms of the Ambra1 protein, or differently modified versions.  
FAK-/- and FAK-WT SCC cell lysates were also incubated with anti-FAK antibody 
and samples immunoblotted with both anti-FAK and anti-Ambra1 antibodies. We 




Figure 5.2 Probing a FAK peptide array with GST-Ambra1-F3 
Immobilized peptide ‘spots’ of overlapping 25-mer peptides each shifted along by five amino acids in 
the entire FAK sequence were incubated with GST-Ambra1-F3 and then probed with anti-GST 
antibody. Black dots represent a positive interaction between Ambra1-F3 and FAK peptides, 
indicating potential interaction sites. Data highlights a previously known proline rich region 2 (PRR2) 




Figure 5.3 Alanine-scanning substitution analysis to probe the binding sites for GST-Ambra1-
F3 in the carboxy-terminal region of FAK 
Each indicated amino acid of 25-mer peptide representing amino acids 271-295 (H271-P295) of C-
terminal region of FAK, were sequentially and individually replaced by alanine (A) or aspartate (D) 
(shown in red) and probed for GST-Ambra1-F3. ‘Dark spots’ disappeared (indicated by solid arrows) 
when P875 or P881 was substituted to A. 
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These immunoprecipitation experiments clearly demonstrate that FAK interacts with 
Ambra1 in SCC cells. 
Using a confocal microscopy, next we examined the subcellular localisation of 
Ambra1 and FAK in both FAK-/- and FAK-WT cells. Cells were plated on cover 
slips and then fixed and stained with anti-FAK (in red) and anti-Ambra1 (in green) 
antibodies (Figure 5.4c). This shows that FAK localises to focal adhesions in FAK-
WT cells (upper left panel), but it is absent in FAK-/- cells (lower left panel), as 
expected. Ambra1 localises mainly in cytoplasm with some staining evident at the 
plasma membrane where FAK is also present (solid arrows indicate plasma 
membrane localization of Ambra1, right panels). However, staining of Ambra1 
implied it was predominantly cytoplasmic.  
5.1.3 Ambra1 is present in Src-containing autophagosomes in 
FAK-/- SCC cells  
In FAK-deficient cells Src is targeted to autophagosomes (Sandilands et al., 2012a), 
and as Ambra1 has been shown to influence autophagy in neural systems (Fimia et 
al., 2007), I wanted to know if it bound to Src and was involved in Src-selective 
autophagy in FAK-deficient cells. 
To investigate whether Ambra1 was in a complex with active Src, FAK-/- and FAK-
WT cell lysates were immunoprecipitated with anti-p-Src-Y416 antibody and then 
probed with anti-Ambra1 and anti-p-Src-Y416 antibodies (Figure 5.5a). We detected 
an interaction between Src and Ambra1 in FAK-WT cells and found that this 
interaction was increased in the absence of FAK. We also found that unlike FAK, 
Src forms complex with several species with molecular weights of ~85 kDa and 130 




Figure 5.4 FAK interacts with Ambra1 in SCC cells 
Cell lysates from FAK-/- and FAK-WT cells were immunoprecipitated with anti-Ambra1 (a) and anti-
FAK (b) antibodies. Purified complexes and corresponding total cell lysates were separated by SDS-
PAGE and immunoblotting performed using anti-Ambra1 and anti-FAK antibodies. (c) FAK-/- and 
FAK-WT cells were fixed and stained with either anti-FAK (red in left panels) or anti-Ambra1 (green 





Figure 5.5 Ambra1is present in Src-containing autophagosomes in FAK-/- SCC cells 
(a) Cell lysates from FAK-/- or FAK-WT cells were immunoprecipitated with anti-p-Src-Y416 
antibody. Purified complexes and corresponding total cell lysates were separated by SDS-PAGE and 
immunoblotted using anti-Ambra1 and anti-p-Src-Y416 antibodies. IgG control is also included. (b) 
FAK-WT (upper panel) and FAK-/- SCC cells (lower panel) were fixed and stained with anti-p-Src-
Y416 (green), anti-Ambra1 (red) and DAPI (blue). Higher magnification images of the outlined areas 
are also shown. Scale bars, 20um. 
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Next we examined co-localisation between p-Src and Ambra1 in FAK-/- and FAK-
WT cells. Cells were fixed and stained for Ambra1 (in red), anti-p-Src-Y416 (in 
green) and DAPI (in blue) (Figure 5.5b). The results show that Ambra1 and anti-p-
Src-Y416 co-localise at focal adhesions at the cell edges in FAK-WT cells, and in 
cytoplasmic puncta in the cytoplasm in FAK-/- cells. These data imply that Ambra1 
is also present in Src-containing autophagosomes in SCC cancer cells that are devoid 
of FAK, and raise the possibility that some Ambra1 is localised to adhesions when 
FAK is present, but is co-targeted to autophagosomes with Src upon loss of FAK. 
5.1.4 Characterization of Ambra1 proficient and deficient MEFs 
Around this time as I was carrying out this work, we were able to obtain Ras 
transformed MEFs with genetic deletion of Ambra1 from Dr Guillermo Velasco 
(Madrid). 
To confirm that these cells were indeed Ambra1 deficient, we first performed RT-
PCR. Total RNA was isolated from Ambra1+/+ and Ambra1-/- MEFs, cDNA 
generated and then PCR performed using specific primers for Ambra1, and for a 
housekeeping gene beta-2-microglobulin (B2M) (Figure 5.6a). The results confirmed 
that Ambra1 transcript was present in Ambra1+/+ but not in Ambra1-/- MEFs and 
that control B2M was present in both, at the same level.  
We next prepared cell lysates from these MEFs and from SCC cells and 
immunoblotted using anti-Ambra1 and anti-actin antibodies to examine the 
expression level of Ambra1 protein (Figure 5.6b). When we analysed the results, we 
were surprised to see multiple species in all samples, including Ambra1-/- MEFs, 
indicating that the Ambra1 antibody we were using was recognising non-specific 
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bands instead of Ambra1. We also observed the same intracellular staining pattern in 
Ambra1+/+ MEFs as in Ambra1-/- MEFs with an anti-Ambra1 antibody from 
Abcam used in our previous experiments, suggesting that this antibody was also not 
specifically detecting Ambra1 (Figure 5.6c). 
These results were very important and indicated that antibodies were being sold by 
commercial providers were not recognising Ambra1specifically, and were mis-
leading – despite recognising multiple species in the right molecular weight range 
consistent with these species being Ambra1. This highlighted to me the dangers of 
assuming that commercially sourced antibodies are specific. 
Therefore we decided to discard all the data generated using the anti-Ambra1 
antibody from Sigma, and test other commercially available anti-Ambra1 antibodies, 
defining specificity using the Ambra1-deficient MEFs and repeating key 
experiments. 
5.1.5 Validation of anti-Ambra1 antibody from Millipore 
We purchased a supposedly specific anti-Ambra1 antibody from Millipore and 
examined Ambra1 protein expression in Ambra1+/+, Ambra1-/- MEFs, and FAK-/- 
and FAK-WT SCC cell lines by Immunoblotting. With this antibody we detected a 
single band ~150kDa in all samples except Ambra1-/- MEFs as expected (Figure 
5.7a). 
We also validated this antibody using Ambra1 siRNA to knockdown Ambra1 in SCC 
cells. FAK-/- SCC cells were transfected with scrambled or Ambra1 siRNA (80nM 
and 100nM). After 72 hours cells were lysed and immunoblotted with anti-Ambra1 




Figure 5.6 characterisation of Ambra1 proficient and Ambra1 deficient MEFs 
(a) RT-PCR of Ambra1 and B2M housekeeping gene in Ambra1+/+ or Ambra1-/- MEFs. (b) FAK-
WT, FAK-/- SCCs, and Ambra1 +/+ and Ambra1-/- MEFs were lysed, and cell lysates were analysed 
by immunoblotting using anti-Ambra1 (Sigma) and anti-actin antibodies. (c) Ambra1+/+ and 





This data shows that Ambra1 siRNA reduces Ambra1 expression in this cell line, and 
that the Millipore antibody is specific, and so useful for our studies. 
To examine whether the anti-Ambra1 antibody worked for IF, the Ambra1+/+ and 
Ambra1-/- cells were fixed and stained for Ambra1 and DAPI. We observed that 
Ambra1 localised to defined punctuate structures in the cytoplasm of Ambra1+/+ 
cells, which were not detected in Amra1-/- cells. However, we did find staining of 
Ambra1-deficient MEFs in the cytoplasm, which is presumably non-specific 
staining.  
Taken together, the data above, gave us confidence to carry out further experiments 
using the anti-Ambra1 antibody obtained from Millipore since it appeared to be 
specifically detecting Ambra1 in both MEFs and SCC cells. 
5.1.6 FAK and Ambra1 interaction 
To confirm whether FAK and Ambra1 were associated in SCC cells, co-IP studies 
using FAK-/- and FAK-WT SCC cells were performed again using the specific 
Ambra1 antibody. IP of FAK from cell lysate using anti-FAK antibody was followed 
by immunoblotting with anti-FAK and anti-Ambra1 antibodies (Figure 5.8). This 
data shows that FAK and Ambra1 do form a complex in these cells. 
In the converse experiment, FAK-/- and FAK-WT cell lysates were 
immunoprecipitated with anti-Ambra1 antibody and then immunoblotted with either 
anti-Ambra1 or anti-FAK antibodies. These data show that there is an interaction 
between FAK and Ambra1 in FAK-WT cells and, as expected, co-IP in FAK-/- cells 




Figure 5.7 Validation of anti-Ambra1 antibody from Millipore 
(a) Ambra1 +/+, Ambra1-/- MEFs, and FAK-/- and FAK-WT SCC cells were lysed and subjected to 
immunoblotting with indicated antibodies. (b) FAK-/- cells were transfected with either scrambled or 
Ambra1 siRNA. After 72 hours cells were lysed and cell lysates were analysed by immunoblotting 
using anti-Ambra1 and anti-GAPDH antibodies. (c) Ambra1+/+ and Ambra1-/- cells were plated, 




Figure 5.8 FAK interacts with Ambra1 in SCC cells 
Cell lysates from FAK-/- or FAK-WT SCC cells were immunoprecipitated with anti-FAK (a) or anti-
Ambra1 (b) antibodies. Purified complexes and corresponding total cell lysates were separated by 




5.1.7 Regulation of FAK/Ambra1 interaction 
To see whether FAK/Ambra1 interaction was regulated by FAK-Y397 
phosphorylation, Src dependent phosphorylation of FAK, or by FAK’s kinase 
activity, we used FAK-/- cells stably re-expressing FAK-WT, FAK-Y397F, FAK-
Y4F-Y9F and FAK-KD mutants [as used before in (Sandilands et al., 2012b; Serrels 
et al., 2010)]. Stable expression of the FAK protein was confirmed by 
immunoblotting (Figure 5.9a). We did not observe any changes in Ambra1 
expression, suggesting that this is not regulated by FAK phosphorylation.  
To determine whether FAK/Ambra1 interaction was affected in SCC cells expressing 
these FAK mutants, co-IP experiments were performed. FAK-WT, FAK-Y397F, 
FAK-Y4F-Y9F, and FAK-KD SCC cells were lysed and then cell lysates were 
immunoprecipitated with either anti-FAK or anti-Ambra1 antibodies (Figure 5.9c). 
The immune complexes were then separated by SDS-PAGE and samples 
immunoblotted for both FAK and Ambra1. The data show that there was a decrease 
in association between FAK and Ambra1 in FAK-397F, FAK-Y4F-Y9F and FAK-
KD expressing SCC cells compared to FAK-WT SCC cells; however the interaction 
was not completely abolished. Representative quantification of the amount of FAK 
binding to Ambra1 is shown in Figure 5.9d. However, we were not able to readily 
quantify the level of Ambra1 binding to FAK since the FAK-Y397F and FAK-Y4F-
Y9F expressing SCC cells displayed lower levels of FAK. 
5.1.8 FAK binds to Beclin1/PI3KC3 multi-protein complex 
In mammals the Beclin1/PI3KC3 containing multi-protein core complex consists of 
PI3KC3 (Vps34), p150 (Vps15) and Beclin1. Beclin1 is a key regulator of 




Figure 5.9 Regulation of FAK/Ambra1 interaction 
(a) FAK-/-, FAK-WT, FAK-Y397F, FAK-Y4F-Y9F, and FAK-KD SCC cells were lysed and cell 
lysates were analysed by immunoblotting using anti-Ambra1, anti-FAK and anti-actin antibodies. 
Lysates from FAK-WT, FAK-Y397F, FAK-Y4F-Y9F, and FAK-KD SCC cells were 
immunoprecipitated with either anti-FAK (b) or anti-Ambra1 (c) antibodies. The complexes were then 
analyzed by immunoblotting with anti-FAK and anti-Ambra1 antibodies. Total cell lysates were also 





of PI3P through PI3KC3-dependent phosphorylation of phosphatidyl inositol (PI) 
(Furuya et al., 2005; Kihara et al., 2001). PI3P is required for the formation of 
autophagosomes (Walker et al., 2008). 
Several proteins have been identified that interact with the autophagy core complex 
and positively or negatively regulate PI3KC3 kinase activity, including UV 
irradiation resistance-associated gene (UVRAG) (Liang et al., 2006), RUN domain 
and cystein-rich domain containing, Beclin1-interacting protein (Rubicon) 
(Matsunaga et al., 2009), Bax-interacting factor 1 (Bif-1) (Takahashi et al., 2007) and 
Ambra1 (Fimia et al., 2007). Since, Ambra1 is a positive regulator of early stages of 
autophagy as it binds to Beclin1 and promotes Beclin1/PI3KC3 interaction (Fimia et 
al., 2007), we set out to determine if this complex included FAK, or was regulated by 
it.  
To investigate whether FAK is also a part of the Ambra1/Beclin1/PI3KC3 multi-
protein complex we performed co-IP experiments. Lysates from FAK-/- and FAK-
WT SCC cells were incubated with anti-PI3KC3 antibody and then immunoblotted 
with anti-FAK and anti-PI3KC3 antibodies (Figure 5.10a). We observed that FAK 
immunoprecipitated with anti-PI3KC3 antibody in FAK-WT cells. In contrast, co-IP 
with control IgG did not precipitate FAK, and there was no complex detected in 
FAK-/- cells, as expected. 
In the converse experiment, FAK-/- and FAK-WT SCC cell lysates were incubated 
with anti-FAK antibody and then immunoblotted with either anti-FAK or anti-
PI3KC3 antibodies (Figure 5.10b). These data confirmed that there is a detectable 




Figure 5.10 FAK interacts with Beclin1/PI3KC3 multi-protein complex 
Lysates from FAK-/- and FAK-WT SCC cells were immunoprecipitated with anti-PI3KC3 (a) or anti-
FAK (b/c) antibody and probed with anti-FAK, anti-PI3KC3, or anti-Beclin1 antibodies. Cell lysates 




Next we examined whether FAK was in a complex with Beclin1. FAK-/- and FAK-
WT SCC cell lysates were immunoprecipitated with anti-FAK antibody and then 
immunoblotted with anti-FAK or anti-Beclin1 antibodies (Figure 5.10c). Beclin1 was 
present in a co-IP with FAK in FAK-WT cells, while control IgG did not precipitate 
Beclin1.  
Taken together, we conclude that FAK is part of the Beclin1/PI3KC3 multi-protein 
complex, although we do not yet know which of these interactions are direct.  
5.1.9 FAK is not required for Beclin1/PI3KC3 multi-protein 
complex formation 
We next examined whether FAK had any effect on the complex formation between 
Beclin1 and PI3KC3 in FAK-/- and FAK-WT SCC cells. Cell lysates were 
immunoprecipitated with anti-Beclin1 antibody, subjected to SDS-PAGE and then 
immunoblotted with both anti-Beclin1 and anti-PI3KC3 antibodies (Figure 5.11a). 
These data show that there is no difference in the interaction between the Beclin1 
and PI3KC3 proteins in the presence and absence of FAK. 
While PI3KC3 is a cytosolic protein, its autophagosomal membrane association 
require its interaction with the myristoylated serine/threonine kinase - p150 
(Panaretou et al., 1997). The p150 protein is also considered to be a regulatory 
subunit of PI3KC3 that enhances its kinase activity.  
Therefore, we examined the complex between PI3KC3 and p150 proteins in both 
FAK-/- and FAK-WT SCC cells. Cell lysates were immunoprecipitated with anti-
PI3KC3 antibody and then immunoblotted with either anti-p150 or anti-PI3KC3 
antibodies (Figure 5.11b). The results show that there is no difference in steady state 




Figure 5.11 Beclin1/PI3KC3 multi-protein complex forms independently of FAK 
Lysates from FAK-/- and FAK-WT SCC cells were immunoprecipitated with anti-PI3KC3 antibody 
and probed with either anti-Beclin 1, and anti-PI3KC3 antibodies (a) or anti-p150, and anti-PI3KC3 





Together, these data allow us to conclude that although FAK is part of the 
Beclin1/PI3KC3 core complex, it is not required for it’s formation or maintenance of 
steady state levels. 
5.1.10 Ambra1 phosphorylation is affected in FAK-/- SCC cells 
Next we asked whether FAK is involved in Ambra1 phosphorylation. To test this, we 
determined the phosphorylation status of endogenous Ambra1 in SCC cells. Lysates 
from FAK-/- and FAK-WT SCC cells were immunoprecipitated with phosho-
Tyrosine (pTyr20) antibody and then immunoblotted with anti-Ambra1 antibody. 
IgG control was also included (Figure 5.12). The results show, that phosphorylation 
of Ambra1 is affected in FAK-/- SCC cells, suggesting that FAK is involved in the 
regulation of phosphorylation of Ambra1. However, we don’t know whether FAK 
directly phosphorylates Ambra1 or does it through another mechanism.  
As FAK is a rather weak kinase with only modest kinase activity and only very few 
examples of FAK-mediated substrate phosphorylation, maybe it is Src that mediates 
Ambra1 phosphorylation.  
5.1.11 Src and Ambra1 interaction 
To determine if Src was involved in regulating Ambra1 function, especially as the 
autophagy regulators Atg7 and LC3 can affect the trafficking of active Src to 
autophagic puncta in the absence of FAK (Sandilands et al., 2012b), and since 
Ambra1 has been reported to be important regulator of autophagy (Fimia et al., 
2007), we addressed whether it was playing a role in the Src-selective autophagy in 




5.12 Ambra1 phosphorylation is affected in FAK-/- SCC cells 
FAK-/- and FAK-WT SCC cell lysates were immunoprecipitated with anti-phosho-Tyrosine (pTyr20) 
antibody and then immunoblotted with anti-Ambra1 antibody. Cell lysates were also probed with anti-
Ambra1 antibody. IgG control was also included. 
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First we investigated whether Ambra1 forms a complex with Src, and if so whether 
this was regulated by FAK. FAK-/- and FAK-WT SCC cell lysates were 
immunoprecipitated with anti-Src antibody and then immunoblotted with either anti-
Ambra1 or anti-Src antibodies (Figure 5.13a). We found that there is not a detectable 
interaction between Src and Ambra1 in FAK-WT SCC cells. However there is a 
strong association between these two proteins in FAK-/- SCC cells. 
Previously have shown that active Src co-localises with known autophagy regulators 
such as Atg12 and Atg5 (Sandilands et al., 2012a), and siRNA of these proteins can 
inhibit Src targeting to the autophagosomes. We investigated whether there was co-
localisation between p-Src-Y416 and Ambra1 in FAK-/- and FAK-WT cells. The 
cells were fixed and stained for Ambra1, p-Src-Y416 and DAPI (Figure 5.13b). This 
showed that some Ambra1 co-localise with p-Src-Y416 at focal adhesions in FAK-
WT cells, and in puncta that were previously identified as autophagosomes in the 
cytoplasm of FAK-/- SCC cells. 
These data imply that Ambra1 forms a complex with Src and co-localises with p-Src-






5.13 Ambra1 associates with Src and co-localise with active Src in FAK-/- cells 
(a) Cell lysates from FAK-/- or FAK-WT SCC cells were immunoprecipitated with anti-Src antibody. 
Purified complexes and corresponding total cell lysates were analysed with SDS-PAGE and 
immunoblotted using anti-Ambra1 and anti-Src antibodies. IgG control is also included (b) FAK-/- 
(upper panel) and FAK-WT (lower panel) SCC cells were fixed and stained with anti-pSrcY416 (red), 
anti-Ambra1 (green) and DAPI (blue). Merged images are also shown. Scale bar 20um 
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5.1.12 Ambra1 siRNA in SCC cells 
Next we investigated the effect of Ambra1 knockdown on localization of active Src 
in SCC cells. FAK-/- and FAK-WT SCC cells were transfected with either scrambled 
or Ambra1 siRNA (100nM). After 24 hours the cells were plated on coverslips and 
left for 24 hours before they were fixed and stained for p-Src-Y416 and DAPI 
(Figure 5.14a). Cells with Src in intracellular puncta were counted and quantified 
(Figure 5.14b). Scrambled or Ambra1 siRNA transfected SCC cells were also lysed 
and cell lysates were examined for Ambra1 knockdown by immunoblotting using 
anti-Ambra1 or anti-actin antibodies (Figure 5.14c). We found that Ambra1 
knockdown has no effect on focal adhesion localisation of active Src in FAK-WT 
SCC cells; however active Src localisation to intracellular puncta was inhibited and 
active Src was restored to the cell periphery when FAK-/- SCC cells were transfected 
with Ambra1 siRNA. Thus, Ambra1 is a key mediator of the trafficking of active Src 
to autophagosomes when FAK is absent. Sine Ambra1 is involved in the formation 
of autophagosomes, we assume that its role is also in the formation of structures 
required to generate the Src-containing autophagic puncta in FAK-deficient cancer 
cells. It binds to FAK, and upon FAK loss, Ambra1 forms a complex with active Src 
and co-traffics to autophagic puncta in a manner that depends on Ambra1.  
Due to time constraints, I was unable to determine the role of Ambra1 in polarisation 
and invasion of the SCC cells in vitro. However, this work is on-going in the Frame 
lab at the moment. We are interested to know whether there is a general link between 
autophagy regulators, in controlling steady state levels of adhesion signalling 
proteins like FAK and Src, especially upon adhesion stress (such as when FAK is 
deleted) and polarisation and invasion that are regulated by the same proteins. 
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Moreover, SCC cancer cells use autophagy to deal with high levels of active tyrosine 
kinases (TKs), like Src and Ret, when their scaffolding protein FAK is missing. 
Therefore understanding this pathway may reveal important new targets that prevent 
survival of cancer cells via autophagy when cells are under adhesion stress. In this 
work, we identified Ambra1 as a new mediator of Src-selective autophagy. However, 
Ambra1 is not an enzyme and not quite clear how it might be targeted since 
generating of small molecular inhibitors of protein-protein interactions (PPIs) is hard. 
The major challenge to target PPIs is that protein-protein binding involves large 
surface areas, which are difficult to disrupt using small compounds. In addition, 
many protein-protein contact surfaces lack defined pockets suitable for small 
molecules to bind. Another challenge is that in some cases, the protein domain 
involved in PPIs may be unfolded until the confirmation is stabilised through binding 
to the interacting partner, which makes protein surface very difficult for the design of 
small molecular targets by using computational techniques [reviewed in (Jin et al., 




5.14 Ambra1 knockdown restores localisation of active Src to the cell periphery 
FAK-/- and FAK-WT SCC cells transfected with either Scrambled or Ambra1 siRNA were (a) fixed 
and stained with anti-p-Src-Y416 (green) and DAPI (blue). Scale bars 20µm, (b) quantification of 




5.2 Discussion  
Using phage display, peptide array analysis and co-immunoprecipitation experiments 
in SCC cells, we identified a potential between FAK and the autophagy regulatory 
protein Ambra1. 
To validate this interaction, we utilised a polyclonal anti-Ambra1 antibody, 
manufactured by Sigma, raised against a 15 amino acid peptide from the C-terminus 
of human Ambra1. This antibody is supposed to specifically detect Ambra1 protein 
in human, rat and mouse and has been shown by Sigma to be suitable for use in 
immunoblotting. In our immunoblotting experiment using SCC cell lysates we 
consistently detected multiple species of different molecular weights between 80-
120kDa. While full length Ambra1 is typically 140kDa, there are at least 7 different 
isoforms of Ambra1 protein, produced by alternative splicing, detected in mice. 
These vary in size between 83 kDa to 140 kDa (reference). Therefore, we concluded 
that the different bands observed in our immunoblots were likely different isoforms 
of Ambra1. We also found that these immune-reactive protein species were reduced 
in the absence of FAK in co-IP experiments. This antibody was not suitable for 
immunofluorescence as there was no staining, so we used an anti-Ambra1 antibody 
from Abcam that according to the manufacturer was suitable for this application. 
With this antibody we detected strong staining throughout the cell cytoplasm, a 
proportion of which seemed to co-localise with active Src in cytoplasmic puncta but 
not with FAK in focal adhesions. 
After repeated failed attempts to knockdown Ambra1 in SCC cells using siRNA or 
shRNA, we obtained Ambra1-/- MEFs and their WT counterparts from the Velasco 
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and Cecconi groups. Using these cells, we observed the same banding pattern in our 
immunoblots (Sigma antibody) and the same intracellular localisation using 
immunofluoresence (Abcam antibody) in cells that were Ambra1+/+ and Ambra1-/- 
(Figure 5.6). These experiments confirmed that these commercial antibodies 
supposedly specific for Ambra1 were not, in fact, detecting Ambra1 but were either 
non-specific or were detecting other proteins within the molecular weight range 
reported for Ambra1 isoforms. This was very frustrating, and wasted significant 
amount of time, but led us to search more widely, and more carefully, for a specific 
bone fide Ambra1 antibody. 
We tested a new anti-Ambra1 antibody from Millipore. We found that this antibody 
reacted specifically with a protein species ~150kDa, and antibody specificity was 
also confirmed by using Ambra1 siRNA and Ambra1-deficient MEFs. Therefore, we 
decided all experiments would now be repeated using this antibody. 
Data presented in this chapter show that there is a physical interaction between FAK 
and Ambra1 proteins in SCC cells, which was demonstrated with co-IP experiments. 
However to show that this interaction is direct, in vitro binding assay needs to be 
done using recombinant Ambra1 and recombinant FAK proteins. While mapping 
potential binding sites suggests that there is a direct interaction between FAK and 
Ambra1 we will, in the future, make a binding effector mutant that will help to show 
the loss of FAK/Ambra1 interaction, and the effects of interfering in binding. 
However, the proline rich region within FAK that may interact with Ambra1 is also a 
potential binding site for p130Cas (Polte and Hanks, 1995), although different 
proline residues are involved.  
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Here we investigated how FAK/Ambra1 interaction was regulated and we found that 
FAK phosphorylation or its kinase activity was required for this interaction. 
It has been reported that Ambra1 regulates autophagy as part of the Beclin1/PI3KC3 
multi-protein complex and that loss of Ambra1 disrupts the Beclin1/PI3KC3 
interaction, and therefore affects PI3KC3 activity (Fimia et al., 2007). We found that 
FAK also present in the Beclin1/PI3KC3 complex.  
One of the mechanisms of autophagy regulation is altering the assembly of 
Beclin1/PI3KC3 core complex, which could affect PI3KC3 kinase activity. Several 
proteins have been identified that function as positive or negative regulators of 
autophagy. For example, UVRAG binds to Beclin1 and enhances Beclin1/PI3KC3 
interaction and PI3KC3 kinase activity (Liang et al., 2006). Moreover, it has been 
shown that Bcl-2 binds to Beclin1 and inhibits the interaction between Beclin1 and 
PI3KC3, and therefore inhibits PI3KC3 activity (Pattingre et al., 2005). We 
examined endogenous Beclin1/PI3KC3 and PI3KC3/p150 interactions in SCC cells 
in the presence and absence of FAK. We found that FAK does not affect these 
interactions, implying that FAK is not required for Beclin1/PI3KC3 multi-protein 
complex formation. 
Post-translational modification of autophagy proteins provides another mechanism of 
how autophagy is regulated. For example, mammalian Ste20-like kinase 1 (Mst1) 
which is a Serine/Threonine kinase, phosphorylates Beclin1 and inhibits autophagy 
by promoting the interaction between Beclin1 and Bcl-2 (Maejima et al., 2013). 
Moreover, Akt inhibits autophagy through phosphorylation of Beclin1 (Wang et al., 
2012). Several studies have previously suggested that Ambra1 activity could be 
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modulated trough its phosphorylation. Autophagy induction leads ULK1-dependent 
phosphorylation of Ambra1, which in turn directs dissociation of Ambra1-DLC1 
complex from the dynein complex, and re-localisation of Ambra1/Beclin1 complex 
to the ER, where autophagy is initiated (Di Bartolomeo et al., 2010). The latter study 
shows that ULK1 activates Ambra1 by phosphorylation. However, phosphorylation 
of Ambra1 could have a negative regulatory effect on autophagy, for example, 
mTOR could inhibit ULK1 stability and activity by phosphorylation of Ambra1 at 
Ser52 (Nazio et al., 2013). To examine the potential role of FAK in the process of 
Ambra1 phosphorylation, we performed immunoprecipitation experiment in FAK-/- 
and FAK-WT SCC cells using anti-Tyr antibody. Phosphorylation of Ambra1 on 
tyrosine residues has never been shown before. Our data suggest that FAK binds to 
Ambra1 and either directly phosphorylates it or acts as a scaffold for other protein 
tyrosine kinase. FAK mediated Ambra1 phosphorylation may negatively regulates 
autophagy by disrupting the interaction between Ambra1 and E3-ligase TRAF6, 
which has been shown to support ULK1 ubiquitylation, and its subsequent 
stabilisation and function (Nazio et al., 2013). When FAK is absent, Ambra1 is 
dephosphorylated. In this condition, Ambra1 may be able to interact with TRAF6 
and enhance ULK1 kinase activity and stability, which in turn leads to ULK1-
dependent Ambra1 phosphorylation and activation.  
Although we don’t know if FAK/Ambra1 interaction plays a role in selective 
autophagy of active Src in SCC cells, we have shown that Ambra1 itself is important 
in this process. When we knockdown Ambra1 expression in FAK -/- SCC cells and 
examine localisation of active Src, we found that p-Src-Y416 localisation was 
restored to focal adhesions in FAK-/- cells. This is in line with the effect of inhibition 
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of several Atg proteins, such as the autophagy regulatory Atg5 and Atg12, whose 
inhibition promotes localisation of Src to focal adhesions (Sandilands et al., 2012a). 
Interestingly, we also saw co-localisation and binding between Src and Ambra1, 
suggesting that Ambra1 may play an additional role than just regulation of general 
autophagy. Since Ambra1 is in a complex with active Src when FAK is absent, and is 
required for Src targeting to autophagosomes, Ambra1 may be required for the 
formation of these autophagosomes at focal adhesions.  
Most of the previous studies on Ambra1 were carried out in relation to its roles in 
neurobiology and starvation-induced autophagy, but the role of Ambra1 in cancer 
biology still remains to be elucidated. Some studies have suggested that autophagy is 
important in cancer cell survival (Buchser et al., 2012; Sandilands et al., 2012b; 
Schoenlein et al., 2009), such as autophagy promotes SCC cell survival by 
modulating the activity of Src, and a recent paper has demonstrated that Ambra1 
promotes autophagy and regulates tumour cell survival in colorectal cancer cells (Gu 
et al., 2014). In addition, it has been reported that Ambra1 overexpression is 
associated with poor outcome in patients with pancreatic ductal adenocarcinoma, 
such as Ambra1 expression positively correlates with the expression of Snail, and 
promotes hepatocellular carcinoma cell invasion through the induction of EMT 
(Nitta et al., 2014). Therefore we think that further studies of FAK/Ambra1 
interaction could contribute to better understanding of the role of Ambra1 in 
processes involved in cancer. A wider study looking at Ambra1 in SCC and other 
cancers would be interesting.  
Summary 
The main findings of this study are: 
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1. We identified Ambra1 as a novel FAK binding protein 
2. It appears that FAK phosphorylation or its kinase activity is required for 
optimal FAK/Ambra1 interaction 
3. FAK not only binds to Ambra1, but it is also a part of the Beclin1/PI3KC3 
multi-protein core complex  
4. FAK is not required for Beclin1/PI3KC3 multi-protein complex formation 
5. FAK directly or indirectly regulates tyrosine phosphorylation of Ambra1 – 
although we do not yet know the significance of this 
6. We found that Ambra1 associates with Src specifically in FAK-/- SCC cells, 
and co-localise in intracellular puncta 
7. Ambra1 is involved in the trafficking of active Src to autophagic puncta in 
absence of FAK, and most likely in the formation of these structures 
Future work 
Characterisation roles of Ambra1 in cancer cells 
1. There is a possibility that there is a general link between autophagy 
regulators, in controlling the steady state levels of adhesion signaling 
molecules such as Src and FAK, and cancer associated cellular processes that 
are mediated by the same proteins such as cell polarisation, migration and 
invasion. Therefore it would be interesting to examine the effects of Ambra1 
siRNA on SCC cell migration, proliferation, polarisation and invasion 
2. To identify the molecular mechanisms of Ambra1 function, Use Reverse 
Phase Protein Array (RPPA) technology to establish differences in protein 
expression in SCC cells expressing Ambra1 siRNA or in Ambra-/- and 
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Ambra1+/+ MEFs under different conditions i.e. in suspension (adhesion 
stress) or upon nutrient deprivation 
3. Use mass spectrometry to identify Ambra1 binding partners in the presence 
and absence of FAK which help us understand the mechanism how SCC cells 
use autophagy to deal with high levels of TKs, such as Src and Ret 
Characterisation of FAK/Ambra1 interaction 
1. Make an effector mutant FAK protein that can’t bind to Ambra1 
2. Make stable cell line expressing effector mutant  
3. Validate binding mutant: a) confirm the loss of interaction with Ambra1 b) 
confirm that mutations do not affect FAK binding with other known 
interacting partners, such as p130Cas  
4. Characterise any changes that loss of FAK/Ambra1 interaction makes, firstly 
look at the localisation of active Src  
5. Use FAK-WT and FAK-/- cells, and FAK-/- cells re-expressing different 
FAK phosphorylation mutants, and also FAK and Src inhibitors to further 
investigate the role of FAK in Ambra1 phosphorylation 
6. Look at the interaction between Ambra1 and the TRAF6 ubiquitin ligase in 
the absence and presence of FAK 
7. Analyse the protein level and Lys-63-linked ubiquitylation of ULK1 in FAK-
/- and FAK-WT cells 
8. Look at the processes that FAK known to play a role in, such as cell 




I have found two new binding partners important for different aspects of FAK 
biology – Axl that is involved in the regulation of SCC cell invasion, and 
Ambra1 that is involved in the trafficking of active Src in autophagic puncta 















Summary and Perspectives 
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6 Summary and Perspectives 
FAK is a non-receptor protein tyrosine kinase that plays an important role in signal 
transduction from integrins and growth factor receptors and implicated in many 
cellular processes including cell proliferations, cell survival, cell migration and 
spreading. FAK is involved in the development and progression of many cancer 
types. However, how FAK regulates these processes needs to be elucidated, 
including whether or not it works predominantly via substrate phosphorylation or by 
its adaptor protein-protein interaction functions that permit the tethering of proteins 
into complexes at integrin adhesions, and potentially also at other sub-cellular 
locations. The purpose of the work presented in this thesis was to identify new 
interacting partners of FAK, and to address their roles in cancer-associated cell 
biology processes, determining whether FAK and its partner binding proteins have 
key roles. If this is the case, then disruption of these interactions in cells, in which 
FAK-mediated processes are mis-regulated, could be useful for therapeutic purposes 
for cancer treatment. However, it is well known that targeting protein-protein 
interactions is not a popular choice of therapeutic strategy – due to the difficulties in 
generating specific and high affinity inhibitors. Therefore, it may be valuable to 
identify new targets, by examining partners of key proteins like FAK, which are 
more easily targeted by small molecular inhibitors.  
By using in vitro screening methods, namely protein microarray and phage display, 
which were already established in our laboratory, I was able to identify, and validate, 
novel FAK interactions. These techniques provide quick and simple strategies for 
examination of protein-protein interactions on a large scale. However, the 
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disadvantages of using these in vitro techniques are that both protein microarray and 
phage display lack posttranslational protein modifications, which are often important 
for many protein functions. Therefore, using mass spectrometry for identification of 
novel protein-protein interactions would be ideal, and is now the method of choice in 
on-going studies.  
To characterise my novel FAK interactions in vitro, I used an SCC cancer cell 
model. This was an excellent model, because we could delete the gene encoding 
FAK and reconstitute with WT and mutant FAK proteins. This provided a 
genetically ‘clean’ system in which to study the role of FAK, or its partner proteins, 
in aspects of cell biology. FAK-/- SCC cells re-expressing various FAK mutants 
enabled me to analyse the contribution of individual phosphorylation sites and 
domains of FAK in specific interactions.  
Identification of Axl as FAK interacting protein 
Through combinations of immunoprecipitation experiments with in vitro binding and 
pulldown assays, I confirmed the direct interactions between FAK and Axl proteins. 
Moreover, I demonstrated that FAK/Axl interaction is not regulated by any of the 
major phosphorylation events characterised for FAK or by its kinase activity. We 
therefore hypothesised that the function of FAK in this regard is as a largely un-
regulated scaffold protein, and Axl knockdown did not affect FAK phosphorylation.  
Axl itself is overexpressed in a variety of cancers and plays some role in tumour 
growth and metastasis in a number of contexts. Moreover, Axl over-expression often 
associates with poor prognosis [reviewed in (Paccez et al., 2014)]. I found that the 
predominant role of Axl in SCC cells was to control cell spreading, cell polarisation 
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and invasive migration in vitro, while cell proliferation was independent of Axl. 
However, we don’t know whether Axl regulates these invasion-associated processes 
through its interaction with FAK – although these processes also require FAK as 
published by the Frame lab, and others, previously. Therefore, while further study is 
required to analyse the importance of this interaction in SCC cell biology, it may be 
that Axl is a potentially useful anti-invasion target. There are Axl inhibitors in pre-
clinical and clinical development, and it will be interesting to assess their roles in 
SCC cancer phenotypes in vitro and in vivo.  
Identification of Ambra1 as FAK interacting protein 
Previous studies in our laboratory demonstrated that in FAK-/- SCC cells, active Src 
is selected for degradation through the autophagy pathway, and this is an adaptive 
mechanism to permit SCC cell survival upon adhesion stress. When FAK-WT is re-
expressed in FAK-/- cells, localisation of active Src is restored to focal adhesions, 
suggesting a negative regulatory role of FAK in selective autophagy of active Src 
(Sandilands et al., 2012a). This work prompted us to also study Ambra1, reported to 
be an autophagy regulatory protein that binds to Beclin1, promoting its interaction 
with PI3KC3, and positively regulating the early stages of autophagy (Fimia et al., 
2007).  
In this thesis, I identified an interaction between FAK and Ambra1, validated in SCC 
cancer cells. I report that this interaction requires FAK phosphorylation and kinase 
activity. Peptide array analysis and alanine scanning showed that FAK likely 
interacts with Ambra1 through a C-terminal proline rich region, which was 
previously identified as close to a binding site for p130Cas protein; however 
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different proline residues were involved in the latter interaction. Ongoing work in the 
Frame lab is generating effector binding mutant proteins predicted to impair the 
binding of Ambra1 to FAK, with a view to re-expressing this in FAK-deficient cells 
and analysing whether cancer-associated functions are impaired. Thus far, we know 
that Ambra1 complexes with FAK and is tyrosine phosphorylated, but when FAK is 
absent after genetic deletion, Ambra1 forms a complex with active Src. This 
association of Src with Ambra1 might bring it into complex with the 
Beclin1/PI3KC3 and promote PI3KC3 activity in the vicinity of adhesion sites, so 
triggering formation of autophagosomes that ultimately remove excess, highly active 
Src from focal adhesions, and for degradation [as described in (Sandilands et al., 
2012b)]. In keeping with this, I have shown that Ambra1 knockdown inhibits 
targeting of active Src to autophagosomes initiated at focal adhesions. 
This work raises the question of what role the FAK/Ambra1 interaction plays when 
FAK is present at high levels, as in the SCC model cells we used here and in many 
cancer cells. To speculate, it is possible that Ambra1 also regulates FAK-mediated, 
cancer associated cellular processes like polarisation and invasive migration. If true, 
this would raise the exciting possibility that autophagy proteins are playing a dual 
role - in autophagy on the one hand and on invasion on the other – dependent on 
which specific cellular protein complexes form. It may be that autophagy and 
invasion are linked and that autophagy is performing a key function to tightly control 
the levels of highly active kinases at adhesion sites and permit their invasive 
regulatory functions. This remains to be tested, and work is ongoing to determine the 
role of Ambra1, and the FAK-Ambra1 complex, in a full range of cancer phenotypes 
in vitro and in vivo.  
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